<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0010.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0012.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h62" class="calibre8"></a><a id="page_5-1" class="calibre8"></a><a href="part0003.html#rh70" class="calibre8">ANEMIA</a></h2>
<p class="center">↓<i class="calibre6"> in RBC mass: Hct</i> &lt;<i class="calibre6">41% or Hb</i> &lt;<i class="calibre6">13.5 g/dL (men); Hct</i> &lt;<i class="calibre6">36% or Hb</i> &lt;<i class="calibre6">12 g/dL (women)</i></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Symptoms: ↓ O<sub class="calibre10">2</sub> delivery → fatigue, exertional dyspnea, angina (if CAD)</p>
<p class="noindent1">• Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension</p>
<p class="noindent1">• Other findings: <b class="calibre7">jaundice</b> (hemolysis), <b class="calibre7">splenomegaly</b> (thalassemia, neoplasm, chronic hemolysis), <b class="calibre7">petechiae/purpura</b> (bleeding disorder), <b class="calibre7">glossitis</b> (iron, folate, vitamin B<sub class="calibre10">12</sub> defic.), <b class="calibre7">koilonychia</b> (iron defic.), <b class="calibre7">neurologic abnormalities</b> (B<sub class="calibre10">12</sub> defic.)</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including <b class="calibre7">pica</b>), FHx</p>
<p class="noindent1">• CBC w/ diff.; RBC params incl. retics, MCV (nb, mixed disorder can → nl MCV), RDW</p>
<p class="noindent1">• <b class="calibre7">Reticulocyte index</b> (RI) = [reticulocyte count × (Pt’s Hct/nl Hct)]/maturation factor maturation factors for a given Hct: 45% = 1, 35% = 1.5, 25% = 2, 20% = 2.5 RI &gt;2% → adequate marrow response; RI &lt;2% → hypoproliferation</p>
<p class="noindent1">• <b class="calibre7">Peripheral smear:</b> select area where roughly ⅓ RBCs touch each other; ✓ RBC size, shape, inclusions (see “Appendix” &amp; “Peripheral Smear”), WBC morphology, plt count</p>
<p class="noindent1">• Additional labs as indicated: hemolysis labs (if RI &gt;2%, see below), iron/TIBC, ferritin, folate, B<sub class="calibre10">12</sub>, LFTs, BUN, &amp; Cr, TFTs, Hb electrophoresis, enzyme/gene mutation screens</p>
<p class="noindent1">• <b class="calibre7">Bone marrow (BM) aspirate and biopsy (bx)</b> with cytogenetics as indicated</p>
<div class="cap">
<p class="caption"><a id="fig5-1" class="calibre4"></a><b class="calibre7">Figure 5-1</b> Approach to anemia and common causes</p>
<p class="imagef1"><img src="../images/00074.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h1cr">M<small class="calibre31">ICROCYTIC</small> A<small class="calibre31">NEMIAS</small></p>
<div class="cap">
<p class="caption"><a id="fig5-2" class="calibre4"></a><b class="calibre7">Figure 5-2</b> Approach to microcytic anemias <span class="sm">(<i class="calibre6">NEJM</i> 2014;371:1324)</span></p>
<p class="imagef1"><img src="../images/00075.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Iron deficiency <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:233)</span></p>
<p class="noindent1">• ↓ marrow iron &amp; depleted body iron stores → ↓ heme synthesis → microcytosis → anemia</p>
<p class="noindent1">• Special clinical manifestations: angular cheilosis, atrophic glossitis, pica (consumption of nonnutritive substances such as ice, clay), koilonychia (nail spooning)</p>
<p class="noindent2">Plummer-Vinson syndrome (iron deficiency anemia, esophageal web &amp; atrophic glossitis)</p>
<p class="noindent1">• Etiologies: <b class="calibre7">chronic bleeding</b> (GI—incl. cancer, menstrual, parasites, NSAIDs, etc.), ↓ <b class="calibre7">supply</b> (malnutrition; ↓ absorp. due to celiac sprue, Crohn’s, ↑ gastric pH, subtotal gastrectomy), ↑ <b class="calibre7">demand</b> (preg; <span class="r2">Blood</span><span class="r1"> 2017;129:940</span>). Iron-refractory iron-defic. anemia (IRIDA; rare genetic disorder due to hepcidin dysregulation; <span class="r2">Nat Genet</span><span class="r1"> 2008;40:569</span>).</p>
<p class="noindent1">• Diagnosis (eval ideally before Rx): ↓ <b class="calibre7">Fe</b>, ↑ <b class="calibre7">TIBC</b>, ↓ <b class="calibre7">ferritin</b> (esp. &lt;15), ↓ <b class="calibre7">transferrin sat</b> (Fe/TIBC; esp. &lt;15%), ↑ soluble transferrin receptor; ↑ plt. Unless hx c/w other etiology, <i class="calibre6">initiate workup for GIB</i>, incl. <i class="calibre6">H. pylori</i> serology. ? Celiac labs (<b class="calibre7">anti-TTG</b>, anti-endomysial IgA Abs). Cytogenetics &amp; molecular testing as indicated (eg, MDS, leukemia).</p>
<p class="noindent1"><a id="page_5-2" class="calibre4"></a>• Treatment: oral Fe TID (~6 wks to correct anemia; ~6 mo to replete Fe stores; nb, oral Fe does not give ⊕ Hemoccult). With severe anemia, persistent losses, prior to Epo Rx, or while inpatient, use <i class="calibre6">IV iron</i> (Fe-sucrose, -gluconate, -dextran).</p>
<p class="h">Thalassemias <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:155)</span></p>
<p class="noindent1">• ↓ synthesis of α- or β-globin chains of Hb → ≠ subunits → destruction of RBCs and erythroid precursors; ∴ anemia from hemolysis <i class="calibre6">and</i> ineffective erythropoiesis</p>
<p class="noindent1">• <b class="calibre7">α-thalassemia</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:1908)</span>: deletions in α-globin gene complex (nl 4 α genes), seen w/ Southeast Asian, Mediterranean, African, Middle East ancestry</p>
<p class="noindent2">3 α → silent carrier; 2 α → α-thal minor = mild anemia, α-thal-1 (--/αα, milder) or</p>
<p class="noindent2">α-thal-2 (-α/-α); 1 α → HbH (β<sub class="calibre10">4</sub>) disease = severe anemia, hemolysis, and splenomegaly</p>
<p class="noindent2">0 α genes → Hb Barts (γ<sub class="calibre10">4</sub>) = intrauterine hypoxia and hydrops fetalis</p>
<p class="noindent1">• β<b class="calibre7">-thalassemia:</b> mutations in β-globin gene → absent or ↓ gene product seen w/ Mediterranean (espec. Greek or Italian), African, or Asian ancestry</p>
<p class="noindent2">1 mutated β gene → thal minor (or trait) = mild anemia (no transfusions)</p>
<p class="noindent2">2 mutated β genes → thal intermedia (occasional transfusions) or thal major (= Cooley’s anemia; transfusion dependent) depending on severity of mutations</p>
<p class="noindent1">• Special clinical manifestations: chipmunk facies, pathologic fractures, hepatosplenomegaly (due to extramedullary hematopoiesis), high-output CHF, bilirubin gallstones, Fe overload</p>
<p class="noindent1">• Dx: MCV &lt;70, <b class="calibre7">normal Fe, ferritin</b>, <b class="calibre7">MCV</b>/<b class="calibre7">RBC count</b> &lt;<b class="calibre7">13</b> [Mentzer Index, 60% Se, 98% Sp; <span class="r1">(</span><span class="r2">Ann Hem</span> <span class="r1">2007;86:486)</span>], ± ↑ retics, basophilic stippling; <b class="calibre7">Hb electrophoresis:</b> ↑ HbA<sub class="calibre10">2</sub> (α<sub class="calibre10">2</sub>δ<sub class="calibre10">2</sub>) in β-thal; <i class="calibre6">normal</i> pattern in α-thal trait, ∴ PCR or supravital stain for dx</p>
<p class="noindent1">• Treatment: folate; transfusions + Fe chelator [either deferoxamine (IV) or deferasirox (PO)]; ? splenectomy if ≥50% ↑ in transfusions; gene therapy in development <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1479)</span>; luspatercept (↓ SMAD signaling) in β-thal major <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:1219)</span></p>
<p class="h">Anemia of chronic inflammation <span class="r">(see below)</span></p>
<p class="h">Sideroblastic anemia</p>
<p class="noindent1">• Defective heme biosynthesis within RBC precursors</p>
<p class="noindent1">• Etiologies: <b class="calibre7">hereditary/X-linked</b> (<i class="calibre6">ALAS2</i> mutations), <b class="calibre7">idiopathic</b>, <b class="calibre7">MDS-RARS</b>, <b class="calibre7">reversible</b> (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia)</p>
<p class="noindent1">• Special clinical manifestations: hepatosplenomegaly, iron overload syndromes</p>
<p class="noindent1">• Dx: social, work, &amp; TB hx; can be micro-, normo-, or macrocytic; variable populations of hypochromic RBCs; ↑ Fe, nl TIBC, ↑ ferritin, basophilic stippling, RBC <b class="calibre7">Pappenheimer bodies</b> (Fe-containing inclusions), <b class="calibre7">ring sideroblasts</b> (w/ iron-laden mitochondria) in BM</p>
<p class="noindent1">• Treatment: treat reversible causes; trial of pyridoxine, supportive transfusions for severe anemia with chelation therapy; high-dose pyridoxine for some hereditary cases</p>
<p class="h1cr">N<small class="calibre31">ORMOCYTIC</small> A<small class="calibre31">NEMIAS</small></p>
<p class="h">Anemia of chronic inflammation <span class="r">(ACI;</span> <span class="r2">NEJM</span> <span class="r1">2012;366:4</span><span class="r">)</span></p>
<p class="noindent1">• ↓ RBC production due to impaired iron utilization and functional iron deficiency from ↑ <b class="calibre7">hepcidin;</b> cytokines (IL-6, TNF-α) cause ↓ Epo responsiveness/production</p>
<p class="noindent1">• Etiologies: autoimmune disorders, chronic infection, inflammation, HIV, malignancy</p>
<p class="noindent1">• Dx: ↓ <b class="calibre7">Fe</b>, ↓ <b class="calibre7">TIBC (usually normal or low transferrin sat)</b>, ± ↑ <b class="calibre7">ferritin;</b> usually normochromic, normocytic (~70% of cases) but can be microcytic if prolonged</p>
<p class="noindent1">• Coexisting iron deficiency common. Dx clues include ↓ serum ferritin levels, absence of iron staining on BM bx, ⊕ response to a trial of oral iron and/or ↑ soluble transferrin receptor/ferritin index <span class="r1">(</span><span class="r2">Am J Clin Pathol</span> <span class="r1">2012;138:642)</span>.</p>
<p class="noindent1">• Treatment: treat underlying disease ± iron and/or erythropoiesis-stimulating agent (ESA; eg, Epo). Iron if ferritin &lt;100 or Fe/TIBC &lt;20%. Consider ESA if Epo &lt;500. Avoid ESA in cancer if treatment goal is cure <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2009;373:1532)</span>. Transfuse PRBCs only if symptomatic &amp; insufficient time to wait for response to Epo or underlying disease Rx.</p>
<p class="h">Anemias of other chronic disorders</p>
<p class="noindent1">• Anemia of CKD: ↓ Epo; treat w/ Epo &amp; iron (see “Chronic Kidney Disease”)</p>
<p class="noindent1">• Endocrine deficiencies: hypometabolism and ↓ O<sub class="calibre10">2</sub> demand with thyroid, pituitary, adrenal, or parathyroid disease → ↓ Epo; can be normocytic or macrocytic</p>
<p class="h">Sideroblastic anemia <span class="r">(see above)</span></p>
<p class="h">Pure red cell aplasia</p>
<p class="noindent1">• Destructive antibodies or lymphocytes → ineffective erythropoiesis</p>
<p class="noindent1">• Associated with thymoma, CLL, parvovirus infection, autoimmunity, drugs</p>
<p class="noindent1">• Diagnostic studies: <b class="calibre7">lack of erythroid precursors on BM bx</b>, other lines normal</p>
<p class="noindent1">• Treatment: thymectomy if thymus enlarged; IVIg if parvovirus and immunosuppressed <span class="r1">(</span><span class="r2">Clin Infect Dis</span> <span class="r1">2013;56:968)</span>; immunosuppression/chemoRx if CLL or idiopathic; supportive care w/ PRBC transfusions; ? erythropoietin receptor agonist if due to antierythropoietin Ab <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2009;361:1848)</span>; consider hematopoietic cell transplantation.</p>
<p class="h1cr"><a id="page_5-3" class="calibre8"></a>M<small class="calibre31">ACROCYTIC</small> A<small class="calibre31">NEMIAS</small></p>
<p class="center"><i class="calibre6">includes megaloblastic and nonmegaloblastic causes</i></p>
<p class="h">Megaloblastic anemia</p>
<p class="noindent1">• <b class="calibre7">Impaired DNA synthesis</b> → cytoplasm matures faster than nucleus → ineffective erythropoiesis and macrocytosis; due to <b class="calibre7">folate</b> or <b class="calibre7">B<sub class="calibre10">12</sub> deficiency;</b> also in <b class="calibre7">MDS</b></p>
<p class="noindent1">• ✓ <b class="calibre7">folate</b> and <b class="calibre7">vitamin B<sub class="calibre10">12</sub>;</b> ↑ LDH &amp; indirect bilirubin (due to ineffective erythropoiesis)</p>
<p class="noindent1">• Smear: <b class="calibre7">neutrophil hypersegmentation, macro-ovalocytes</b>, anisocytosis, poikilocytosis</p>
<p class="h">Folate deficiency</p>
<p class="noindent1">• Folate present in leafy green vegetables and fruit; total body stores sufficient for <b class="calibre7">2–3 mo</b></p>
<p class="noindent1">• Etiologies: <b class="calibre7">malnutrition</b> (alcoholics, anorectics, elderly), ↓ absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim; <span class="r2">NEJM</span><span class="r1"> 2015;373:1649</span>), ↑ requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis)</p>
<p class="noindent1">• Diagnosis: ↓ folate; ↓ RBC folate, ↑ homocyst. but nl methylmalonic acid (unlike B<sub class="calibre10">12</sub> defic.)</p>
<p class="noindent1">• Treatment: folate 1–5 mg PO qd for 1–4 mo or until complete hematologic recovery; <i class="calibre6">critical to r</i>/<i class="calibre6">o B</i><sub class="calibre10">12</sub> <i class="calibre6">deficiency first (see below)</i></p>
<p class="h">Vitamin B<sub class="calibre10">12</sub> deficiency <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:149)</span></p>
<p class="noindent1">• B<sub class="calibre10">12</sub> present only in foods of animal origin; total body stores sufficient for <b class="calibre7">2–3 y</b></p>
<p class="noindent1">• Binds to <b class="calibre7">intrinsic factor</b> (IF) secreted by gastric parietal cells; absorbed in terminal ileum</p>
<p class="noindent1">• Etiologies: malnutrition (alcoholics, vegans), <b class="calibre7">pernicious anemia</b> (PA, autoimmune disease against gastric parietal cells, a/w polyglandular endocrine insufficiency and ↑ risk of gastric carcinoma), other causes of ↓ absorption (gastrectomy, sprue, Crohn’s disease), ↑ competition (intestinal bacterial overgrowth, fish tapeworm)</p>
<p class="noindent1">• Clinical manifestations: <b class="calibre7">neurologic</b> changes (<b class="calibre7">subacute combined degeneration</b>) affecting peripheral nerves, posterior &amp; lateral columns of the spinal cord and cortex → numbness, paresthesias, ↓ vibratory &amp; positional sense, ataxia, dementia, mood</p>
<p class="noindent1">• Dx: ↓ B<sub class="calibre10">12</sub> (even low nl); ↑ homocysteine &amp; methylmalonic acid; anti-IF Ab; ↑ gastrin in PA</p>
<p class="noindent1">• Treatment: 1 mg B<sub class="calibre10">12</sub> IM qd × 7 d → q wk × 4–8 wk → q month for life</p>
<p class="noindent2">neurologic abnormalities are reversible if treated w/in 6 mos</p>
<p class="noindent2">folate can reverse <i class="calibre6">hematologic</i> abnormalities of B<sub class="calibre10">12</sub> deficiency but not <i class="calibre6">neurologic</i> changes (and can “steal” B<sub class="calibre10">12</sub> stores → worsening of neuro complications)</p>
<p class="noindent2">oral supplementation (2 mg qd) appears feasible as well <span class="r1">(</span><span class="r2">Cochrane Rev</span> <span class="r1">CD004655)</span> even w/o IF</p>
<p class="h">Nonmegaloblastic macrocytic anemias</p>
<p class="noindent1">• <b class="calibre7">Liver disease:</b> often macrocytic, may see target cells, or spur cell anemia w/ hemolysis</p>
<p class="noindent1">• <b class="calibre7">Alcoholism:</b> BM suppression &amp; macrocytosis independent of folate/B<sub class="calibre10">12</sub> defic. or cirrhosis</p>
<p class="noindent1">• <b class="calibre7">Other causes:</b> reticulocytosis; hypothyroid; MDS; meds impairing DNA synth (zidovudine, 5-FU, hydroxyurea, Ara-C); hereditary orotic aciduria; Lesch-Nyhan syndrome</p>
<p class="h1cr">P<small class="calibre31">ANCYTOPENIA</small></p>
<p class="h">Etiologies</p>
<p class="noindent1">• Hypocellular bone marrow (nl cellularity ~100 – age): <b class="calibre7">aplastic anemia</b>, hypoplastic MDS</p>
<p class="noindent1">• Cellular bone marrow: <b class="calibre7">MDS</b>, aleukemic leukemia, PNH, severe megaloblastic anemia</p>
<p class="noindent1">• Myelophthesis (marrow replacement, PMF); systemic dis. (hypersplen, sepsis, EtOH/toxin)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Anemia → fatigue; neutropenia → recurrent infections; thrombocytopenia → mucosal bleeding &amp; easy bruisability</p>
<p class="h">Aplastic anemia (stem cell failure) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:35)</span></p>
<p class="noindent1">• Epidemiology: 2–5 cases/10<sup class="calibre19">6</sup>/y; biphasic (major peak in adolescents, 2<sup class="calibre19">nd</sup> peak in elderly)</p>
<p class="noindent1">• Diagnosis: pancytopenia w/ ↓ retics, BM bx w/ hypocellularity, usually nl cytogenetics</p>
<p class="noindent1">• Etiologies: <b class="calibre7">idiopathic</b> (½ – ⅔ of cases)</p>
<p class="noindent2"><b class="calibre7">Stem cell destruction: radiation, chemotherapy, chemicals</b> (eg, benzene)</p>
<p class="noindent2"><b class="calibre7">Med rxn</b> (eg, chloramphenicol, NSAIDs, sulfa drugs, gold, carbamazepine, antithyroid)</p>
<p class="noindent2"><b class="calibre7">Viruses</b> (HHV-6, HIV, EBV, parvovirus B19); <b class="calibre7">post-viral hepatic failure</b> (not Hep A/B/C)</p>
<p class="noindent2"><b class="calibre7">Immune disorders</b> (SLE, GVHD post-HSCT, thymoma)</p>
<p class="noindent2">PNH (see below); Fanconi’s anemia (congenital disorder w/ pancytopenia, macrocytic anemia, ↑ risk of MDS, AML, &amp; SCC of head &amp; neck, and multiple physical anomalies)</p>
<p class="noindent2">Shortened telomeres: seen w/ telomerase (<i class="calibre6">TERT, TERC</i>) mut. (10% of aplastic anemia), dyskeratosis congenita/DKC1 mut; a/w IPF, cirrhosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;361:2353)</span></p>
<p class="noindent2">Somatic mutations: PNH clones in ~50% of aplastic anemia <span class="r1">(</span><span class="r2">Haematologica</span> <span class="r1">2010;95:1075)</span></p>
<p class="noindent1">• Treatment and prognosis</p>
<p class="noindent2"><b class="calibre7">Immunosuppression</b> (CsA/tacrolimus, ATG): 70–80% respond, with 80–90% 5-y survival in responders (96% vs. 76% w/ horse vs. rabbit ATG; <span class="r2">NEJM</span><span class="r1"> 2011;365:430</span>); 15–20% 10-y incidence of clonal disorders (mostly MDS, AML, PNH)</p>
<p class="noindent2"><a id="page_5-4" class="calibre4"></a><b class="calibre7">TPO mimetics</b> (eg, eltrombopag): use 1<sup class="calibre19">st</sup>-line w/ immunosuppression <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2022;386:11)</span></p>
<p class="noindent2"><b class="calibre7">Supportive care:</b> transfusions, abx, possible utility of G-CSF &amp; Epo (if Epo &lt;500)</p>
<p class="noindent2"><b class="calibre7">Allogeneic HSCT:</b> for <i class="calibre6">young</i> Pts → ~80% long-term survival and significantly ↓ risk of malignant evolution, but has risk of transplant-related morbidity &amp; mortality; if possible, avoid transfusions (risk of alloimmunization) pretransplant</p>
<p class="h">Myelodysplastic syndromes (MDS) <span class="r">(qv)</span></p>
<p class="h">Paroxysmal nocturnal hemoglobinuria (PNH) <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2009;113:6522)</span></p>
<p class="noindent1">• Acquired clonal stem cell disorder = inactivating somatic mutation of <i class="calibre6">PIG-A</i> gene → deficiency of GPI-anchor for CD55 &amp; CD59 (inhib of complement) → complement-mediated RBC lysis, plt aggregation, &amp; hypercoagulability</p>
<p class="noindent1">• Clinical: intravascular <b class="calibre7">hemolytic anemia</b>, <b class="calibre7">hypercoagulability</b> (venous &gt;arterial; esp. intraabdominal, cerebral), smooth muscle dystonias, <b class="calibre7">deficient hematopoiesis</b> (cytopenias); a/w aplastic anemia, MDS and evolution to AML</p>
<p class="noindent1">• Dx: <b class="calibre7">flow cytometry</b> (↓ CD55 &amp; CD59) on RBCs and granulocytes; urine hemosiderosis</p>
<p class="noindent1">• Treatment: supportive care (iron, folate, transfusions); consider anticoagulation.</p>
<p class="noindent2">Allogeneic HSCT for hypoplasia or severe thrombosis.</p>
<p class="noindent2">Pegcetacoplan (binds C3, prevents complement cascade activation) superior to eculizumab (Ab inactivates terminal complement C5s) in ↓ hemolysis &amp; stabilizing Hb levels <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:1028)</span>. Eculizumab effective in pregnancy <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:1032)</span>; must have meningococcal vaccination.</p>
<p class="h">Myelophthisic anemia <span class="r">(see also “Primary Myelofibrosis”)</span></p>
<p class="noindent1">• Infiltration of bone marrow by cancer (commonly metastatic solid tumors), leukemia, infection, fibrosis (primary myelofibrosis), granulomas, lysosomal storage disorders</p>
<p class="h1cr">H<small class="calibre31">EMOLYTIC</small> A<small class="calibre31">NEMIAS</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre23"/>
<col class="calibre18"/>
<col class="calibre12"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Causes of Hemolytic Anemia by Mechanism</b> <span class="sm">(<i class="calibre6">Lancet</i> 2000;355:1169 &amp; 1260)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cause</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Mechanism</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Examples</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Mode</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1" rowspan="4"><p class="tbody"><b class="calibre7">Intrinsic</b></p></td>
<td class="th1"><p class="tbody">Enzyme deficiency</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">G6PD</i> deficiency</p></td>
<td class="tb" rowspan="3"><p class="tbody"><b class="calibre7">Hereditary</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hemoglobinopathies</p></td>
<td class="th1"><p class="tbody">Sickle cell anemia, thalassemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1" rowspan="2"><p class="tbody">Membrane abnormalities</p></td>
<td class="th1"><p class="tbody">Hereditary spherocytosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PNH, spur cell anemia in liver disease</p></td>
<td class="tb" rowspan="5"><p class="tbody"><b class="calibre7">Acquired</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1" rowspan="4"><p class="tbody"><b class="calibre7">Extrinsic</b></p></td>
<td class="th1"><p class="tbody">Immune-mediated</p></td>
<td class="th1"><p class="tbody">Autoimmune; drug-induced, tx rxn</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Traumatic</p></td>
<td class="th1"><p class="tbody">MAHA; prostheses (valves, TIPS)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Direct infections, toxins</p></td>
<td class="th1"><p class="tbody">Malaria, babesiosis; snake &amp; spider venoms; Wilson’s; hypotonic infusions</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Entrapment</p></td>
<td class="th1"><p class="tbody">Hypersplenism</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• ↑ retic count (RI &gt;2%), ↑ LDH, ↓ hapto (83% Se, 96% Sp), ↑ indirect bili, ✓ vit C &amp; Cu</p>
<p class="noindent1">• Autoimmune hemolysis: Coombs’ test = direct antiglobulin test (DAT) → ⊕ if agglutination occurs when antisera against Ig or C3 are applied to patient RBCs</p>
<p class="noindent1">• Location of hemolysis (many conditions can include components of both)</p>
<p class="noindent2"><b class="calibre7">Intravascular</b>: RBC destruction in vessels (shear by mech valve, DIC, toxins); assoc. w/ hemoglobinemia, hemoglobinuria, hemosiderinuria, ↑↑ LDH, ↓ haptoglobin.</p>
<p class="noindent2"><b class="calibre7">Extravascular</b>: more common cause. Mϕ clear damaged/opsonized RBC; splenomegaly (reticuloendothelial expansion in spleen, liver, BM, LNs); ↑ LDH ↓ hapto</p>
<p class="noindent1">• Family h/o anemia; personal or family h/o cholelithiasis</p>
<p class="h">Glucose-6-phosphate dehydrogenase (G6PD) deficiency <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2008;371:64)</span></p>
<p class="noindent1">• X-linked defect of metabolism (<i class="calibre6">G6PD</i> mutations) w/ ↑ susceptibility to oxidative damage</p>
<p class="noindent1">• Most common in ♂ of African or Mediterranean descent (malaria-endemic areas)</p>
<p class="noindent1">• Hemolysis precipitated by <b class="calibre7">drugs</b> (sulfonamides, dapsone, nitrofurantoin, rasburicase, primaquine, doxorubicin, methylene blue), <b class="calibre7">infxn</b>, <b class="calibre7">DKA</b>, <b class="calibre7">foods</b> (favism, <span class="r2">NEJM</span><span class="r1"> 2018;378:60</span>)</p>
<p class="noindent1">• Diagnosis: smear may show RBC <b class="calibre7">Heinz bodies</b> (oxidized Hb) that result in <b class="calibre7">bite cells</b> once removed by spleen; ↓ G6PD levels (<i class="calibre6">may be normal after acute hemolysis</i> because older RBCs have already lysed and young RBCs may still have near-normal levels)</p>
<p class="h">Sickle cell anemia <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:1561 &amp;</span> <span class="r2">Lancet</span><span class="r1"> 2017;390:311)</span></p>
<p class="noindent1">• Recessive β-globin mutation → structurally abnl hemoglobin (HbS). ~8% African Americans heterozygotes (“sickle trait”; usually w/o sx); ~1/400 homozygotes (sickle cell disease).</p>
<p class="noindent1">• ↓ O<sub class="calibre10">2</sub> → HbS polymerizes → RBC sickles, ↓ RBC deformability → <b class="calibre7">hemolysis</b> &amp; <b class="calibre7">microvascular occlusion</b> due to endothelial activ. &amp; PMN adhesion <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2013;122:3892)</span></p>
<p class="noindent1">• <b class="calibre7">Anemia:</b> chronic hemolysis ± acute aplastic (parvo. B19) or splenic sequestration crises</p>
<p class="noindent1">• <b class="calibre7">Vaso-occlusion &amp; infarction:</b> acute chest syndrome &amp; stroke (high mortality), pulmonary HTN, painful crises, splenic sequestration, renal papillary necrosis, avascular necrosis, dactylitis (hand–foot syndrome), priapism</p>
<p class="noindent1"><a id="page_5-5" class="calibre4"></a>• <b class="calibre7">Infection:</b> splenic infarction → overwhelming infection by <b class="calibre7">encapsulated organisms;</b> infarcted bone → <b class="calibre7">osteomyelitis</b> (<i class="calibre6">Salmonella</i>, <i class="calibre6">Staph. aureus</i>), can be life threatening</p>
<p class="noindent1">• Diagnosis: sickle-shaped RBCs and Howell-Jolly bodies on smear; Hb electrophoresis</p>
<p class="noindent1">• Treatment: hydroxyurea, folic acid; voxelotor (Hgb S polymerization inhibitor) ↓ hemolysis &amp; ↑ Hgb <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;381:509)</span></p>
<p class="noindent1">• Vaccines: pneumo, meningo, H flu, HBV</p>
<p class="noindent1">• Pain &amp; vaso-occlusive crises: analgesia (consider PCA; ask Pt what worked prev.), IVF, transfusion only if sx &amp; <i class="calibre6">Hgb below Pt’s baseline</i> (often low) given alloimmunization &amp; Fe accumulation (need chelation); Ppx w/ crizanlizumab (anti-P-selectin; <span class="r2">NEJM</span><span class="r1"> 2017;376:429</span>)</p>
<p class="noindent1">• Acute chest (fever, ↑ WBC, pulm. infilt., r/o other causes): O<sub class="calibre10">2</sub>, abx, IVF, exchange txfusion</p>
<p class="noindent1">• TIA/stroke: often exchange transfusion (goal Hgb 10) ± thrombolytics</p>
<p class="noindent1">• Gene therapy in development <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:205)</span></p>
<p class="h">Hereditary spherocytosis (HS) <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2008;372:1411)</span></p>
<p class="noindent1">• Defect in cytoskeleton of RBC membrane (ankyrin, α- and β-spectrin, band 3, &amp; pallidin)</p>
<p class="noindent1">• Most common in N. European populations (1/5000 births); ⊕ FHx (75% of Pts)</p>
<p class="noindent1">• Anemia, jaundice (mostly neonates), splenomegaly, pigmented gallstones</p>
<p class="noindent1">• Diagnosis: spherocytes on smear, ⊕ osmotic fragility test (~80% Se), ↓ eosin-5-maleimide (EMA) binding (93% Se; 99% Sp; <span class="r2">Haemat</span><span class="r1"> 2012;97:516</span>), acidified glycerol lysis test (Se 95%)</p>
<p class="noindent1">• Treatment: folate, transfusions, splenectomy for moderate and severe HS (balance w/ ↑ risk of future thrombosis and infection; <span class="r2">J Thromb Haemost</span> <span class="r1">2008;6:1289</span>)</p>
<p class="h">Paroxysmal nocturnal hemoglobinuria <span class="r">(see above)</span></p>
<p class="h">Autoimmune hemolytic anemia (AIHA)</p>
<p class="noindent1">• Acquired, antibody-mediated RBC destruction</p>
<p class="noindent1">• <b class="calibre7">Warm AIHA: IgG</b> Abs opsonize RBCs <i class="calibre6">at body temp</i> → removal by spleen</p>
<p class="noindent2">Etiologies: idiopathic, lymphoproliferative (CLL, NHL), autoimmune (SLE), drugs, HIV, babesiosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:939)</span></p>
<p class="noindent1">• <b class="calibre7">Cold AIHA: IgM</b> Ab binds to RBCs <i class="calibre6">at temp</i> &lt;<i class="calibre6">37</i>°<i class="calibre6">C</i> → <b class="calibre7">complement fixation</b> → intravascular hemolysis and acrocyanosis on exposure to cold</p>
<p class="noindent2">Etiologies: idiopathic, lymphoprolif. disorders (eg, Waldenström’s; monoclonal), <b class="calibre7"><i class="calibre6">Mycoplasma pneumoniae</i></b> infxn and infectious mononucleosis (polyclonal)</p>
<p class="noindent1">• Diagnosis: spherocytes on smear, ⊕ <b class="calibre7">Coombs’;</b> ✓ cold agglutinin titer, splenomegaly</p>
<p class="noindent1">• Treatment <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2017;129:2971)</span>: treat underlying disease</p>
<p class="noindent2"><b class="calibre7">Warm AIHA:</b> corticosteroids ± splenectomy, IVIg, cytotoxic agents, rituximab</p>
<p class="noindent2"><b class="calibre7">Cold AIHA:</b> avoid cold; steroids ineffective; rituximab <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2004;103:2925)</span>; complement inhibitors (sutimlimab) approved for cold agglutinin disease <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:1323)</span></p>
<p class="h">Drug-induced hemolytic anemia</p>
<p class="noindent1">• Acquired, Ab-drug mediated destruction vs. direct drug effect. Abx: ceph., sulfa drugs, rifampin, ribavirin. CV: methyldopa, procainamide, quinidine, thiazides. TCAs, phenothiazines, NSAIDs, sulfonylureas, MTX, 5-FU, rasburicase (G6PD defic.)</p>
<p class="noindent1">• Diagnosis: Coombs’ usually negative, ↑ LDH; Treatment: discontinue offending agent</p>
<p class="h">Microangiopathic hemolytic anemia <span class="r1">(</span><span class="r2">MAHA; NEJM</span> <span class="r1">2014;371:654)</span></p>
<p class="noindent1">• Intra-arteriolar fibrin damages RBCs → acquired intravascular hemolysis</p>
<p class="noindent1">• Etiologies: <b class="calibre7">hemolytic-uremic syndrome</b> (<b class="calibre7">HUS</b>), <b class="calibre7">thrombotic thrombocytopenic purpura</b> (<b class="calibre7">TTP</b>), <b class="calibre7">disseminated intravascular coagulation</b> (<b class="calibre7">DIC</b>), malignancy, malignant HTN, eclampsia/HELLP, mech. cardiac valves, infected vascular prostheses</p>
<p class="noindent1">• Diagnosis: <b class="calibre7">schistocytes</b> ± ↓ plts ± ↑ PT in DIC, ↑ Cr in HUS, ↑ LFTs in HELLP</p>
<p class="noindent1">• Rx: see “DIC” section in “Coagulopathies” and “TTP/HUS” sections in “Platelet Disorders”</p>
<p class="h">Hypersplenism</p>
<p class="noindent1">• Stasis/trapping in spleen → Mϕ attack/remodel RBCs → spherocytosis → hemolysis</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Causes of Splenomegaly</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Etiology</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments<sup class="calibre27"><a id="fn89-s1" class="calibre8"></a><a href="part0011.html#rfn89-s1" class="calibre8">*</a></sup></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">RES hyperplasia</p></td>
<td class="th1"><p class="tbody">Hemolytic anemia, sickle cell disease, <b class="calibre7">thalassemia major</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Immune hyperplasia</p></td>
<td class="th1"><p class="tbody">Infxn [HIV, EBV, CMV, TB, <b class="calibre7">malaria</b>, <b class="calibre7">kala azar</b> (“black water fever” from visceral leishmaniasis), <b class="calibre7"><i class="calibre6">Mycobacterium avium</i></b> complex], autoimmune disorders (SLE, RA w/ Felty’s syndrome), sarcoidosis, serum sickness</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Congestion</p></td>
<td class="th1"><p class="tbody">Cirrhosis, CHF, portal/splenic vein thrombosis, <b class="calibre7">schistosomiasis</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Infiltration (nonmalignant)</p></td>
<td class="th1"><p class="tbody">Lysosomal storage disorders (<b class="calibre7">Gaucher’s</b>, Niemann-Pick), glycogen storage diseases, histiocytosis X, splenic cysts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">MPN (CML, PMF, PV, ET), CMML, leukemia, lymphoma (NHL, HL, hairy cell leukemia, CLL, PLL, WM),</b> T-LGL, myeloma, amyloid</p></td>
</tr>
</tbody>
</table>
<p class="tfn">RES = reticuloendothelial system; <sup class="calibre22"><a id="rfn89-s1" class="calibre8"></a><a href="part0011.html#fn89-s1" class="calibre8">*</a></sup><b class="calibre7">boldface</b> = causes of massive splenomegaly.</p>
<h2 class="ct"><a id="h63" class="calibre8"></a><a id="page_5-6" class="calibre8"></a><a href="part0003.html#rh71" class="calibre8">DISORDERS OF HEMOSTASIS</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Clinical Characteristics of Bleeding Disorders</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Platelet/Vascular Defect</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Coagulation Defect</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Site</p></td>
<td class="th1"><p class="tbody">Skin, mucous membranes</p></td>
<td class="th1"><p class="tbody">Deep in soft tissues (muscles, joints)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Lesions</p></td>
<td class="th1"><p class="tbody">Petechiae, ecchymoses</p></td>
<td class="th1"><p class="tbody">Hemarthroses, hematomas</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Bleeding</p></td>
<td class="th1"><p class="tbody">After minor cuts: yes</p>
<p class="tbody">After surgery: immediate, mild</p></td>
<td class="th1"><p class="tbody">After minor cuts: unusual</p>
<p class="tbody">After surgery: delayed, severe</p></td>
</tr>
</tbody>
</table>
<div class="cap">
<p class="caption"><a id="fig5-3" class="calibre4"></a><b class="calibre7">Figure 5-3</b> Approach to abnormal hemostasis <span class="sm">(<i class="calibre6">NEJM</i> 2014;370:847)</span></p>
<p class="imagef1"><img src="../images/00076.jpeg" alt="" class="calibre5"/></p>
</div>
<div class="cap">
<p class="caption"><a id="fig5-4" class="calibre4"></a><b class="calibre7">Figure 5-4</b> Coagulation cascade and sites of action for anticoagulants <span class="sm">(<i class="calibre6">NEJM</i> 2008;359:938)</span></p>
<p class="imagef1"><img src="../images/00077.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">See “Coagulopathies” for reversal agents for anticoagulants. APC, activated protein C; AT, antithrombin; PrC, protein C; PrS, protein S; TF, tissue factor; TFPI, tissue factor pathway inhib.</p>
<p class="h">Purpura <span class="r">(</span><i class="calibre6">nonblanching</i> <span class="r">purple/red lesions due to extravasation of RBCs into dermis)</span></p>
<p class="noindent1">• <b class="calibre7">Nonpalpable</b> (macular; ≤3 mm in diameter = petechiae; &gt;3 mm = ecchymoses)</p>
<p class="noindent2"><b class="calibre7">platelet disorder:</b> thrombocytopenia, defect in platelet fxn</p>
<p class="noindent2"><b class="calibre7">thromboemboli:</b> DIC, TTP, cholesterol or fat emboli, other thrombotic microangiopathies</p>
<p class="noindent2"><b class="calibre7">trauma or vascular fragility</b>: amyloidosis, Ehlers-Danlos, scurvy</p>
<p class="noindent1">• <b class="calibre7">Palpable</b> (papular); <b class="calibre7">vasculitis:</b> leukocytoclastic, HSP, PAN, RMSF; <b class="calibre7">infectious emboli:</b> meningococcemia, bacterial endocarditis</p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">Purpura fulminans</i></b> (aka retiform purpura): <b class="calibre7">purpura</b> + <b class="calibre7">hypotension</b> + <b class="calibre7">DIC;</b> typically due to infxn/sepsis, protein C or S deficiency or APS (see section on DIC)</p>
<h2 class="ct"><a id="h64" class="calibre8"></a><a id="page_5-7" class="calibre8"></a><a href="part0003.html#rh72" class="calibre8">PLATELET DISORDERS</a></h2>
<p class="h1cr">T<small class="calibre31">HROMBOCYTOPENIA</small> <span class="r5">(Plt count &lt;150,000/μL)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Thrombocytopenia and Risk of Bleeding</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Platelet Count</b> (cells/µL)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Risk</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">50,000–100,000</p></td>
<td class="th1"><p class="tbody">Risk with major trauma; can proceed with general surgery</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;50,000</p></td>
<td class="th1"><p class="tbody">Risk with minor trauma or surgery</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;20,000</p></td>
<td class="th1"><p class="tbody">Risk of <i class="calibre6">spontaneous</i> bleeding (less so with ITP)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;10,000</p></td>
<td class="th1"><p class="tbody">Risk of severe, life-threatening bleeding</p></td>
</tr>
</tbody>
</table>
<p class="h">Etiologies</p>
<p class="noindent1">• <b class="calibre7">↓ production</b></p>
<p class="noindent2"><b class="calibre7">Hypocellular bone marrow:</b> aplastic anemia (qv), rarely MDS, drugs (eg, thiazides, antibiotics, chemotherapy), alcohol, cirrhosis, viral infection</p>
<p class="noindent2"><b class="calibre7">Hypercellular bone marrow:</b> MDS, leukemia, severe megaloblastic anemia</p>
<p class="noindent2"><b class="calibre7">Marrow replacement:</b> myelofibrosis, hematologic and solid malignancies, granulomas</p>
<p class="noindent1">• <b class="calibre7">↑ destruction</b></p>
<p class="noindent2"><b class="calibre7">Immune-mediated</b> (distinguish primary from secondary; <span class="r2">Blood</span><span class="r1"> 2009;113:2386</span>)</p>
<p class="noindent3">1° (idiopathic): immune thrombocytopenic purpura (<b class="calibre7">ITP</b>, see below)</p>
<p class="noindent3">2°: infxn (<b class="calibre7">HIV</b>, <b class="calibre7">HCV</b>, HSV), collagen vascular dis. (<b class="calibre7">SLE</b>), APS, lymphoprolif. (<b class="calibre7">CLL</b>, lymphoma), drugs (<i class="calibre6">many</i>, including <b class="calibre7">heparin</b>, abciximab, quinidine, sulfonamides, vanco), alloimmune (posttransfusion), vaccine-induced</p>
<p class="noindent2"><b class="calibre7">Non–immune-mediated: MAHA</b> (DIC, HUS, TTP), ticlopidine/clopidogrel, vasculitis, preeclampsia/HELLP, cardiopulm bypass, CVVH, IABP, cavernous hemangioma, viral</p>
<p class="noindent1">• <b class="calibre7">Abnormal distribution or pooling:</b> splenic sequestration, dilutional, hypothermia</p>
<p class="noindent1">• <b class="calibre7">Critical illness</b>: multifactorial <span class="r1">(</span><span class="r2">Hematology Am Soc Hematol Educ Program</span> <span class="r1">2017;1:660)</span></p>
<p class="noindent1">• <b class="calibre7">Unknown:</b> ehrlichiosis/anaplasmosis, babesiosis, RMSF</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• H&amp;P: meds, infxns, underlying conditions, splenomegaly, lymph nodes, <b class="calibre7">bleeding hx</b></p>
<p class="noindent1">• <b class="calibre7">CBC with differential:</b> isolated thrombocytopenia <i class="calibre6">vs.</i> multilineage involvement</p>
<p class="noindent1">• <b class="calibre7">Peripheral smear</b> (r/o pseudothrombocytopenia due to platelet clumping)</p>
<p class="noindent2">↑ destruction → look for large plts, ↑ MPV, <b class="calibre7">schistocytes</b> (see “Peripheral Smear” inserts)</p>
<p class="noindent2">↓ production → rarely limited to platelets → look for <b class="calibre7">blasts</b>, hypersegmented PMNs, leukoerythroblastic Δs; can see inclusion bodies (anaplasma), parasites (<i class="calibre6">Babesia</i>)</p>
<div class="cap">
<p class="caption"><a id="fig5-5" class="calibre4"></a><b class="calibre7">Figure 5-5</b> Approach to thrombocytopenia</p>
<p class="imagef1"><img src="../images/00078.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="noindent1">• Additional laboratory evaluations as indicated (eg, viral titers, flow cytometry, ANA, APLA)</p>
<p class="noindent2">if anemia: ✓ reticulocyte count, LDH, haptoglobin, bilirubin to detect hemolysis</p>
<p class="noindent2">if hemolytic anemia: ✓ PT, PTT, fibrinogen, D-dimer, Coombs, ANA</p>
<p class="noindent2">BM bx for unexplained thrombocytopenia, esp. if associated with splenomegaly</p>
<p class="h">Primary immune thrombocytopenic purpura (ITP) <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2010;115:168)</span></p>
<p class="noindent1">• Isolated thrombocytopenia due to immune plt <i class="calibre6">destruction</i> (auto-Ab to plts) &amp; ↓ <i class="calibre6">production</i> (auto-Ab to megakaryocytes) without precipitant</p>
<p class="noindent1">• Clinical manifestations: insidious onset of mucocutaneous bleeding; ♀:♂ = 3:1</p>
<p class="noindent1">• <i class="calibre6">Diagnosis of exclusion (r/o 2</i><b class="calibre7">°</b><i class="calibre6"> ITP);</i> no robust clinical or lab parameters, but typically:</p>
<p class="noindent2">CBC: isolated ↓ plt (&lt;100,000/µL); 10% have ITP + AIHA = Evans syndrome</p>
<p class="noindent2">Peripheral smear: large platelets (not specific), r/o pseudothrombocytopenia</p>
<p class="noindent2">BM bx: ↑ megakaryocytes, nl cellularity. Consider if other CBC or smear abnl or diagnostic uncertainty <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2011;117:4910)</span>.</p>
<p class="noindent2">✓ HBSAg &amp; anti-HBc prior to rituximab (and before IVIg, which could alter results)</p>
<p class="noindent1">• Treatment: rarely indicated if plt &gt;50,000/µL unless bleeding, trauma/surgery, anticoag.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><a id="page_5-8" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Treatment of Primary ITP in Adults</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Approach</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Notes</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbody"><b class="calibre7">First-line or upfront therapy</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Steroids:</b> prednisone 0.5–2 mg/kg/d PO tapered ~4 wk, or dexamethasone 40 mg PO × 4 d</p></td>
<td class="th1"><p class="tbody">↓ Mϕ FcR &amp; ↓ anti-plt Ab</p>
<p class="tbody">70–90% have initial response</p>
<p class="tbody">~20% sustained remission</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">IVIg</b> (1 g/kg/d IV × 2–3 d)</p>
<p class="tbody"><i class="calibre6">Consider if need rapid</i> ↑ <i class="calibre6">in plt in 24–48 hrs; lasts 2–6 wks</i></p></td>
<td class="th1"><p class="tbody">Blocks Mϕ FcR, ↓ anti-plt Ab</p>
<p class="tbody">Interferes w/ Mϕ uptake Ab-coated plts; 80% have initial response</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Anti-Rh(D) Ig: alternative to IVIg if RBC Rh(D) ⊕; 50–75 mcg/kg/d</p></td>
<td class="th1"><p class="tbody">Ab-coated RBCs overwhelm Mϕ FcR</p>
<p class="tbody">Avoid if h/o hemolysis; <i class="calibre6">not often used</i></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="5"><p class="tbody"><b class="calibre7">Second-line or maint. therapy</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Romiplostim</b>, <b class="calibre7">el/avatrombopag</b></p></td>
<td class="th1"><p class="tbody">TPO-R agonists → ↑ plt prod</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Rituximab</b> (anti-CD20) ± dex</p></td>
<td class="th1"><p class="tbody">anti–B-cell Ab</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Splenectomy<sup class="calibre27"><a id="fn92-s1" class="calibre8"></a><a href="part0011.html#rfn92-s1" class="calibre8">*</a></sup></b> <i class="calibre6">(less common)</i></p></td>
<td class="th1"><p class="tbody">~65% long-term remission</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AZA, CYC, MMF</p></td>
<td class="th1"><p class="tbody">Immunosuppressants</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Danazol: 600 mg/d</p></td>
<td class="th1"><p class="tbody">Androgen (hirsutism) ↓ plt clearance</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbody"><b class="calibre7">Chronic/ refractory</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Romiplostim</b> or <b class="calibre7">eltrombopag</b></p></td>
<td class="th1"><p class="tbody">Allows splenectomy to be deferred</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Fostamatinib:</b> 75–150 mg BID</p></td>
<td class="th1"><p class="tbody">Spleen tyrosine kinase (SYK) inhibitor</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Vinca alkaloids</b></p></td>
<td class="th1"><p class="tbody">Good initial response, less durable</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbody"><b class="calibre7">Bleeding</b></p></td>
<td class="th1"><p class="tbody">Aminocaproic acid</p></td>
<td class="th1"><p class="tbody">Inhibits plasmin activation</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Methylprednisolone 1 g/d IV × 3 d</p></td>
<td class="th1"><p class="tbody">See above</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">IVIg</p></td>
<td class="th1"><p class="tbody">See above</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Platelet transfusion</p></td>
<td class="th1"><p class="tbody">Given w/ IVIg or anti-Rh(D)</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn92-s1" class="calibre8"></a><a href="part0011.html#fn92-s1" class="calibre8">*</a></sup>Post-splenectomy vaccinations needed. (<i class="calibre6">Blood Adv</i> 2019;3:3829; <i class="calibre6">Eur J Haem</i> 2018;100:304)</p>
<p class="h">Secondary immune thrombocytopenic purpura (2° ITP)</p>
<p class="noindent1">• Diagnosis: viral serologies (HIV, HCV, HBV, EBV), <i class="calibre6">H. pylori</i> Ab, ANA, pregnancy test, APLA, TSH, parvovirus, &amp; CMV PCR. <i class="calibre6">Anti-plt Ab tests often sent but less useful.</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Heparin-Induced Thrombocytopenias</b> <span class="sm">(<i class="calibre6">Chest</i> 2012;141:e495S; <i class="calibre6">NEJM</i> 2015;373:252)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Type I</b> (not clin. signif)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Type II</b> (clinically significant HIT)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mechanism</b></p></td>
<td class="th1"><p class="tbody">Direct effect of heparin (non-immune)</p></td>
<td class="th1"><p class="tbody">Immune (Ab)-mediated</p>
<p class="tbody">IgG against plt factor 4—heparin complex</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Incidence</b></p></td>
<td class="th1"><p class="tbody">10–20%</p></td>
<td class="th1"><p class="tbody">1–3% with UFH, 0–0.8% LMWH</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Onset</b></p></td>
<td class="th1"><p class="tbody">After 1–4 d of heparin therapy</p></td>
<td class="th1"><p class="tbody">After 4–10 d, but can occur in &lt;24 h if prior exposure w/in 100 d (persistent Ab). Postop highest risk. Can occur after heparin d/c.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Platelet nadir</b></p></td>
<td class="th1"><p class="tbody">&gt;100,000/µL</p></td>
<td class="th1"><p class="tbody">~60,000/µL, ↓ &gt;50%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Sequelae</b></p></td>
<td class="th1"><p class="tbody">None</p></td>
<td class="th1"><p class="tbody">Thrombotic events <b class="calibre7">(HITT)</b> in 30–50%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Management</b></p></td>
<td class="th1"><p class="tbody">Can continue heparin and observe</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Discontinue heparin</b></p>
<p class="tbody">Alternative anticoagulation</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Treat underlying etiology</p>
<p class="noindent1">• Pathophysiology (type II): Ab binds heparin-PF4 → immune complex binds to plt → <b class="calibre7">plt activation</b>, further PF4 release → plt aggregates removed from circulation → <b class="calibre7">thrombocytopenia;</b> procoagulants released by plts and tissue factor released by endothelial cells damaged by HIT Abs → <b class="calibre7">prothrombotic state</b></p>
<p class="noindent1">• Diagnosis <i class="calibre6">(need clinical + pathologic)</i></p>
<p class="noindent2"><b class="calibre7">Clinical:</b> plt &lt;100k <i class="calibre6">or</i> ↓ 50% from baseline; or <b class="calibre7">venous</b> (DVT/PE) or <b class="calibre7">arterial</b> (limb ischemia, CVA, MI) thrombosis (4:1 ratio); skin necrosis; ? ↑ heparin resistance</p>
<p class="noindent2"><b class="calibre7">Pathologic:</b> ⊕ HIT Ab using PF4-heparin ELISA (≥90% Se, IgG-specific ELISA Sp 94%), may confirm w/ functional plt assay (serotonin-release) (&gt;95% Se/Sp)</p>
<p class="noindent2">Clinical context important: HIT Ab (esp. IgM ELISA) may be ⊕ in 10–20% of Pts on UFH/LMWH <span class="r1">(</span><span class="r2">Am J Hem</span> <span class="r1">1996;52:90)</span>, up to 50% of cardiac bypass Pts <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">1997;95:1242)</span></p>
<p class="noindent2">Pretest prob w/ <b class="calibre7">“4 T’s” criteria</b> <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2012;120:4160)</span>: ≤3 points → 99% NPV, investigate other causes; 4–5 points 22% PPV &amp; 6–8 points 64% PPV, ✓ lab test &amp; replace UFH</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre20"/>
<col class="calibre20"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Evaluation of Suspected HIT (“4T’s”)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Factor</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">2 Points</b></p></td>
<td class="th1"><p class="tbody">1 <b class="calibre7">Point</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">0 Points</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Thrombo-cytopenia</b></p></td>
<td class="th1"><p class="tbody">↓ &gt;50% <i class="calibre6">and</i> nadir ≥20k</p></td>
<td class="th1"><p class="tbody">↓ 30–50% <i class="calibre6">or</i> nadir 10–19k</p></td>
<td class="th1"><p class="tbody">↓ &lt;30% <i class="calibre6">or</i> nadir &lt;10k</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Timing</b></p></td>
<td class="th1"><p class="tbody">5–10 d <i class="calibre6">or</i> ≤1 d if heparin w/in 30 d</p></td>
<td class="th1"><p class="tbody">? 5–10 d (but not clear), &gt;10 d <i class="calibre6">or</i> ≤1 d if hep w/in 30–100 d</p></td>
<td class="th1"><p class="tbody">≤4 d w/o recent hep</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Thrombosis</b></p></td>
<td class="th1"><p class="tbody">New thromb, skin necrosis, acute rxn after IV UFH</p></td>
<td class="th1"><p class="tbody">Prog/recurrent thromb, suspect thromb or non-nec skin lesion</p></td>
<td class="th1"><p class="tbody">None</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Other cause</b></p></td>
<td class="th1"><p class="tbody">None apparent</p></td>
<td class="th1"><p class="tbody">Possible</p></td>
<td class="th1"><p class="tbody">Definite</p></td>
</tr>
</tbody>
</table>
<p class="noindent1"><a id="page_5-9" class="calibre4"></a>• Treatment of HIT (type II) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:252;</span> <span class="r2">Blood Adv</span> <span class="r1">2018;2:3360)</span></p>
<p class="noindent2"><b class="calibre7">Discontinue heparin</b> <i class="calibre6">(incl. flushes, LMWH Ppx, heparin lines).</i> Avoid plts (anecdotal link w/ thrombosis); if given warfarin, give vit K to reverse, prevent warfarin skin necrosis.</p>
<p class="noindent2"><b class="calibre7">Nonheparin anticoag</b> (argatroban, bivalirudin; <span class="r2">NEJM</span><span class="r1"> 2013;368:737</span>) <i class="calibre6">regardless of thrombosis;</i> start warfarin when plt &gt;150k, overlap ≥5 d or DOAC <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2017;130:1104)</span></p>
<p class="noindent2">⊕ thrombosis (HITT): anticoagulate for ≥3–6 mo</p>
<p class="noindent2">⊖ thrombosis (HIT): screen for DVT; unclear duration of subsequent anticoag (until plt count recovers, often ~2–3 mo if no clot); <i class="calibre6">25–50% thrombosis rate w/in 30 d</i></p>
<p class="noindent1">• H/o HIT: if PF4 Ab ⊖ or SRA ⊖ (typically &gt;100 d after dx) → may consider re-exposure to UFH (eg, for surgery); HIT recurrence low but can be seen <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2014;123:2485)</span></p>
<p class="h">Thrombotic microangiopathies <span class="r">(TMA;</span> <span class="r2">NEJM</span><span class="r1"> 2014;371:654;</span> <span class="r2">Lancet</span><span class="r1"> 2017;390:681</span><span class="r">)</span></p>
<p class="noindent1">• Endothelial injury → plt aggreg. &amp; microvasc. thrombosis → ↓ plt &amp; RBC hemolysis (MAHA)</p>
<p class="noindent1">• Dx: unexplained <b class="calibre7">thrombocytopenia</b> (typically &lt;20k) + <b class="calibre7">MAHA</b> → <i class="calibre6">sufficient for dx</i> ⊕ <b class="calibre7">schistocytes</b> (&gt;2–3/hpf), ⊖ Coombs, normal PT/PTT &amp; fibrinogen ↑↑ LDH (tissue ischemia + hemolysis), ↑ indirect bili., ↓↓ haptoglobin, ↑ Cr (esp. in HUS)</p>
<p class="noindent2">Biopsy: arterioles filled with platelet hyaline thrombi</p>
<p class="noindent2">Ddx: DIC, vasculitis, malignant hypertension, preeclampsia/HELLP syndrome</p>
<p class="noindent1">• <b class="calibre7">Thrombotic thrombocytopenic purpura (TTP)</b></p>
<p class="noindent2">Pathophys: ↓↓ ADAMTS13 protease activity (hereditary [Upshaw Schulman Syn.] or autoAb) → vWF multimers persist on endothelial surface → plt adhesion/aggregation → thrombosis</p>
<p class="noindent2">Clinical: <b class="calibre7">pentad</b> (all 5 in only ~5%) = ↓ plts + MAHA (100%) ± Δ MS (65%) ± renal failure (50%, late feature) ± fever (25%)</p>
<p class="noindent2">PLASMIC score to discriminate TTP from other TMAs <span class="r1">(</span><span class="r2">Lancet Haematol.</span> <span class="r1">2017;4:157)</span></p>
<p class="noindent2">Rx: <b class="calibre7">urgent plasma exchange</b> ± glucocorticoids; FFP if delay to plasma exchange, caplacizumab <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:335)</span>, rituximab for 2° prevention <span class="r1">(</span><span class="r2">Blood Adv.</span> <span class="r1">2017;1:1159)</span>,</p>
<p class="noindent2"><i class="calibre6">plt transfusions contraindic.</i> → ↑ microvascular thromb <span class="r1">(</span><span class="r2">J Thromb Haemost.</span> <span class="r1">2020;18:2496)</span></p>
<p class="noindent1">• <b class="calibre7">Hemolytic-uremic syndrome (HUS)</b></p>
<p class="noindent2">Pathophys: (1) Shiga toxin damages renal endothelial cells → intrarenal thrombi; <i class="calibre6">or</i> (2) complement dysregulation (hereditary or acquired), so-called “atypical HUS”</p>
<p class="noindent2">Clinical: <b class="calibre7">triad</b> = thrombocytopenia + MAHA + renal failure (bloody diarrhea if Shiga)</p>
<p class="noindent2">Rx: supportive care; eculizumab <span class="r1">(</span><span class="r2">J Nephrol</span> <span class="r1">2017;30:127)</span>; plasma exchange if CNS sx</p>
<p class="noindent1">• <b class="calibre7">Drug-induced TMA</b> (clinically similar to TTP; <span class="r2">Blood</span><span class="r1"> 2017;129:2857</span>)</p>
<p class="noindent2">Immune-mediated (Ab reacts w/ plts &amp; endothelial cells): eg, quinine, gemcitabine?</p>
<p class="noindent2">Direct toxicity mediated: eg, gemcitabine, mitomycin, tacrolimus, CsA, bevacizumab</p>
<p class="h">Disseminated intravascular coagulation (DIC): <span class="r">see “Coagulopathies”</span></p>
<p class="h1cr">D<small class="calibre31">ISORDERS</small> <small class="calibre31">OF</small> P<small class="calibre31">LATELET</small> F<small class="calibre31">UNCTION</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Mechanisms and Etiologies of Platelet Function Abnormalities</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Function</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Inherited</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Acquired</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Adhesion</b></p></td>
<td class="th1"><p class="tbody">Bernard-Soulier; vWD</p></td>
<td class="th1"><p class="tbody">Uremia; acquired vWD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Aggregation</b></p></td>
<td class="th1"><p class="tbody">Afibrinogenemia</p>
<p class="tbody">Glanzmann’s thrombasthenia</p></td>
<td class="th1"><p class="tbody">P2Y<sub class="calibre17">12</sub> inhibitors, GP IIb/IIIa inhibitors</p>
<p class="tbody">Dysproteinemias (myeloma)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Granule</b></p>
<p class="tbody"><b class="calibre7">release</b></p></td>
<td class="th1"><p class="tbody">Chediak-Higashi syndrome</p>
<p class="tbody">Hermansky-Pudlak syndrome</p></td>
<td class="th1"><p class="tbody">Drugs (ASA, NSAIDs); liver disease; MPN; cardiopulmonary bypass</p></td>
</tr>
</tbody>
</table>
<p class="h">Tests of platelet function</p>
<p class="noindent1">• Platelet aggregation tests: measure aggregation in response to agonists (eg, ADP)</p>
<p class="h">von Willebrand’s disease (vWD) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:2067)</span></p>
<p class="noindent1">• von Willebrand’s factor (vWF) function = platelet glue &amp; plasma carrier of factor VIII</p>
<p class="noindent1">• vWD most common inherited bleeding disorder; ~85% (type 1) have partial quantitative vWF defic., ~15% (type 2) qualitative defic., &lt;1% (type 3) total/near-total absence of vWF</p>
<p class="noindent1">• Acquired vWD: a/w many disorders (malig, MPN w/ ↑ plt count; autoimmune; hypo-thyroidism; drugs) and caused by different mechanisms (anti-vWF Abs, ↑ clearance, ↓ synthesis); Heyde’s syndrome = vWF destruction by severe AS, a/w GI AVMs/bleed</p>
<p class="noindent1">• Diagnosis: ↓ <b class="calibre7">vWF:Ag</b>, ↓ <b class="calibre7">vWF activity</b> (measured by ristocetin cofactor assay), ↓ <b class="calibre7">factor VIII</b>, ± ↑ PTT, ± ↓ platelets; confirm with <b class="calibre7">vWF multimer analysis</b></p>
<p class="noindent1">• Clinical condition, factor VIII levels and ristocetin cofactor assay useful to guide Rx decision</p>
<p class="noindent1">• Rx: <b class="calibre7">desmopressin</b> (dDAVP, IV/IN; tachyphylaxis) → ↑ endothelial cell release of vWF; efficacy depends on type (avoid in type 2), ∴ ✓ response before use w/ bleeding or procedures; <b class="calibre7">vWF replacement:</b> cryo, vWF-rich factor VIII concentrates, recomb. vWF</p>
<p class="h">Uremic bleeding</p>
<p class="noindent1">• Uremia → platelet dysfunction including ↓ aggregation, impaired adhesiveness</p>
<p class="noindent1">• Treatment: <b class="calibre7">dDAVP</b>, cryoprecipitate, correct anemia (improves plt aggregation and adhesion by increasing plt interactions with endothelium), consider holding anti-plt agents</p>
<h2 class="ct"><a id="h65" class="calibre8"></a><a id="page_5-10" class="calibre8"></a><a href="part0003.html#rh73" class="calibre8">COAGULOPATHIES</a></h2>
<p class="imaget"><img src="../images/00079.jpeg" alt="" class="calibre5"/></p>
<p class="h">Further coagulation tests <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;316:2146)</span></p>
<p class="noindent1">• Mixing study: useful if ↑ PT or PTT; mix Pt’s plasma 1:1 w/ normal plasma and retest</p>
<p class="noindent2">PT/PTT normalizes → factor <b class="calibre7">deficiency;</b> PT/PTT remains elevated → factor <b class="calibre7">inhibitor</b></p>
<p class="noindent1">• Coagulation factor levels: useful if mixing study suggests factor deficiency</p>
<p class="noindent2">DIC → all factors consumed; ∴ ↓ factors V and VIII</p>
<p class="noindent2">Liver disease → ↓ all factors <i class="calibre6">except</i> VIII; ∴↓ factor V, normal factor VIII</p>
<p class="noindent2">Vitamin K deficiency → ↓ factors II, VII, IX, X (and protein C, S); ∴ normal V and VIII</p>
<p class="noindent1">• <b class="calibre7">DIC screen:</b> ↓ fibrinogen (consumed), fibrin degradation products (FDPs, ⊕ from intense fibrinolysis), ↑ D-dimer (more specific FDP test that detects degradation of X-linked fibrin)</p>
<p class="h">Hemophilias <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:187)</span></p>
<p class="noindent1">• X-linked recessive <b class="calibre7">factor VIII</b> (hemophilia A) or <b class="calibre7">factor IX</b> (hemophilia B) <b class="calibre7">deficiency</b></p>
<p class="noindent1">• Classification: mild (5–25% normal factor activity), moderate (1–5%), or severe (&lt;1%)</p>
<p class="noindent1">• Clinical manifestations: hematomas, hemarthroses, bruising, bleeding (mucosal, GI, GU)</p>
<p class="noindent1">• Diagnosis: ↑ PTT (normalizes w/mixing study), normal PT &amp; vWF, ↓ factor VIII or IX</p>
<p class="noindent1">• Prophylaxis indicated if &lt;1% activity of factor VIII or IX</p>
<p class="noindent1">• Rx: purified/recomb. factor VIII or IX; desmopressin (mild disease); anti-fibrinolytics (aminocaproic acid; tranexamic acid); cryo (FVIII); emicizumab (bridges factor IX and X), effective for hemophilia A w/ and w/o inhibitors <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:809 &amp; 2018;379:811)</span></p>
<p class="h">Coagulation factor inhibitors <span class="r">(anti-factor antibodies; anti-factor VIII most common)</span></p>
<p class="noindent1">• Etiologies: hemophilia; postpartum; lymphoproliferative &amp; autoimmune disorders; cancers</p>
<p class="noindent1">• Diagnosis: ↑ PTT (does <i class="calibre6">not</i> normalize w/ mixing study); Bethesda assay quantitates titer</p>
<p class="noindent1">• Rx: if high titer → <b class="calibre7">recomb. factor VIIa</b>, porcine factor concentrates, activated prothrombin complex; for others → high-purity human factor, plasmapheresis, immunosuppression</p>
<p class="h">Disseminated intravascular coagulation (DIC) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:847)</span></p>
<p class="noindent1">• Etiologies: trauma, shock, infection, malignancy (esp. APL), obstetric complications</p>
<p class="noindent1">• Pathogenesis: <i class="calibre6">massive</i> activation of coagulation that overwhelms control mechanisms</p>
<p class="noindent2"><b class="calibre7">Thrombosis</b> in microvasculature → ischemia + microangiopathic hemolytic anemia</p>
<p class="noindent2">Acute consumption of coagulation factors and platelets → <b class="calibre7">bleeding</b></p>
<p class="noindent2">Chronic DIC → able to compensate by ↑ factors and platelets → <b class="calibre7">thrombosis</b></p>
<p class="noindent1">• Diagnosis: ↑ PT, ↑ PTT, ↓ <b class="calibre7">fibrinogen</b> (may be <i class="calibre6">nl</i> b/c acute phase), ⊕ <b class="calibre7">FDP</b>/<b class="calibre7">D-dimer</b>, ↓ plts, ⊕ schistos, ↑ LDH, ↓ hapto; <i class="calibre6">chronic</i> DIC: ⊕ FDP/D-dimer, variable plts, other labs nl</p>
<p class="noindent1">• Treatment: Rx underlying process; support w/ <b class="calibre7">FFP</b>, <b class="calibre7">cryo</b> (goal fbgn &gt;100 mg/dL) &amp; <b class="calibre7">plts</b></p>
<p class="h">Vitamin K deficiency</p>
<p class="noindent1">• Etiologies: malnutrition, ↓ absorption (antibiotic suppression of vitamin K-producing intestinal flora or malabsorption), liver disease (↓ stores), warfarin</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre25"/>
<col class="calibre25"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Properties and Antidotes for Anticoagulants &amp; Fibrinolytics</b> <span class="sm">(<i class="calibre6">Circ</i> 2016;134:248)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Anticoag.</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">t</b><sub class="calibre17">1<b class="calibre7">/2</b></sub></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Labs</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Rx for O/D w/ Serious Bleeding</b> (+ d/c anticoag)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">UFH</p></td>
<td class="th1"><p class="tbodyc">60–90′, RES</p></td>
<td class="th1"><p class="tbodyc">↑ PTT</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Protamine</b> IV 1 mg/100 U UFH (max 50 mg). For infusions, dose to reverse 2× UFH given per h.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">LMWH</p></td>
<td class="th1"><p class="tbodyc">2–7°, K</p></td>
<td class="th1"><p class="tbodyc">anti-Xa<sup class="calibre27"><a id="fn96-s1" class="calibre8"></a><a href="part0011.html#rfn96-s1" class="calibre8">*</a></sup></p></td>
<td class="th1"><p class="tbodyh">Protamine reverses ~60%. 1 mg per 1 mg enox.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Bivalirudin</p></td>
<td class="th1"><p class="tbodyc">25′, K</p></td>
<td class="th1"><p class="tbodyc">↑ PTT</p></td>
<td class="th1"><p class="tbodyh">Dialysis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Argatroban</p></td>
<td class="th1"><p class="tbodyc">45′, L</p></td>
<td class="th1"><p class="tbodyc">↑ PTT</p></td>
<td class="th1"><p class="tbodyh">? Dialysis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Warfarin</p></td>
<td class="th1"><p class="tbodyc">36°, L</p></td>
<td class="th1"><p class="tbodyc">↑ PT</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">No bleeding:</i> vit K 2.5 mg PO if INR &gt;9, o/w no e/o clinical benefit <span class="sm">(<i class="calibre6">Blood Adv</i> 2019;3:789)</span></p>
<p class="tbodyh"><i class="calibre6">Bleeding:</i> <b class="calibre7">vit. K</b> 10 mg IV + either 4F-PCC (KCentra, 25, 35, or 50 U/kg for INR 2–4, 4–6, or &gt;6) or <b class="calibre7">FFP</b> 2–4 U IV q6–8h (slower, more volume)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fibrinolytic</p></td>
<td class="th1"><p class="tbodyc">20′, LK</p></td>
<td class="th1"><p class="tbodyc">↓ fbgn</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Cryo</b>, <b class="calibre7">FFP</b>, ± tranexamic or aminocaproic acid</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh">Rivaroxaban</p>
<p class="tbodyh">Apixaban</p>
<p class="tbodyh">Edoxaban</p></td>
<td class="th1"><p class="tbodyc">8–12°,</p>
<p class="tbodyc">K &gt;L</p></td>
<td class="th1"><p class="tbodyc">↑ PT<sup class="calibre27"><a href="part0011.html#rfn96-s1" class="calibre8">*</a></sup></p>
<p class="tbodyc">anti-Xa<sup class="calibre27"><a href="part0011.html#rfn96-s1" class="calibre8">*</a></sup></p></td>
<td class="th1"><p class="tbodyh">Andexanet alfa (factor Xa decoy receptor): 800 mg bolus (30 mg/min) → 8 mg/min infusion (½ of above if taking ½ dose DOAC or ≥8 hrs since last dose; <span class="sm"><i class="calibre6">NEJM</i> 2019;380:1326)</span>; 4F-PCC if andexanet not available</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Dabigatran</p></td>
<td class="th1"><p class="tbodyc">~12°, K</p></td>
<td class="th1"><p class="tbodyc">↑ PTT<sup class="calibre27"><a href="part0011.html#rfn96-s1" class="calibre8">*</a></sup></p></td>
<td class="th1"><p class="tbodyh">Idarucizumab: mAb binds drug <span class="sm">(<i class="calibre6">NEJM</i> 2017;377:431)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn96-s1" class="calibre8"></a><a href="part0011.html#fn96-s1" class="calibre8">*</a></sup>Routine monitoring not performed. Mode of excretion: K, kidney; L, liver; RES, reticuloendothelial system. 4F-PCC: prothrombin complex concentrate (FII, VII, IX, X; Protein C &amp; S). Anti-fibrinolytics: tranexamic, aminocaproic acid.</p>
<h2 class="ct"><a id="h66" class="calibre8"></a><a id="page_5-11" class="calibre8"></a><a href="part0003.html#rh74" class="calibre8">HYPERCOAGULABLE STATES</a></h2>
<p class="h2c"><i class="calibre6">Suspect in Pts with venous or arterial thrombosis at young age or unusual locations, recurrent thromboses or pregnancy loss, or</i> ⊕ <i class="calibre6">FHx</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre25"/>
<col class="calibre28"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Inherited Hypercoagulable States</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Risk Factor</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Prevalence</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">VTE<sup class="calibre27"><a id="fn97-s1" class="calibre8"></a><a href="part0011.html#rfn97-s1" class="calibre8">*</a></sup></b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Factor V Leiden</p></td>
<td class="th1"><p class="tbody">3–7%</p></td>
<td class="th1"><p class="tbody">2.65</p></td>
<td class="th1"><p class="tbody">Activated protein C (APC) resistance</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Prothrombin mutation</p></td>
<td class="th1"><p class="tbody">2%</p></td>
<td class="th1"><p class="tbody">1.45</p></td>
<td class="th1"><p class="tbody">G20210A → ↑ prothrombin level</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hyperhomocysteinemia</p></td>
<td class="th1"><p class="tbody">5–10%</p></td>
<td class="th1"><p class="tbody">_</p></td>
<td class="th1"><p class="tbody">Inherited or acquired (vitamin defic., hypothyroid, renal insufficiency)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Protein C deficiency</p></td>
<td class="th1"><p class="tbody">0.02–0.05%</p></td>
<td class="th1"><p class="tbody">2.8</p></td>
<td class="th1"><p class="tbody">Warfarin-induced skin necrosis risk</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Protein S deficiency</p></td>
<td class="th1"><p class="tbody">0.01–1%</p></td>
<td class="th1"><p class="tbody">2.8</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Antithrombin III def.</p></td>
<td class="th1"><p class="tbody">0.04%</p></td>
<td class="th1"><p class="tbody">2.8</p></td>
<td class="th1"><p class="tbody">May be heparin resistant</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn97-s1" class="calibre8"></a><a href="part0011.html#fn97-s1" class="calibre8">*</a></sup>Relative risk of <b class="calibre7">recurrent</b> VTE compared to patient w/o respective thrombophilia (<i class="calibre6">JAMA</i> 2009;301:2472)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Vascular Beds Affected by Inherited and Acquired Hypercoagulable States</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Venous</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Venous and Arterial</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Inher.</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Factor V Leiden</b></p>
<p class="tbodyh">Prothrombin mutation ↓ protein C, S or AT III</p></td>
<td class="th1"><p class="tbodyh">Hyperhomocysteinemia (inherited or acquired)</p>
<p class="tbodyh">Dysfibrinogenemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Acquired</b></p></td>
<td class="th1"><p class="tbodyh">Stasis: immobilization, surgery, CHF</p>
<p class="tbodyh">Malignancy</p>
<p class="tbodyh">Hormonal: OCPs, HRT, tamoxifen, pregnancy</p>
<p class="tbodyh">Nephrotic syndrome</p></td>
<td class="th1"><p class="tbodyh">Platelet defects: myeloproliferative disorders, HIT, PNH (although venous &gt;arterial)</p>
<p class="tbodyh">Hyperviscosity: polycythemia vera, Waldenström’s -macroglobulinemia, sickle cell, acute leukemia</p>
<p class="tbodyh">Vessel wall defects: vasculitis, trauma, foreign bodies</p>
<p class="tbodyh">Others: <b class="calibre7">antiphospholipid syndrome,</b> IBD</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic evaluation <span class="r">(not routinely required for initial VTE;</span> <span class="r2">NEJM</span><span class="r1"> 2017;377:1177</span>)</p>
<p class="noindent1">• APC resistance screen; prothrombin PCR test; functional assays for proteins C and S, ATIII; homocysteine level; factor VIII levels; anticardiolipin and lupus anticoagulant Ab. Also consider nephrotic syndrome, PNH (esp. if mesenteric thrombus).</p>
<p class="noindent1">• Consider <i class="calibre6">JAK2</i> mutation testing if suspect MPN or splanchnic thrombosis</p>
<p class="noindent1">• Proteins C &amp; S and ATIII levels unreliable during acute thrombosis and anticoagulation ∴ levels best assessed ≥2 wk after completing anticoagulation course</p>
<p class="noindent1">• Age-appropriate malignancy screening (occult cancer in ~4% of initial unprovoked VTE; no benefit of routine abd/pelvis CT; <span class="r2">NEJM</span><span class="r1"> 2015;373:697</span>)</p>
<p class="h">Treatment</p>
<p class="noindent1">• Asx w/ inherited risk factor: consider prophylactic anticoag. if develops acquired risk factor</p>
<p class="noindent1">• Thrombosis w/ inherited risk factor: see “Venous Thromboembolism”</p>
<p class="h">Antiphospholipid syndrome (APS) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;398:2010)</span></p>
<p class="noindent1">• Definition: dx requires ≥1 clinical &amp; ≥1 laboratory criteria</p>
<p class="noindent2">Clinical: <b class="calibre7">thrombosis</b> (any) or <b class="calibre7">complication of pregnancy</b> (≥3 spont. abortions before 10 wk or ≥1 fetal loss after 10 wk or premature birth before 34 wk)</p>
<p class="noindent2">Laboratory: ⊕ lupus anticoagulant (LA), or ⊕ <b class="calibre7">moderate–high titer</b> anticardiolipin (ACL),  or ⊕ β<sub class="calibre10">2</sub>-glycoprotein-I (β<sub class="calibre10">2</sub>-GP-I) Ab, on ≥2 occasions, at least 12 wk apart</p>
<p class="noindent1">• Features: <b class="calibre7">DVT/PE/CVA</b>, <b class="calibre7">recurrent fetal loss</b>, ↓ plts, hemolytic anemia, livedo reticularis</p>
<p class="noindent1">• “<b class="calibre7">Catastrophic APS</b>”: ≥3 organ systems in &lt;1 wk w/ ⊕ APLA &amp; tissue microthrombi; 44% mortality <span class="r1">(</span><span class="r2">Arth Rheum</span> <span class="r1">2006;54:2568)</span>; Rx w/ plasmapheresis, rituximab</p>
<p class="noindent1">• <b class="calibre7">Antiphospholipid antibodies (APLA)</b></p>
<p class="noindent2">✓<i class="calibre6"> if: SLE, age</i> &lt;<i class="calibre6">40 y &amp; arterial thromb, recurrent venous thromb, spontaneous abortion</i></p>
<p class="noindent2">ACL: Ab against cardiolipin, a mitochondrial phospholipid; IgG more specific than IgM</p>
<p class="noindent2">LA: Ab that prolongs phospholipid-dependent coagulation reactions; ∴ ↑ <b class="calibre7">PTT</b> that does <i class="calibre6">not</i> correct with mixing study but does correct with excess phospholipids or platelets; PT not affected b/c the reaction contains much more phospholipid</p>
<p class="noindent2">β<sub class="calibre10">2</sub>-GP-I: Ab against β<sub class="calibre10">2</sub>-glycoprotein-I, IgG or IgM (uncertain role of Abs in pathogenesis)</p>
<p class="noindent2">False ⊕ VDRL nontreponemal test for syphilis (cardiolipin is part of Ag complex)</p>
<p class="noindent2">Risk of thromboembolic phenomena may increase with titer of APLs</p>
<p class="noindent1">• Etiologies: primary (idiopathic) or secondary due to <b class="calibre7">autoimmune syndromes</b> (eg, SLE), <b class="calibre7">malignancy</b>, <b class="calibre7">infections</b>, drug reactions</p>
<p class="noindent1">• Treatment: UFH/LMWH → warfarin (lifelong for most Pts)</p>
<p class="noindent2">Rivaroxaban inferior to warfarin in triple positive (⊕ ACL, LA, &amp; β<sub class="calibre10">2</sub>-GP) <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2018;132:1365)</span></p>
<p class="noindent2">Initial <i class="calibre6">venous thrombosis:</i> INR 2–3 <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:1133;</span> <span class="r2">J Thromb Haemost</span> <span class="r1">2005;3:848)</span></p>
<p class="noindent2">Initial <i class="calibre6">arterial thrombosis:</i> typically INR 2–3 + ASA 81 mg/d</p>
<p class="noindent2"><i class="calibre6">Recurrent thrombosis</i> on warfarin: consider INR 3–4 vs. LMWH or fondaparinux</p>
<h2 class="ct"><a id="h67" class="calibre8"></a><a id="page_5-12" class="calibre8"></a><a href="part0003.html#rh75" class="calibre8">DISORDERS OF LEUKOCYTES</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Neutrophilia (&gt;7500–</b>1<b class="calibre7">0,000/µL)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Infection</p></td>
<td class="th1"><p class="tbody">Usually bacterial; ± toxic granulations, Döhle bodies</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Inflammation</p></td>
<td class="th1"><p class="tbody">Burn, tissue necrosis, MI, PE, collagen vascular disease</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Drugs and toxins</p></td>
<td class="th1"><p class="tbody">Corticosteroids, β-agonists, lithium, G-CSF; cigarette smoking</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Stress</p></td>
<td class="th1"><p class="tbody">Release of endogenous glucocorticoids and catecholamines</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Marrow stimulation</p></td>
<td class="th1"><p class="tbody">Hemolytic anemia, immune thrombocytopenia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Asplenia</p></td>
<td class="th1"><p class="tbody">Surgical, acquired (sickle cell), congenital (dextrocardia)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody">Can be 1° (MPN) or paraneoplastic (eg, carcinomas of lung, GI)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Leukemoid reaction</p></td>
<td class="th1"><p class="tbody">&gt;50,000/µL + left shift, not due to leukemia; unlike CML, ↑ LAP</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Neutropenia (&lt;</b>1<b class="calibre7">000/µL)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Congenital</p></td>
<td class="th1"><p class="tbody">Myelokathexis, Shwachman-Diamond-Oski, Chédiak-Higashi, retic dysgen., WHIM syndrome, cyclic neutropenia, monoMAC syndrome (↓ monos, NKs)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Infection</p></td>
<td class="th1"><p class="tbody">Viral (CMV, EBV, HIV); bacterial (<i class="calibre6">Brucella</i>, <i class="calibre6">Rickettsia</i>, TB); malaria</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nutritional</p></td>
<td class="th1"><p class="tbody">Vitamin B<sub class="calibre17">12</sub> or copper deficiency</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Drugs and toxins</p></td>
<td class="th1"><p class="tbody">Chemotherapeutics, clozapine, methimazole, TMP-SMX, NSAIDs, sulfasalazine, phenytoin <span class="sm">(<i class="calibre6">Am J Hem</i> 2009;84:428)</span>, alcohol</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody">MDS, leukemia (AML, ALL, hairy cell, LGL, others)</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Monocytosis (&gt;500/µL)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Infection</p></td>
<td class="th1"><p class="tbody">Usually TB, SBE, <i class="calibre6">Listeria</i>, <i class="calibre6">Brucella</i>, <i class="calibre6">Rickettsia</i>, fungi, parasites, syphilis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Inflammation</p></td>
<td class="th1"><p class="tbody">IBD, sarcoidosis, collagen vascular diseases</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Stress</p></td>
<td class="th1"><p class="tbody">MI, splenectomy, exercise <span class="sm">(<i class="calibre6">Cytokine</i> 2013;61:364)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody">Hodgkin lymphoma, leukemias, MPNs, carcinomas</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Eosinophilia (&gt;500/µL)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Infection</p></td>
<td class="th1"><p class="tbody">Usually parasitic (helminths)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Allergic</p></td>
<td class="th1"><p class="tbody">Drugs; asthma, hay fever, eczema; ABPA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Collagen vasc dis.</p></td>
<td class="th1"><p class="tbody">RA, EGPA (Churg-Strauss), eosinophilic fasciitis, PAN</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Endocrine</p></td>
<td class="th1"><p class="tbody">Adrenal insufficiency</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody">HL, CML, mycosis fungoides, carcinomas, systemic mastocytosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Atheroembolic dis.</p></td>
<td class="th1"><p class="tbody">Cholesterol emboli syndrome</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hypereosinophilic syndrome</p></td>
<td class="th1"><p class="tbody">Multiorgan involvement incl. heart &amp; CNS, a/w FIP1L1-PDGFRA fusion <span class="sm">(<i class="calibre6">NEJM</i> 2003;348:1201)</span>; often steroid resistant</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Basophilia (&gt;200/µL)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody">MPN, CML, AML, Hodgkin lymph.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Infection</p></td>
<td class="th1"><p class="tbody">TB, smallpox, parasites</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Alteration in BM or reticuloendothelial compartment</p></td>
<td class="th1"><p class="tbody">Hemolytic anemia, splenectomy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Inflammation or allergy</p></td>
<td class="th1"><p class="tbody">IBD, chronic airway inflammation</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Lymphocytosis (&gt;4000–5000/µL)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Infection</p></td>
<td class="th1"><p class="tbody">Usually viral; “atypical lymphocytes” with mononucleosis syndromes Other: pertussis, toxoplasmosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hypersensitivity</p></td>
<td class="th1"><p class="tbody">Drug-induced, serum sickness</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Autoimmune</p></td>
<td class="th1"><p class="tbody">Rheumatoid arthritis (large granular lymphocytes), malignant thymoma</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody">Leukemia (eg, CLL, hairy cell, LGL), lymphoma (eg, mantle cell, folic.)</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Lymphadenopathy</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Viral</p></td>
<td class="th1"><p class="tbody">HIV, EBV, CMV, HSV, VZV, hepatitis, measles, rubella</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Bacterial</p></td>
<td class="th1"><p class="tbody">Generalized (brucellosis, leptospirosis, TB, atypical mycobacteria, syphilis)</p>
<p class="tbody">Localized (streptococci, staphylococci, cat-scratch disease, tularemia)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fungal/parasitic</p></td>
<td class="th1"><p class="tbody">Histo, coccidio, paracoccidioidomycosis, toxoplasmosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Immunologic</p></td>
<td class="th1"><p class="tbody">Collagen vascular disease, drugs (eg, phenytoin), serum sickness, histiocytosis X, Castleman’s and Kawasaki disease</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neoplasm</p></td>
<td class="th1"><p class="tbody">Lymphoma, leukemia, amyloidosis, metastatic carcinoma</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Other</p></td>
<td class="th1"><p class="tbody">Sarcoidosis; lipid storage diseases</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Factors that favor biopsy</p></td>
<td class="th1"><p class="tbody">Pt &gt;40 y, &gt;2 cm, location (supraclavicular always abnl), duration &gt;1 mo</p>
<p class="tbody">Consistency (hard <i class="calibre6">vs.</i> rubbery <i class="calibre6">vs.</i> soft) &amp; tenderness are not reliable</p>
<p class="tbody">Exicisional biopsy preferred over fine needle aspiration (FNA)</p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h68" class="calibre8"></a><a id="page_5-13" class="calibre8"></a><a href="part0003.html#rh76" class="calibre8">TRANSFUSION THERAPY</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Blood Products and Indications</b> <span class="sm">(<i class="calibre6">Lancet</i> 2013;381:1845)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Packed red blood cells (PRBCs)</p></td>
<td class="th1" colspan="3"><p class="tbodyh">For acute blood loss or to ↑ O<sub class="calibre17">2</sub>-carrying capacity if end organ ischemia. 1 U PRBC → ↑ Hb by ~1 g/dL. Hb goal &gt;7 g/dL adequate for UGIB &amp; critically ill <span class="sm">(<i class="calibre6">NEJM</i> 2013;368:11 &amp; 2014;371:1381)</span>, ≥8 in acute MI and peri-cardiac surgery <span class="sm">(<i class="calibre6">NEJM</i> 2018;379;1224; <i class="calibre6">JAMA</i> 2021;325:552)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Platelets (plts) <span class="sm">(<i class="calibre6">Annals Int Med</i> 2015;162:205)</span></p></td>
<td class="th1" colspan="3"><p class="tbodyh">For plts &lt;10k <span class="sm">(<i class="calibre6">NEJM</i> 2010;362:600)</span> due to chemo/abx. If &lt;20k or if &lt;50k w/ active bleeding. Variable pre-procedure.100k for neurosurgery. 1 U → ↑ plt ~30–60k. Single donor plt apheresis ↓ alloimmunization.</p>
<p class="tbodyh"><i class="calibre6">Contraindic:</i> TTP/HUS, HELLP, HIT.</p>
<p class="tbodyh"><i class="calibre6">Refractory</i> if ↑ &lt;5k 30–60′ post-plts. Suggests consumption such as ITP, DIC, or alloimmunization → trial ABO-matched plts &amp; give more. If still refractory ✓ panel reactive Abs to assess utility of HLA-matched plts.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fresh frozen plasma (FFP)</p></td>
<td class="th1" colspan="3"><p class="tbodyh">Contains all coagulation factors. For bleeding due to defic. of multiple coag factors (eg, DIC, TTP/HUS, liver disease, dilution). Nb, reverse warfarin w/ Kcentra = 4 factor PCC <span class="sm">(<i class="calibre6">JACC</i> 2020;76:594)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cryoprecipitate</p></td>
<td class="th1" colspan="3"><p class="tbodyh">Enriched for fibrinogen, vWF, VIII, and XIII. 1<sup class="calibre27">st</sup> line for fibrinogen &lt;100 mg/dL. For bleeding in vWD factor XIII deficiency, use if other products not available.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Irradiated</p></td>
<td class="th1" colspan="3"><p class="tbodyh">Prevents donor T-cell engraftment and risk of transfusion-assoc. GVHD (HSCT, heme malignancy, congenital immunodeficiency).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">CMV-negative</p></td>
<td class="th1" colspan="3"><p class="tbodyh">From CMV-negative donors. For CMV-seronegative pregnant women, transplant candidates/recipients, SCID, AIDS Pts.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Leuko- reduced</p></td>
<td class="th1" colspan="3"><p class="tbodyh">WBCs cause HLA alloimmunization &amp; fever (cytokines) and carry CMV. For chronically transfused Pts, potential Tx recip., h/o febrile nonhemolytic transfusion rxn, cases in which CMV-neg products desired but unavailable.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">IV immune globulin (IVIg)</p></td>
<td class="th1" colspan="3"><p class="tbodyh">Polyvalent IgG from &gt;1000 donors. For postexposure prophylaxis (eg, HAV), certain autoimmune disorders (eg, ITP, Guillain-Barré, MG, CIDP), congenital or acquired hypogammaglobulinemia (CVID, CLL).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Therapeutic apheresis</p></td>
<td class="th1" colspan="3"><p class="tbodyh">Removes plasma large molec wt subst. (eg, cryoglobulinemia, Goodpasture’s, Guillain-Barré, hyperviscosity syndrome), or cells (eg, leukemia w/ hyperleukocytosis, sx thrombocytosis) from plasma. TTP: replace ADAMTS13. RBC exchange for SCD acute chest or stroke.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Massive transfusion</p></td>
<td class="th1" colspan="3"><p class="tbodyh">Large-vol. PRBC → ↓ Ca, ↑ K, ↓ plt, ↑ coags; initial ratio of 1 PRBC: 1 plt:1 FFP accepted but controversial, follow labs <span class="sm">(<i class="calibre6">JAMA Surg</i> 2017;152:574)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Transfusion Complications</b> <span class="sm">(<i class="calibre6">NEJM</i> 2017;377:1261)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Noninfectious</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Risk (per unit)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Infectious</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Risk (per unit)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Febrile</p></td>
<td class="th1"><p class="tbody">1:100</p></td>
<td class="th1"><p class="tbody">CMV</p></td>
<td class="th1"><p class="tbody">Common</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Allergic</p></td>
<td class="th1"><p class="tbody">1:100</p></td>
<td class="th1"><p class="tbody">Hepatitis B</p></td>
<td class="th1"><p class="tbody">1:220,000</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Delayed hemolytic</p></td>
<td class="th1"><p class="tbody">1:50–75,000</p></td>
<td class="th1"><p class="tbody">Hepatitis C</p></td>
<td class="th1"><p class="tbody">1:1,600,000</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Acute hemolytic</p></td>
<td class="th1"><p class="tbody">1:200,000</p></td>
<td class="th1"><p class="tbody">HIV</p></td>
<td class="th1"><p class="tbody">1:1,800,000</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Febr. non-hemolytic</p></td>
<td class="th1"><p class="tbody">1:200</p></td>
<td class="th1"><p class="tbody">Bacteria (PRBCs)</p></td>
<td class="th1"><p class="tbody">1:500,000</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">TRALI</p></td>
<td class="th1"><p class="tbody">1:5000</p></td>
<td class="th1"><p class="tbody">Bacteria (platelets)</p></td>
<td class="th1"><p class="tbody">1:12,000</p></td>
</tr>
</tbody>
</table>
<p class="h">Transfusion reactions</p>
<p class="noindent1">• Reason why blood products (unless massive txfusion) run 1 at a time. For all rxns (except minor allergic): <b class="calibre7">stop txfusion;</b> send remaining blood product + fresh blood draw to blood bank.</p>
<p class="noindent1">• <b class="calibre7">Acute hemolytic:</b> fever, HoTN, flank pain, AKI w/in 24 h. Due to ABO incompatibility → preformed Abs vs. donor RBCs. Rx: IVF, ↑ UOP w/ diuretics, mannitol, or dopamine.</p>
<p class="noindent1">• <b class="calibre7">Delayed hemolytic:</b> generally less severe than acute hemolytic; 5–7 d after transfusion, but can be severe → hyperhemolysis. Due to undetected allo-Abs vs. minor antigens → anamnestic response. Rx usually not required; dx important for future transfusion.</p>
<p class="noindent1">• <b class="calibre7">Febrile nonhemolytic:</b> fever, rigors 0–6 h post transfusion. Due to Abs vs. donor WBCs and cytokines in blood product. Rx: acetaminophen ± meperidine; r/o infection, hemolysis.</p>
<p class="noindent1">• <b class="calibre7">Allergic:</b> urticaria; rarely, <b class="calibre7">anaphylaxis</b> due to rxn to txfused proteins, especially in IgA-deficient Pts w/ anti-IgA Abs (use washed products). Rx: urticaria → diphenhydramine; anaphylaxis → epinephrine ± steroids. Washed products ↓ rxns in chronic txfusions.</p>
<p class="noindent1">• <b class="calibre7">Transfusion-associated circulatory overload</b> (TACO): ↑ volume → pulm. edema, ↑ BP. Rx: slow transfusion rate, diuretics, O<sub class="calibre10">2</sub>, ± nitrates, ± positive pressure ventilation.</p>
<p class="noindent1">• <b class="calibre7">Transfusion-related acute lung injury</b> (TRALI): non-cardiogenic pulm. edema due to donor allo-Abs (from multiparous ♀ plasma) binding recipient WBCs, which then aggregate in pulmonary vasculature and release mediators causing ↑ capillary permeability. Rx: see “ARDS.” No longer seen in US as plasma only from ♂ donors.</p>
<h2 class="ct"><a id="h69" class="calibre8"></a><a id="page_5-14" class="calibre8"></a><a href="part0003.html#rh77" class="calibre8">MYELODYSPLASTIC SYNDROMES (MDS)</a></h2>
<p class="h">Myeloid neoplasm overview <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2016;127:2391)</span></p>
<p class="noindent1">• Categories based on clinical features, morphology, immunophenotyping, and genetics</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre18"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">WHO 2016 Classification of Myeloid Neoplasms &amp; Acute Leukemia</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Acute myeloid leukemia</p></td>
<td class="th1"><p class="tbody">Clonal myeloid stem cell (SC) disorder w/ ≥20% blasts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Myelodysplastic syndromes</p></td>
<td class="th1"><p class="tbody">Dysplastic clonal myeloid SC disorder → cytopenias; &lt;20% blasts, risk of leukemic transformation</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Myeloproliferative neoplasms</p></td>
<td class="th1"><p class="tbody">Nondysplastic multipotent myeloid SC clonal expansion</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MDS/MPN neoplasms</p></td>
<td class="th1"><p class="tbody">Features of MDS &amp; MPN (eg, CMML, atypical CML)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Myeloid/lymphoid malig. w/ eos &amp; rearrangements of <i class="calibre6">PDGFR</i> or <i class="calibre6">FGFR</i>1 or w/ <i class="calibre6">PCM</i>1<i class="calibre6">-JAK2</i></p></td>
<td class="th1"><p class="tbody">May be responsive to TKI therapy (eg, imatinib) for <i class="calibre6">PDGFR</i> rearrangement</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Mastocytosis</p></td>
<td class="th1"><p class="tbody">Clonal mast cell disorder, assoc w/ <i class="calibre6">KIT</i> mutations</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Myeloid neoplasms w/ germ line predisposition</p></td>
<td class="th1"><p class="tbody">MDS, MDS/MPN, acute leukemias in background of predisposing germline mutations (eg, <i class="calibre6">DDX4</i>1)</p></td>
</tr>
</tbody>
</table>
<p class="h">Myelodysplastic syndromes (MDS) overview <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2014;383:2239)</span></p>
<p class="noindent1">• Acquired clonal stem cell disorder → ineffective hematopoiesis → <b class="calibre7">cytopenias</b>, <b class="calibre7">dysmorphic blood cells and precursors</b>, variable risk of <b class="calibre7">leukemic transformation</b></p>
<p class="noindent1">• Epidemiology: 20–30,000 cases/y; median age ~70 y; male predominance (1.8×)</p>
<p class="noindent1">• <b class="calibre7">Idiopathic</b> or 2° to chemo w/ <b class="calibre7">alkylating agents;</b> ↑ risk w/ radiation, benzene</p>
<p class="noindent1">• Clinical manifestations: <b class="calibre7">anemia</b> (85%), neutropenia (50%), thrombocytopenia (40–65%)</p>
<p class="noindent1">• Diagnosis: dysplasia (usually multilineage) in peripheral smear (oval macrocytes, <b class="calibre7">pseudo-Pelger-Huët anomaly</b>) and bone marrow (≥10% dysplasia with blasts ± RS)</p>
<p class="noindent1">• Both <b class="calibre7">cytogenetic</b> [eg, del(5q), mono 7, del(7q), trisomy 8, del(20q)] and <b class="calibre7">molecular</b> abnl (<b class="calibre7"><i class="calibre6">TP53</i></b>, <i class="calibre6">EZH2</i>, <i class="calibre6">ETV6</i>, <i class="calibre6">RUNX1</i>, <i class="calibre6">ASXL1</i>, <i class="calibre6">SF3B1</i>, <i class="calibre6">DNMT3A</i>) may carry prognostic signif</p>
<p class="noindent1">• Prior to dx MDS: exclude AML (≥20% blasts) and CMML (monos &gt;1 × 10<sup class="calibre19">9</sup>/L); r/o 2° BM Δs (defic. of B<sub class="calibre10">12</sub>, folate, copper); viral infxn (eg, HIV); EtOH; lead, arsenic exposures</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre12"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">WHO 20</b>1<b class="calibre7">6 Classification Systems for MDS</b> <span class="sm">(<i class="calibre6">Blood</i> 2016;127:2391)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Classification</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">WHO 2008</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Features</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MDS w/ single lineage dysplasia (MDS-SLD)</p></td>
<td class="th1"><p class="tbody">RCUD</p>
<p class="tbody">(RA/RN/RT)</p></td>
<td class="th1"><p class="tbody">1 dysplastic lineage, 1–2 cytopenias, &lt;15% RS<sup class="calibre27"><a id="fn108-s1" class="calibre8"></a><a href="part0011.html#rfn108-s1" class="calibre8">*</a></sup>, &lt;5% BM/ &lt;1% PB blasts, no Auer rods</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MDS w/ multilineage dysplasia (MDS-MLD)</p></td>
<td class="th1"><p class="tbody">RCMD</p></td>
<td class="th1"><p class="tbody">2–3 dysplastic lineages, 1–3 cytopenias, &lt;15% RS<sup class="calibre27"><a href="part0011.html#rfn108-s1" class="calibre8">*</a></sup>, &lt;5% BM/ &lt;1% PB blasts, no Auer rods</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MDS w/ ring sideroblast (MDS-RS)</p></td>
<td class="th1"><p class="tbody">RARS</p></td>
<td class="th1"><p class="tbody">≥15% RS or ≥5% RS if <i class="calibre6">SF3B</i>1 mut. is present, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MDS w/ isolated del(5q)</p></td>
<td class="th1"><p class="tbody">Del(5q)</p></td>
<td class="th1"><p class="tbody">Del(5q) alone or w/ 1 abnl except –7 or del(7q)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MDS w/ excess blasts (MDS-EB)</p></td>
<td class="th1"><p class="tbody">RAEB-1</p>
<p class="tbody">RAEB-2</p></td>
<td class="th1"><p class="tbody">EB-1: 5–9% BM/2–4% PB blasts, no Auer rods</p>
<p class="tbody">EB-2: 10–19% BM/5–19% PB blasts or Auer rods</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MDS, unclassifiable (MDS-U)</p></td>
<td class="th1"><p class="tbody">MDS-U</p></td>
<td class="th1"><p class="tbody">w/ 1% PB blasts, single lineage dysplasia &amp; pancytopenia, or defining cytogenetic alteration</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Certain cytogenetics [eg, t(15;17), t(8;21), inv16, t(16;16), or <i class="calibre6">MLL</i> rearrangement] classified as AML, regardless of BM blast count. BM, bone marrow; PB, peripheral blood; RS, ring sideroblast. <sup class="calibre22"><a id="rfn108-s1" class="calibre8"></a><a href="part0011.html#fn108-s1" class="calibre8">*</a></sup> &lt;5% RS if <i class="calibre6">SF3B</i>1 mutation.</p>
<p class="noindent1">• Rx <span class="r1">(</span><span class="r2">Am J Hematol</span> <span class="r1">2012;87:692)</span>: intensity based on IPSS-R (qv), age, performance status (PS)</p>
<p class="noindent2">Poor PS, any risk → supportive care (transfusions, G-CSF, Epo, TPO-mimetic, abx prn)</p>
<p class="noindent2">Very low/low risk (IPSS-R) → ESA if Epo &lt;500; lenalidomide (esp. for 5q synd.; <span class="r2">Blood</span> <span class="r1">2011;118:3765</span>); luspatercept (MDS-RS). TPO-mimetic agents, transfusions.</p>
<p class="noindent2">Interm/high risk (IPSS-R) → <b class="calibre7">allogeneic HSCT</b> if medically fit, <b class="calibre7">DNA methyltransferase inh</b> azacitadine or decitabine <span class="r1">(</span><span class="r2">Lancet Oncol</span> <span class="r1">2009;10:223)</span> or oral decitabine/cedazuridine</p>
<p class="noindent2">Hypoplastic MDS (rare) → consider <b class="calibre7">immunosuppression</b> (CsA, ATG), HSCT</p>
<p class="noindent1">• Prognosis: mutations in<i class="calibre6">TP53</i>, <i class="calibre6">ASXL1, EZH2, RUNX1, ETV6</i> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011; 364:2496)</span> ↓ survival</p>
<p class="imaget"><img src="../images/00080.jpeg" alt="" class="calibre5"/></p>
<h2 class="ct"><a id="h70" class="calibre8"></a><a id="page_5-15" class="calibre8"></a><a href="part0003.html#rh78" class="calibre8">MYELOPROLIFERATIVE NEOPLASMS (MPN)</a></h2>
<p class="h">General <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:2168)</span></p>
<p class="noindent1">• Results from clonal expansion of multipotent hematopoietic stem cell</p>
<p class="noindent1">• Categories of MPN: <b class="calibre7">polycythemia vera</b> (PV); <b class="calibre7">essential thrombocythemia</b> (ET); <b class="calibre7">primary myelofibrosis</b> (PMF); chronic myelogenous leukemia (CML; <i class="calibre6">BCR-ABL1</i> ⊕); atypical CML (aCML); chronic neutrophilic leukemia (CNL); systemic mastocytosis; chronic eosinophilic leukemia; MPN-NOS/unclassifiable</p>
<p class="noindent1">• MDS/MPN neoplasms: proliferative and dysplastic features</p>
<p class="noindent1">• Mutations useful as clonal markers &amp; dx tools:</p>
<p class="noindent2">Gain of fxn mutations in <b class="calibre7"><i class="calibre6">JAK2</i></b> V617F (Janus kinase) frequently present (PV ~95%, ET ~50%, PMF ~50%; <span class="r2">NEJM</span><span class="r1"> 2005;352:1779</span>)</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">BCR-ABL1</i></b> fusion in <b class="calibre7">all</b> cases of CML; <b class="calibre7"><i class="calibre6">SETBP1</i></b> in aCML</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">CALR</i></b> exon 9 mutation, type I and II (most MPNs w/o <i class="calibre6">JAK2</i> or <i class="calibre6">MPL</i> mutation, including ~25% of ET, ~35% of myelofibrosis Pts; <span class="r2">NEJM</span><span class="r1"> 2013;369:2379 &amp; 2391</span>)</p>
<p class="noindent2">Type I has better prognosis.</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">MPL</i></b>, <b class="calibre7"><i class="calibre6">TET2, &amp; ASXL1</i></b> mutation w/ lower frequency</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">CSF3R</i></b> mutation present in ~60% of CNL; <b class="calibre7"><i class="calibre6">KIT</i></b> D816V in 90% of systemic mastocytosis</p>
<p class="h1cr">P<small class="calibre31">OLYCYTHEMIA</small> V<small class="calibre31">ERA</small> (PV)</p>
<p class="h">Definition</p>
<p class="noindent1">• ↑ in RBC mass ± ↑ granulocytes and platelets in the absence of physiologic stimulus</p>
<p class="h">Etiologies of erythrocytosis <span class="r">(absolute</span> <b class="calibre7">↑</b><span class="r"> RBC)</span></p>
<p class="noindent1">• Acquired 1°: PV (usually <i class="calibre6">JAK2</i>+) or other MPN</p>
<p class="noindent1">• Germline 1°: Chuvash (hypoxia-sensing disorder due to <i class="calibre6">VHL</i> mutation), <i class="calibre6">EGLN</i> mutations</p>
<p class="noindent1">• Secondary: <b class="calibre7">carboxyhemoglobinemia; hypoxia</b> (OSA, COPD<b class="calibre7">); inappropriate erythropoietin</b> (renal, hepatic); Cushing’s syndrome</p>
<p class="noindent1">• Mimics: <i class="calibre6">relative</i> ↑ RBC (↓ plasma) due to dehydration; “stress” erythrocytosis (Gaisböck’s syndrome)</p>
<p class="h">Clinical manifestations <span class="r">(common between PV and ET)</span></p>
<p class="noindent1">• Symptoms (often termed “vasomotor”)</p>
<p class="noindent2"><b class="calibre7">Hyperviscosity</b> (erythrocytosis): headache, dizziness, tinnitus, blurred vision</p>
<p class="noindent2"><b class="calibre7">Thrombosis</b> (hyperviscosity, thrombocytosis): <b class="calibre7">↑ risk of DVT</b>, <b class="calibre7">MI</b>, <b class="calibre7">stroke</b>; transient visual disturbances (amaurosis, ocular migraine); Budd-Chiari syndrome; erythromelalgia = intense burning, pain and erythema of extremities due to microvascular ischemia</p>
<p class="noindent2"><b class="calibre7">Bleeding</b> (abnormal platelet function): easy bruising, epistaxis, GI bleeding</p>
<p class="noindent2">↑ histamine from basophils → <b class="calibre7">pruritus</b>, peptic ulcers; ↑ uric acid (cell turnover) → gout</p>
<p class="noindent1">• Signs: <b class="calibre7">plethora</b>, <b class="calibre7">splenomegaly</b>, hypertension, engorged retinal veins</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• Men: Hb &gt;16.5 g/dL or Hct &gt;49%, women: Hb &gt;16 g/dL or Hct &gt;48%</p>
<p class="noindent1">• ± ↑ WBC, platelets, basophils; ↑ uric acid, leukocyte alkaline phosphatase, vit B<sub class="calibre10">12</sub></p>
<p class="noindent1">• Peripheral smear → no morphologic abnormalities</p>
<p class="noindent1">• ✓ Epo to rule out secondary causes of erythrocytosis; <b class="calibre7">if Epo</b> ↓, <b class="calibre7">PV more likely</b> If Epo ↑, then ✓ SaO<sub class="calibre10">2</sub> or PaO<sub class="calibre10">2</sub>, carboxyhemoglobin, BM exam</p>
<p class="noindent1">• BM bx → hypercellularity for age, trilineage growth, pleomorphic mature megakaryocytes</p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">JAK2</i> V617F</b> mutation in ~95% of PV; other Pts typically harbor <i class="calibre6">JAK2</i> exon 12 mutations</p>
<p class="h">Treatment for <i class="calibre6">JAK2</i> + PV</p>
<p class="noindent1">• <b class="calibre7">Phlebotomy</b> to goal Hct &lt;45% <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:22)</span>, consider &lt;42% in women</p>
<p class="noindent1">• <b class="calibre7">Low-dose ASA</b> in all Pts <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2004;350:114)</span></p>
<p class="noindent1">• <b class="calibre7">Hydroxyurea</b> if high risk of thrombosis (age ≥60, prior thrombosis) or if inadequate Hct by phlebotomy alone</p>
<p class="noindent1">• PEG IFNα preferred in younger Pts and pregnancy <span class="r1">(</span><span class="r2">Lancet Haematol</span> <span class="r1">2017;4:e165)</span></p>
<p class="noindent1">• Ruxolitinib (JAK1/2 inhibitor) if refractory to or intolerant of hydroxyurea <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:426)</span></p>
<p class="noindent1">• Supportive: allopurinol (gout), H<sub class="calibre10">2</sub>-blockers/antihistamines (pruritus). Avoid iron supp.</p>
<p class="noindent1">• Data for optimal mgmt of other types of PV (secondary, germline, etc.) currently lacking</p>
<p class="h">Prognosis</p>
<p class="noindent1">• Median survival w/ Rx ~13.5 y <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2014;124:2507)</span>; ↑ age, WBC, additional acquired somatic mutations → worse prognosis <span class="r1">(</span><span class="r2">Haematol</span> <span class="r1">2013;160:251)</span></p>
<p class="noindent1">• Post-PV myelofibrosis (spent phase) occurs in 10–20% of cases, usually after 10 y</p>
<p class="noindent1">• Risk of transformation into acute leukemia (&lt;2–5% lifetime)</p>
<p class="h1cr"><a id="page_5-16" class="calibre8"></a>E<small class="calibre31">SSENTIAL</small> T<small class="calibre31">HROMBOCYTHEMIA</small> (ET)</p>
<p class="h">Definition</p>
<p class="noindent1">• Sustained ↑ in platelets (&gt;450,000/µL) ± ↑ RBC and granulocytes</p>
<p class="h">Etiologies of thrombocytosis</p>
<p class="noindent1">• 1° = ET or other MPN; myelodysplastic syndromes (5q-syndrome); RARS-T</p>
<p class="noindent1">• 2° = <b class="calibre7">reactive thrombocytosis:</b> inflammation (RA, IBD, vasculitis), infection, trauma, acute bleed, iron deficiency, postsplenectomy, neoplasms (eg, Hodgkin lymphoma)</p>
<p class="noindent1">• Of patients with plt &gt;1,000,000/µL, &lt;1 in 6 will have ET</p>
<p class="h">Clinical manifestations <span class="r">(also see “Polycythemia Vera”)</span></p>
<p class="noindent1">• Thrombosis with erythromelalgia (risk of thrombosis highest in Pts with leukocytosis), bleeding (acquired vWD), pruritus; mild splenomegaly; migraine, TIA; early fetal loss</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• Peripheral smear: large hypogranular platelets</p>
<p class="noindent1">• BM bx: megakaryocytic hyperplasia; ⊖ Phil chr; rarely minor reticulin fibrosis; nl Fe; if atypical megakaryoctyes or ↑ reticulin, consider pre-PMF (Rx same as ET, but ↑ risk MF)</p>
<p class="noindent1">• Mutations: <b class="calibre7"><i class="calibre6">JAK2</i> V617F</b> in ~50%; <b class="calibre7"><i class="calibre6">CALR</i></b> in ~45%; <b class="calibre7"><i class="calibre6">MPL</i></b> in 5–10%; triple negative &lt;5%</p>
<p class="noindent1">• Patients should not meet WHO criteria for diagnosis of CML, PV, PMF, or MDS</p>
<p class="noindent1">• Check vWF in pts w/ plt&gt;1,000,000 and hold ASA (vide infra) if acquired vWD</p>
<p class="imaget"><img src="../images/00081.jpeg" alt="" class="calibre5"/></p>
<p class="h">Prognosis</p>
<p class="noindent1">• Low-risk Pts have overall survival ≈ control population</p>
<p class="noindent1">• Risk of transformation into acute leukemia &lt;2–3% lifetime; risk of progression to MF ~10%</p>
<p class="h1cr">P<small class="calibre31">RIMARY</small> M<small class="calibre31">YELOFIBROSIS</small> (PMF)</p>
<p class="h">Definition</p>
<p class="noindent1">• Clonal myeloproliferation with reactive marrow fibrosis &amp; extramedullary hematopoiesis</p>
<p class="noindent1">• Prefibrotic stage (pre-PMF): megakaryocyte prolif, grade 1 reticulin fibrosis, ↑ BM cellularity. Compared w/ ET, pre-PMF has ↑ thrombosis, ↑ progression, ↓ survival <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2012;120:569)</span>.</p>
<p class="h">Etiologies of myelofibrosis</p>
<p class="noindent1">• 1° myelofibrosis (PMF): myeloproliferative neoplasm</p>
<p class="noindent1">• 2° myelofibrosis: post-PV/ET myelofibrosis, other hematologic (CML, AML, ALL, MDS) and solid cancers (breast, prostate), autoimmune (eg, SLE), toxin (benzene), radiation, granulomas (TB, fungal, sarcoid), deposition diseases (eg, Gaucher’s)</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">BJH</span> <span class="r1">2012;158:453)</span></p>
<p class="noindent1">• Ineffective erythropoiesis → anemia; extramedullary hematopoiesis → <b class="calibre7">massive splenomegaly</b> (abdominal pain, early satiety) ± hepatomegaly</p>
<p class="noindent1">• Tumor bulk and ↑ cell turnover → fatigue, weight loss, fever, sweats</p>
<p class="h">Diagnostic evaluation <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2010;115:1703 &amp; 2016;127:2391)</span></p>
<p class="noindent1">• Anemia with variable WBC and platelet counts</p>
<p class="noindent1">• Peripheral smear → “<b class="calibre7">leukoerythroblastic</b>” (<b class="calibre7">teardrop cells</b>, nucleated RBCs, immature WBCs); large abnormal platelets</p>
<p class="noindent1">• BM aspirate → “dry” tap; BM bx → <b class="calibre7">severe fibrosis</b>, replacement by reticulin &amp; collagen</p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">JAK2</i> V617F</b> in 45–50%; <b class="calibre7"><i class="calibre6">CALR</i></b> mut in 45–50%, <b class="calibre7"><i class="calibre6">MPL</i></b> mut in 7–10%, triple neg in 1–2%</p>
<p class="noindent1">• No <i class="calibre6">BCR-ABL</i> translocation; Pts should not meet criteria for PV or MDS</p>
<p class="noindent1">• DIPSS score for prognosis. High-risk factors: age &gt;65, WBC &gt;25k, Hgb &lt;10, peripheral blasts &gt;1%, symptoms, complex cytogenetics, absence of <i class="calibre6">CALR</i> type 1.</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Am J Hematol</span> <span class="r1">2021;96:145)</span></p>
<p class="noindent1">• In absence of adverse prognostic factors (eg, anemia or sx) → no treatment</p>
<p class="noindent1">• Allogeneic HSCT only potential cure → consider in young Pts w/ high-risk disease</p>
<p class="noindent1">• Supportive care: <b class="calibre7">transfusions;</b> ESA if Epo &lt;500 (risk ↑ splenomegaly); consider androgens vs. immunomodulatory agents (eg, lenalidomide) + prednisone; hydroxyurea; ? splenectomy if refractory to transfusions, failed chemoRx, painful splenomegaly</p>
<p class="noindent1">• JAK inh: ruxolitinib (JAK1/2) ↓ sx, ↓ splenomegaly, ↑ survival; preferred <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;366:787 &amp; 799)</span>; fedratinib (JAK2; <span class="r2">JAMA Oncol</span> <span class="r1">2015;1:643</span>); pacritinib &amp; momelotinib under study</p>
<p class="noindent1">• Median survival ~6 y <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2012;30:2981)</span>; transformation into AML occurs at a rate of ~8%/y</p>
<h2 class="ct"><a id="h71" class="calibre8"></a><a id="page_5-17" class="calibre8"></a><a href="part0003.html#rh79" class="calibre8">LEUKEMIA</a></h2>
<p class="h1cr">A<small class="calibre31">CUTE</small> L<small class="calibre31">EUKEMIA</small></p>
<p class="h">Definition</p>
<p class="noindent1">• Clonal proliferation of hematopoietic progenitor with failed differentiation into mature elements → ↑ blasts in bone marrow and periphery → ↓ RBCs, platelets, and neutrophils</p>
<p class="h">Epidemiology and risk factors</p>
<p class="noindent1">• Acute myelogenous (AML): ~20k cases/y in U.S.; median age 68 y</p>
<p class="noindent1">• Acute lymphocytic (ALL): ~6k cases/y in U.S.; median age 15 y but 2<sup class="calibre19">nd</sup> peak in older adults</p>
<p class="noindent1">• Risk factors: <b class="calibre7">radiation</b>, <b class="calibre7">chemo</b> (alkylating agents, topo II inhib), benzene, smoking, ? rising from acquired somatic mutations and clonal hematopoiesis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:2477)</span></p>
<p class="noindent1">• Secondary to acquired hematopoietic dis.: MDS, MPN (esp. CML), aplastic anemia, PNH</p>
<p class="noindent1">• Inherited: Down’s, Klinefelter’s, Fanconi’s anemia, Bloom synd., ataxia telangiectasia, germline mut. in <i class="calibre6">TP53</i> (Li-Fraumeni syndrome)<i class="calibre6">, DDX41, RUNX1</i>, <i class="calibre6">CEBPa,</i> &amp; <i class="calibre6">GATA2</i></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Cytopenias → <b class="calibre7">fatigue</b> (anemia), <b class="calibre7">infection</b> (neutropenia), <b class="calibre7">bleeding</b> (thrombocytopenia)</p>
<p class="noindent1">• <b class="calibre7">Leukostasis</b> (more in AML): blast &gt;50k, ↓ S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>, HA, blurry vision, confusion, TIA/CVA</p>
<p class="noindent1">• <b class="calibre7">Tumor lysis syndrome</b> (TLS) from rapid turnover of cells</p>
<p class="noindent1">• <b class="calibre7">Disseminated intravascular coagulation</b> (<b class="calibre7">DIC</b>; especially with APL)</p>
<p class="noindent1">• Other: leukemic infiltration of skin, gingiva (esp. with monocytic subtypes); chloroma (myeloid sarcoma): extramedullary tumor of leukemic cells, any location; anterior mediastinal mass and SVC syndrome (T-ALL/LBL); hepatosplenomegaly (ALL and monocytic leukemias); CNS (~10% of ALL; also in monocytic &gt;myeloid leukemias): cranial neuropathies, HA</p>
<p class="h">Diagnostic evaluation <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2009;114:937)</span></p>
<p class="noindent1">• <b class="calibre7">Peripheral smear:</b> thrombocytopenia, <b class="calibre7">blasts</b> (seen in &gt;95%; ⊕ Auer Rods in AML)</p>
<p class="noindent1">• <b class="calibre7">Bone marrow:</b> &gt;20% blasts; mostly hypercellular; test for cytogenetics and flow cytometry for immunophenotype (AML/ALL)</p>
<p class="noindent1">• <b class="calibre7">Cytogenetic anomalies</b>: eg, in AML, t(15;17), t(8;21), inv(16) or t(16;16), complex; in ALL, Ph-chromosome [t(9;22)], hyper or hypodiploid, complex</p>
<p class="noindent1">• Molecular mutations in AML: esp <i class="calibre6">FLT3</i> (ITD and TKD), <i class="calibre6">TP53, NPM1;</i> ALL<i class="calibre6">: BCR-ABL1</i></p>
<p class="noindent1">• Evaluate for complications: TLS (↑ uric acid, ↑ LDH, ↑ K, ↑ PO<sub class="calibre10">4</sub>, ↓ Ca), DIC (PT, PTT, fibrinogen, D-dimer, haptoglobin, bilirubin), check for G6PD (prior to giving rasburicase)</p>
<p class="noindent1">• LP (w/ <b class="calibre7">co-admin of intrathecal chemotherapy</b> to avoid seeding CSF w/ circulating blasts) for all Pts w/ ALL (CNS is sanctuary site) and for Pts w/ AML w/ CNS sx</p>
<p class="noindent1">• TTE before use of anthracyclines</p>
<p class="noindent1">• <b class="calibre7">HLA typing</b> of Pt, siblings &gt;parents/children for potential allogeneic HSCT candidates</p>
<p class="h1cr">A<small class="calibre31">CUTE</small> M<small class="calibre31">YELOGENOUS</small> L<small class="calibre31">EUKEMIA</small> (AML)</p>
<p class="h">Classification <span class="r">(WHO;</span> <span class="r2">Blood</span><span class="r1"> 2016;127:2391</span><span class="r">)</span></p>
<p class="noindent1">• Features used to confirm myeloid lineage and subclassify AML to guide treatment: morphology: <b class="calibre7">blasts</b>, ⊕ <b class="calibre7">granules</b>, ± <b class="calibre7">Auer rods</b> (eosinophilic needle-like inclusions)</p>
<p class="noindent1">• Immunophenotype: precursor: CD34, CD45, HLA-DR; myeloid: CD13, CD33, CD117; monocyte: CD11b, CD64, CD14, CD15</p>
<p class="noindent1">• Histochem.: myeloperoxidase (myeloid), non-specific esterase, and lysozyme (monocytic)</p>
<p class="noindent1">• Prognosis: <i class="calibre6">age</i>, prior <i class="calibre6">antecedent MPN/MDS</i> and <i class="calibre6">genetics</i> (cytogenetics + molecular mutation status) are key independent risk factors of poor prognosis</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">ENL 20</b>1<b class="calibre7">7 Genetic Risk Classification</b> <span class="sm">(<i class="calibre6">Blood</i> 2017;129:424)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Risk Category</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Genetic Abnormality</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Favorable</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">APL</i>: t(15;17); <i class="calibre6">PML-RARa;</i></p>
<p class="tbodyh">t(8;21): <i class="calibre6">RUNX</i>1<i class="calibre6">-RUNX</i>1<i class="calibre6">T</i>1; inv(16): <i class="calibre6">CBFB-MYH</i>1;</p>
<p class="tbodyh">mutated <i class="calibre6">NPM</i>1 <i class="calibre6">w/o FLT3-ITD or w/ FLT3-ITD<sup class="calibre27">low</sup></i><sup class="calibre27">*</sup>;</p>
<p class="tbodyh">biallelic mutation in <i class="calibre6">CEBPA</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Intermediate</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">FLT3-ITD</i><sup class="calibre27">low</sup><sup class="calibre27">*</sup>; mutated <i class="calibre6">NPM</i>1 &amp; <i class="calibre6">FLT3-ITD</i><sup class="calibre27">high</sup><sup class="calibre27">*</sup>; t(9;11): <i class="calibre6">MLL-MLLT3</i>;</p>
<p class="tbodyh">cytogenetic abnl not classified as favorable or adverse, including normal karyotype w/o mutations in <i class="calibre6">FLT3-ITD</i> &amp; <i class="calibre6">NPM</i>1</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Adverse</p></td>
<td class="th1"><p class="tbodyh">-5 or del(5q); -7; -17/abn(17p); complex or monosomal karyotype;</p>
<p class="tbodyh">t(6;9): <i class="calibre6">DEK-NUP2</i>1<i class="calibre6">4</i>; t(9;22) <i class="calibre6">BCR-ABL</i>1; inv(3): <i class="calibre6">GATA2-MECOM</i>;</p>
<p class="tbodyh">wildtype <i class="calibre6">NPM</i>1 &amp; <i class="calibre6">FLT-ITD<sup class="calibre27">high</sup></i><sup class="calibre27">*</sup>; mutated <i class="calibre6">TP53, RUNX</i>1<i class="calibre6">, ASXL</i>1</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><sup class="calibre27">*</sup> low/high: <i class="calibre6">FLT3-ITD</i> variant allele frequency (VAF); reflects burden of mut. leukemic cells</p></td>
</tr>
</tbody>
</table>
<p class="h">Upfront treatment</p>
<p class="noindent1">• <b class="calibre7">Induction chemo</b> “7+3”: 7d cont. infusion cytarabine (Ara-C) + 3d bolus anthracycline (daunorubicin or idarubicin)</p>
<p class="noindent1"><a id="page_5-18" class="calibre4"></a>• Ability to tolerate 7+3 regimen key determinant in subsequent Rx received (vide infra)</p>
<p class="noindent1">• Obtain BM bx 14–21 days after start of induction chemo to assess response</p>
<p class="noindent1">• Regimens for <b class="calibre7"><i class="calibre6">fit</i></b> (generally age &lt;75 y)</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">FLT3</i>-ITD/TKD</b> mutation: 7+3+midostaurin (early generation FLT3 inhib; <span class="r2">NEJM</span><span class="r1"> 2017;377:454</span>)</p>
<p class="noindent2"><b class="calibre7">Core-binding factor</b> ⊕: t(8;21) or inv(16): 7+3 ± gemtuzumab ozogamicin (mAb targ. CD33)</p>
<p class="noindent2">2° AML or w/ MDS-related changes: CPX-351 (liposomal Ara-C &amp; daunorubicin)</p>
<p class="noindent2">Other: age &lt;60 y: 7+3 (high-dose daunorubicin 90 mg/m<sup class="calibre19">2</sup>); &gt;60 y: dauno 60 mg/m<sup class="calibre19">2</sup></p>
<p class="noindent1">• Regimens for <b class="calibre7"><i class="calibre6">unfit</i></b> (may include age ≥75 y or &lt; 75y w/ ECOG ≥3 or severe cardiac or pulmonary comorbidity; <span class="r2">Leukemia</span><span class="r1"> 2013;27:997</span>)</p>
<p class="noindent2">Azacitadine + venetoclax (Bcl2 inhibitor) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:617)</span></p>
<p class="noindent2"><i class="calibre6">IDH1/2</i> mutation: ivosidenib or enasedinib</p>
<p class="h">Consolidation therapy</p>
<p class="noindent1">• If c<i class="calibre6">omplete remission</i> (CR) = ANC &gt;10<sup class="calibre19">3</sup>, plt &gt;100, no RBC Rx, &lt;5% BM blasts; <b class="calibre7">CR ≠ cure</b></p>
<p class="noindent1">• Favorable risk: high-dose cytarabine (HiDAC); Intermediate/Poor risk: Allo-HSCT</p>
<p class="noindent1">• Consider maintenance azacitadine if cannot complete curative intent Rx <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:2526)</span></p>
<p class="h">Refractory/relapsed disease</p>
<p class="noindent1">• <i class="calibre6">Repeating mutation analysis</i> key b/c clonal evolution common and may affect Rx</p>
<p class="noindent1">• <i class="calibre6">FLT3</i>-ITD/TKD mutation: gilteritinib (potent FLT3 inhibitor)</p>
<p class="noindent1">• <i class="calibre6">IDH1</i> mutation: ivosidenib; <i class="calibre6">IDH2</i> mutation: enasidenib (small-molecule inhib of IDH1 or 2)</p>
<p class="noindent1">• Chemo: MEC (mitoxantrone, etoposide, Ara-C); FLAG-Ida (fludarabine, Ara-C, G-CSF, &amp; idarubicin); CLAM (clofarabine, Ara-C, mitoxantrone), gemtuzumab</p>
<p class="h">Prognosis</p>
<p class="noindent1">• CR achieved in 70–80% of Pts &lt;60 y and in 40–50% of Pts &gt;60 y</p>
<p class="noindent1">• Overall survival variable, depends on prognostic factors: ranges from &lt;10% of older Pts w/ poor-risk tumor genetics to &gt;65% of younger Pts w/ favorable prognostic factors</p>
<p class="h">Acute promyelocytic leukemia (APL) <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2009;113:1875)</span></p>
<p class="noindent1">• Rare, ~8% of AML in U.S.; &gt;90% cure rates</p>
<p class="noindent1">• Atypical promyelocytes (large, granular cells; bilobed nuclei) in blood and bone marrow</p>
<p class="noindent1">• Defined by translocation of retinoic acid receptor: <b class="calibre7">t(15;17); <i class="calibre6">PML-RARA</i></b> (&gt;95% of cases)</p>
<p class="noindent1">• <b class="calibre7">Medical emergency</b> with <b class="calibre7">DIC</b> and <b class="calibre7">bleeding</b> common</p>
<p class="noindent1">• Remarkable responses to<b class="calibre7"> all-<i class="calibre6">trans</i>-retinoic acid (ATRA)</b> &amp; <b class="calibre7">arsenic trioxide (ATO)</b>  which induce differentiation of leukemic blasts. ∴ <b class="calibre7"><i class="calibre6">early initiation of ATRA if APL suspected</i></b></p>
<p class="noindent1">• Non-high-risk APL: ATRA + ATO (induction + 4 cycles consolidation) → CR ~100%; event-free survival 97% and overall survival 99% at 2 y <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;362:111)</span></p>
<p class="noindent1">• High-risk APL: WBC &gt;10k at diagnosis. No clear consensus. In general, chemo (anthracycline or gemtuzumab ozogamicin) added to ATRA + ATO induction and consolidation.</p>
<p class="noindent1">• Differentiation syndrome (ATRA): ~25% of Pts; fever, pulm. infiltrates, SOB, edema, HoTN, AKI; tx w/ dexamethasone 10 mg bid, supportive care (eg, diuresis) <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2008;113:775)</span></p>
<p class="h1cr">A<small class="calibre31">CUTE</small> L<small class="calibre31">YMPHOBLASTIC</small> L<small class="calibre31">EUKEMIA</small> <span class="r5">(ALL;</span> <span class="r4">Lancet</span> <span class="r3">2020;395:1146</span><span class="r5">)</span></p>
<p class="h">Classification</p>
<p class="noindent1">• Lymphoblastic neoplasms may present as acute leukemia (ALL) w/ &gt;<b class="calibre7">20% BM blasts</b> or as lymphoblastic lymphoma (LBL, more common in T-cell) w/ mass lesion w/ &lt;20% BM blast</p>
<p class="noindent1">• Morphology: <b class="calibre7">no granules</b> (granules seen in myeloid lineage)</p>
<p class="noindent1">• Cytochemistry: ⊕ terminal deoxynucleotidyl transferase (TdT) in 95% of ALL, MPO ⊖</p>
<p class="noindent1">• Immunophenotype</p>
<p class="noindent2">Precursor: CD34, TdT</p>
<p class="noindent2">B: CD19; variable CD10, CD22, CD79a</p>
<p class="noindent2">T: CD1a, CD2, cytoplasmic CD3, CD5, CD7</p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Induction chemo</b></p>
<p class="noindent2">Ph ⊕ t(9;22) (seen in ~25% of B-ALL): tyrosine kinase inhibitor + chemo/steroids</p>
<p class="noindent2">Ph ⊖: Adolescents &amp; young adults (&lt;40 y): pedi-like regimen typically w/ PEG-asparaginase. Adults (40–60 y): multiagent chemo incl. anthracycline, vincristine, steroids, cyclophosphamide (CYC). Older (&gt;60 y): reduced-intensity chemo.</p>
<p class="noindent1">• <b class="calibre7">CNS prophylaxis:</b> intrathecal MTX/cytarabine ± cranial irradiation <i class="calibre6">or</i> systemic MTX</p>
<p class="noindent1">• <b class="calibre7">Post-remission therapy</b> (choice depends on risk of recurrence)</p>
<p class="noindent2">1) Average risk: consolidation/intensification chemo (~7 mo) → maintenance (~2–3 y)</p>
<p class="noindent2">2) High risk: high-dose chemo w/ allo-HSCT considered for Pts in CR1. High-risk disease includes: Ph ⊕; Ph-like (based on gene expression); MLL translocation t(4;11); complex karyotype; hypodiploid (&lt;44 chromosomes); early T-cell phenotype (ETP; lacks CD1a, CD8, CD5<sup class="calibre19">weak</sup>, myeloid markers); minimal residual disease (MRD) = morphologic remission but flow cytometry or molec. markers of tumor still detectable.</p>
<p class="noindent1"><a id="page_5-19" class="calibre4"></a>• <b class="calibre7">Relapse/refractory:</b> salvage therapy (<i class="calibre6">below</i>), then allogeneic HSCT if able</p>
<p class="noindent2"><i class="calibre6">B cell:</i> blinatumomab (CD19 BiTE-bispecific T-cell engager; <span class="r2">NEJM</span><span class="r1"> 2017;376:836</span>), inotuzumab (CD22 Ab drug conjugate; <span class="r2">NEJM</span><span class="r1"> 2016;375:740</span>); tisagenlecleucel and brexucabtagene autoleucel (CD19 CAR-T, <span class="r2">NEJM</span><span class="r1"> 2018;378:449;</span> <span class="r2">Lancet</span> <span class="r1">2021;398:491</span>), TKI+chemo/steroids (Ph ⊕t(9;22) only)</p>
<p class="noindent2"><i class="calibre6">T cell:</i> nelarabine ± cyclophosphamide and etoposide</p>
<p class="noindent2"><i class="calibre6">Both B &amp; T cell:</i> chemo including high dose cytarabine regimens; clofarabine</p>
<p class="h1cr">C<small class="calibre31">HRONIC</small> M<small class="calibre31">YELOGENOUS</small> L<small class="calibre31">EUKEMIA</small> <span class="r5">(CML;</span> <span class="r4">Lancet</span><span class="r3"> 2021;398:1914</span><span class="r5">)</span></p>
<p class="h">Definition <span class="r1">(</span><span class="r2">Blood</span><span class="r1"> 2009;114:937)</span></p>
<p class="noindent1">• <b class="calibre7">Myeloproliferative neoplasm</b> with clonal overproduction of hematopoietic myeloid stem cells that can differentiate</p>
<p class="noindent1">• <b class="calibre7">Philadelphia chromosome</b> (Ph) = t(9;22) → <b class="calibre7"><i class="calibre6">BCR-ABL1</i></b> fusion → ↑ Abl kinase activity</p>
<p class="noindent2"><i class="calibre6">BCR-ABL1 required for diagnosis</i> (make via karyotyping or FISH; PCR)</p>
<p class="h">Epidemiology and risk factors</p>
<p class="noindent1">• ~6600 new cases/y in U.S.; median age ~64 at presentation; ~15% of adult leukemias</p>
<p class="noindent1">• ↑ risk with irradiation; no clear relation to cytotoxic drugs</p>
<p class="h">Disease classification &amp; manifestations <span class="r">(WHO;</span> <span class="r2">NCCN</span><span class="r1"> v 2.2022</span><span class="r">)</span></p>
<p class="noindent1">• <b class="calibre7">Chronic phase (CP):</b> &lt;10% blasts (peripheral or bone marrow). Risk stratification based on Sokal <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">1984;63:789)</span> or Euro scores <span class="r2">(J Clin Pathol</span> <span class="r1">2001;54:491)</span>.</p>
<p class="noindent1">• <b class="calibre7">Accelerated phase (AP):</b> 10–19% blasts, ≥20% basos, plts &lt;100k, clonal evolution (karyotype changes) not seen at dx</p>
<p class="noindent1">• <b class="calibre7">Blastic phase (BP):</b> ≥20% blasts (peripheral or marrow) and/or extramedullary leukemia</p>
<p class="noindent1">• Most Pts asx or may have mild constitutional s/s related to splenomegaly.</p>
<p class="noindent1">• Worsening constitutional sx, bone pain, rapid ↑ in spleen size herald disease progression</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• <b class="calibre7">Peripheral smear: leukocytosis</b>, left-shifted with <i class="calibre6">all stages of myeloid maturation;</i> thrombocytosis, <b class="calibre7">basophilia</b></p>
<p class="noindent1">• <b class="calibre7">Bone marrow w/ karyotype:</b> hypercellular, ↑myeloid:erythroid ratio, micromegakaryocytes</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;385:1447;</span> <span class="r2">Hematol Oncol Clin North Am</span> <span class="r1">2017;31:577)</span></p>
<p class="noindent1">• <b class="calibre7">Tyrosine kinase inhibitors (TKI)</b> inhibit abl kinase activity.</p>
<p class="noindent2">1<sup class="calibre19">st</sup> gen: imatinib, 1<sup class="calibre19">st</sup> TKI against <i class="calibre6">BCR-ABL1</i> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:917)</span></p>
<p class="noindent2">2<sup class="calibre19">nd</sup> gen: nilotinib, dasatinib, bosutinib. ↑ response but ↑ toxicity. No survival difference.</p>
<p class="noindent2">3<sup class="calibre19">rd</sup> gen: ponatinib; a/w ↓ risk of disease progress, preferred for int-high risk, but ↑ toxicity</p>
<p class="noindent2">Imatinib, dasatinib, nilotinib, &amp; bosutinib approved for 1<sup class="calibre19">st</sup> line Rx. Nilotinib, dasatinib, bosutinib, ponatinib, &amp; asciminib approved for resistant disease; only ponatinib &amp; asciminib effective on T315I mutation <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:2075,</span> <span class="r2">Blood</span> <span class="r1">2021;138:2031)</span>.</p>
<p class="noindent2">STAMP (allosteric inhibitor): asciminib <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;381:2315)</span>; after ≥2 prior TKIs</p>
<p class="noindent2">Resistance: due to ↑ <i class="calibre6">BCR-ABL1</i> expression, often 2/2 <i class="calibre6">ABL</i> kinase mutation or amplification</p>
<p class="noindent2">Side effects: N/V, diarrhea, muscle cramps, cytopenias, ↓ PO<sub class="calibre10">4</sub>, ↑ QT, rarely CHF; dasatinib: pericardial &amp; pleural effusions and pulm. HTN; nilotinib: ↑ bili &amp; lipase, CV toxicity; ponatinib: pancreatitis and arterial vascular events (cerebral, cardiac, &amp; PAD)</p>
<p class="noindent1">• TKI discontinuation: consider if complete molecular response (&gt;4.5 log reduction in <i class="calibre6">BCR-ABL1</i> transcript) for &gt;2 y. Up to 50% of Pts remain off TKI at 2 y (ie, no molec. recurrence). Success proportional to duration of CMR and risk score at presentation.</p>
<p class="noindent1">• Consider allogeneic HSCT for AP and BP.</p>
<p class="noindent1">• CML in pregnancy: hydroxyurea &amp; all TKIs contraind. If Rx needed, IFN (only option).</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre21"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Milestones of Therapy</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Definition</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Optimal Time</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">BCR-ABL</i>1 ratio &lt;10% IS = 1-log reduction by QT- PCR</p></td>
<td class="th1"><p class="tbodyc">3 mo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">BCR-ABL</i>1 ratio &lt;1% IS = 2-log reduction by QT-PCR (CCyR)</p></td>
<td class="th1"><p class="tbodyc">6 mo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">BCR-ABL</i>1 ratio &lt;0.1% IS = 3-log reduction by QT-PCR (MMR)</p></td>
<td class="th1"><p class="tbodyc">12 mo</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><i class="calibre6">BCR-ABL</i>1 ratio: Pt <i class="calibre6">BCR-ABL</i>1 mRNA: <i class="calibre6">ABL</i> mRNA in peripheral blood. International Scale (IS) standardizes across labs by normalizing to <i class="calibre6">BCR-ABL</i>1:<i class="calibre6">ABL</i>1 ratio in a cohort of unRx’d patients.</p></td>
</tr>
</tbody>
</table>
<p class="h">Prognosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:917)</span></p>
<p class="noindent1">• Chronic phase CML Rx’d w/ imatinib: 89% 5-y overall survival, 95% survival free of CML-related deaths, 7% progression to blast phase at 5 y <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;355:2408)</span>. Pts in CCyR (~equal to QT-PCR if 1% IS) have normal life expectancy. QT-PCR &gt;4-log ↓ can consider TKI discontinuation trial <span class="r1">(</span><span class="r2">Lancet Onc</span> <span class="r1">2018;19:747)</span>.</p>
<p class="h1cr">C<small class="calibre31">HRONIC</small> L<small class="calibre31">YMPHOCYTIC</small> L<small class="calibre31">EUKEMIA</small> (CLL)</p>
<p class="center"><i class="calibre6">see “Small Lymphocytic Lymphoma”</i></p>
<h2 class="ct"><a id="h72" class="calibre8"></a><a id="page_5-20" class="calibre8"></a><a href="part0003.html#rh80" class="calibre8">LYMPHOMA AND CLL</a></h2>
<p class="h">Definition</p>
<p class="noindent1">• Malignant disorder of lymphoid cells that reside predominantly in lymphoid tissues</p>
<p class="noindent1">• Generally characterized as <b class="calibre7">Hodgkin lymphoma</b> (HL) or <b class="calibre7">non-Hodgkin lymphoma</b> (NHL)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Lymphadenopathy (usually nontender)</p>
<p class="noindent2"><b class="calibre7">HL:</b> superficial (usually <b class="calibre7">cervical</b>/<b class="calibre7">supraclavicular</b>) ± mediastinal LAN; <b class="calibre7">nodal</b> disease with <b class="calibre7">orderly</b>, <b class="calibre7">anatomic spread</b> to adjacent nodes</p>
<p class="noindent2"><b class="calibre7">NHL:</b> diffuse; <b class="calibre7">nodal and/or extranodal</b> disease with <b class="calibre7">noncontiguous spread;</b> symptoms reflect involved sites (abdominal fullness, bone pain)</p>
<p class="noindent1">• Constitutional (“B”) symptoms: <b class="calibre7">fever</b> (&gt;38°), drenching <b class="calibre7">sweats</b>, ↓ <b class="calibre7">weight</b> (&gt;10% in 6 mo)</p>
<p class="noindent2"><b class="calibre7">HL:</b> periodic, recurrent “Pel-Ebstein” fever; 10–15% have pruritus; ~35% “B” symptoms</p>
<p class="noindent2"><b class="calibre7">NHL:</b> “B” symptoms vary between subtypes, ~15–50%</p>
<p class="h">Diagnostic and staging evaluation</p>
<p class="noindent1">• Physical exam: lymph nodes, liver/spleen size, Waldeyer’s ring, testes (~1% of NHL), skin</p>
<p class="noindent1">• Pathology: <b class="calibre7">excisional lymph node bx</b> (<i class="calibre6">not FNA</i> b/c need surrounding architecture) with immunophenotyping and cytogenetics (<b class="calibre7">Reed-Sternberg</b> (RS) <b class="calibre7">cells in HL)</b>; <b class="calibre7">BM</b> bx if cytopenias; CLL by peripheral flow in patients w/ peripheral disease; LP if CNS involvement clinically suspected</p>
<p class="noindent1">• Lab tests: CBC, BUN/Cr, LFTs, ESR, LDH, UA, Ca, alb; ✓ HBV &amp; HCV (and must ✓ HBsAg &amp; anti-HBc if planning rituximab Rx due to risk of HBV reactivation); <span class="r">HIV</span></p>
<p class="noindent1">• Imaging: <b class="calibre7">PET-CT</b> to assess disease burden and guide biopsy/therapy, especially in HL, DLBCL. Head CT/MRI <i class="calibre6">only</i> if neurologic symptoms.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Ann Arbor Staging System with Cotswolds Modifications</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Stage</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Features</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">I</p></td>
<td class="th1"><p class="tbody">Single lymph node (LN) region</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">II</p></td>
<td class="th1"><p class="tbody">≥2 LN regions on the same side of the diaphragm</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">III</p></td>
<td class="th1"><p class="tbody">LN regions on both sides of the diaphragm</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">IV</p></td>
<td class="th1"><p class="tbody">Disseminated involvement of one or more extralymphatic organs</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody">Modifiers: A = no symptoms; B = fever, night sweats or weight loss; X = ”bulky” mediastinal disease or mass &gt;10 cm; E = single contiguous extranodal site; H = hepatic; S = splenic</p></td>
</tr>
</tbody>
</table>
<p class="h1cr">H<small class="calibre31">ODGKIN</small> L<small class="calibre31">YMPHOMA</small> (HL) <span class="r3">(</span><span class="r4">Am J Hematol</span> <span class="r3">2018;93:704;</span> <span class="r4">Lancet</span> <span class="r3">2021;398:1518)</span></p>
<p class="h">Epidemiology and risk factors</p>
<p class="noindent1">• ~9,000 cases/y; bimodal distribution (15–35 &amp; &gt;50 y); ↑ ♂; role of EBV in subsets of HL, esp. immunocompromised patients (eg, HIV)</p>
<p class="h">Pathology</p>
<p class="noindent1">• Affected nodes show RS cells (&lt;1%) in background of non-neoplastic inflammatory cells</p>
<p class="noindent1">• Classic RS cells: bilobed nucleus &amp; prominent nucleoli with surrounding clear space (“owl’s eyes”). RS cells are <b class="calibre7">clonal B-cells:</b> CD15+, CD30+, CD20– (rarely +).</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">WHO Histologic Classification of Classical HL</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Nodular sclerosis</b></p></td>
<td class="th1"><p class="tbodyc">60–80%</p></td>
<td class="th1"><p class="tbody">Collagen bands; frequent mediastinal LAN; young adults; female predominance; usually stage I or II at dx</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Mixed cellularity</b></p></td>
<td class="th1"><p class="tbodyc">15–30%</p></td>
<td class="th1"><p class="tbody">Pleomorphic; older age; male predominance; ≥50% stage III or IV at presentation; intermediate prognosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Lymphocyte rich</b></p></td>
<td class="th1"><p class="tbodyc">5%</p></td>
<td class="th1"><p class="tbody">Abundant normal-appearing lymphocytes; mediastinal LAN uncommon; male predominance; good prognosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Lymphocyte depleted</b></p></td>
<td class="th1"><p class="tbodyc">&lt;1%</p></td>
<td class="th1"><p class="tbody">Diffuse fibrosis and large numbers of RS cells; older, male patients; disseminated at dx; seen in HIV; worst prognosis</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Nonclassical HL</b> (5%): nodular lymphocyte predominant (NLP); involves peripheral LN</p>
<p class="noindent2">80% present in stages I–II, Rx w/ RT vs. chemoRT w/ 4-yr PFS 88% and OS 96% <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2008;26:434)</span>; consider rituximab because most NLP RS cells are CD20+</p>
<p class="noindent2">Stages III–IV treated with combination chemo (see below)</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v5.2021)</span></p>
<p class="noindent1">• <b class="calibre7">Stages I–II</b>: PET adapted <b class="calibre7">ABVD</b> (doxorubicin, bleomycin, vinblastine, dacarbazine) ± RT Favorable: ABVD × 2–4 cycles ± RT (if PET ⊖ after 2 cycles reduce chemo or RT)</p>
<p class="noindent2">Unfavorable (&gt;50 y, bulky mediastinum, “B” sx, ESR &gt;50, &gt;3 nodal sites): ABVD × 4–6 + RT (stop at 4 cycles if PET ⊖ after 2 cycles)</p>
<p class="noindent1"><a id="page_5-21" class="calibre4"></a>• <b class="calibre7">Stages III–IV: ABVD</b> × 6 cycles (can omit B if PET ⊖ after 2 cycles; <span class="r2">NEJM</span><span class="r1"> 2016;374:2419</span>); brentuximab (anti-CD30) may replace bleo but more toxic <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:331);</span> add RT for select Pts as consolidation</p>
<p class="noindent1">• Refractory/relapsed disease: salvage chemo + auto HSCT ± RT</p>
<p class="noindent2">brentuximab vedotin post-ASCT yields some long-term remissions <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2016;128:1562)</span></p>
<p class="noindent2">PD1/PDL1 blockade (pembrolizumab or nivolumab) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:311,</span> <span class="r2">JCO</span> <span class="r1">2017;35:19)</span></p>
<p class="noindent1">• Late treatment effects include ↑ risk for:</p>
<p class="noindent2"><b class="calibre7">Second cancers:</b> ~4.6× risk for up to 40 y <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:2499)</span></p>
<p class="noindent3"><i class="calibre6">breast</i> (if RT), ∴ annual screening at age 40 or 8–10 y post RT; <i class="calibre6">leukemia/MDS; NHL</i></p>
<p class="noindent2"><b class="calibre7">Cardiac disease</b> (if RT or anthracycline), ? role of echo/stress at 10 y (controversial)</p>
<p class="noindent2"><b class="calibre7">Pulmonary toxicity</b> (if bleomycin);<b class="calibre7"> Hypothyroidism</b> (if RT), ∴ annual TSH (if neck RT)</p>
<p class="noindent1">• <b class="calibre7">International Prognostic Score</b> (IPS; <span class="r2">JCO</span><span class="r1"> 2012;30:3383</span>) risk factors: albumin &lt;4 g/dL, Hb &lt;10.5 g/dL, male gender, age &gt;45 y, stage IV, WBC ≥15 k/µL, lymphocytes &lt;600/µL or &lt;8% of diff. 5-yr PFS 62–88% based on # of risk factors.</p>
<p class="h1cr">N<small class="calibre31">ON</small>-H<small class="calibre31">ODGKIN</small> L<small class="calibre31">YMPHOMA</small> (NHL)</p>
<p class="h">Epidemiology and risk factors</p>
<p class="noindent1">• 79 types of NHL, ~70,000 new cases/y; median age dx 65 y; ♂ predom; 85% B-cell origin</p>
<p class="noindent1">• Associated conditions: immunodeficiency (eg, HIV, posttransplant); autoimmune</p>
<p class="noindent2">disorders (eg, Sjögren’s, RA, SLE); infection (eg, EBV, HTLV-I, <i class="calibre6">H. pylori</i>)</p>
<p class="noindent1">• Burkitt lymphoma: (1) endemic or African (jaw mass, 80–90% EBV-related); (2) sporadic or American (20% EBV-related); (3) HIV-related</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre18"/>
<col class="calibre18"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">WHO Classification of Lymphoid Malignancies</b> <span class="sm">(<i class="calibre6">Blood</i> 2016;127:2375)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Examples</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Associated Abnormalities</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Mature B cell</b></p>
<p class="tbodyc"><img src="../images/00082.jpeg" alt="" class="calibre5"/></p>
<p class="tbodyc"><i class="calibre6">aggressiveness</i></p></td>
<td class="th1"><p class="tbodyh">Burkitt’s lymphoma</p>
<p class="tbodyh">Diffuse large B-cell lymphoma (DLBCL)</p>
<p class="tbodyh">Mantle cell</p>
<p class="tbodyh">Marginal zone lymphoma (nodal, extranodal, splenic)</p>
<p class="tbodyh">Hairy cell leukemia (⊕ TRAP)</p>
<p class="tbodyh">Follicular lymphoma</p>
<p class="tbodyh">CLL/small lymphocytic lymphoma</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">8q24, c-MYC</i></p>
<p class="tbodyh"><i class="calibre6">BCL2, MYC, MLL2, CREBBP, etc.</i></p>
<p class="tbodyh"><i class="calibre6">t(</i>11;1<i class="calibre6">4) BCL</i>1<i class="calibre6">-IgH</i> → cyclin D1</p>
<p class="tbodyh"><i class="calibre6">AP</i>1<i class="calibre6">2-MALT</i>1 <i class="calibre6">&amp; BCL-</i>1<i class="calibre6">0-Ig enh</i></p>
<p class="tbodyh"> </p>
<p class="tbodyh"><i class="calibre6">BRAF V600E</i></p>
<p class="tbodyh"><i class="calibre6">IGH-BCL2, MLL2, CREBBP</i></p>
<p class="tbodyh"><i class="calibre6">IGHV, TP53, ATM, SF3B</i>1<i class="calibre6">, etc.</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Mature T cell &amp; NK cell</b></p></td>
<td class="th1"><p class="tbodyh">Peripheral T-cell lymphoma</p>
<p class="tbodyh">Mycosis fungoides (cutaneous lymphoma)/ Sézary syndrome (+ LAN)</p>
<p class="tbodyh">Anaplastic large-cell lymphoma</p>
<p class="tbodyh">Angioimmunoblastic T-cell lymphoma</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">TET2 and DNMT3A</i></p>
<p class="tbodyh"> </p>
<p class="tbodyh">Some <i class="calibre6">ALK</i>1 ⊕</p></td>
</tr>
</tbody>
</table>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;390:298)</span></p>
<p class="noindent1">• Treatment and prognosis determined by histopathologic classification rather than stage</p>
<p class="noindent1">• Rituximab (anti-CD20; <span class="r2">NEJM</span><span class="r1"> 2012;366:2008</span>) if CD20+</p>
<p class="noindent1">• <b class="calibre7">Indolent:</b> generally no cure (except allo HSCT), goal sx mgmt (bulky dis, cytopenia, “B” sx)</p>
<p class="noindent2">Follicular Lymphoma Int’l Prog. Index (FLIPI; <span class="r2">Blood</span> <span class="r1">2004;104:1258</span>): risk factors = age &gt;60, stage III/IV, Hb &lt;12 g/dL, &gt;4 nodal areas, LDH &gt;nl. 5-yr OS 52–90% based on score.</p>
<p class="noindent2">Initial: RT if localized, rituximab + chemo (bendamustine, CVP, fludarabine), ibrutinib.</p>
<p class="noindent3">Obinutuzumab (anti-CD20) + chemo w/ obin maint ↑ PFS but ↑ tox <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2017;377:1331)</span>.</p>
<p class="noindent2">Maintenance: rituximab in indolent, aggressive, and relapsed disease <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2011;377:42)</span></p>
<p class="noindent2"><span class="underline">Hairy cell</span>: cladribine; oral BRAF inhibitor if relapsed/refractory <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:1733)</span></p>
<p class="noindent2"><span class="underline">Gastric MALT</span>: ✓ <i class="calibre6">H. pylori</i>; can cure by treating <i class="calibre6">H. pylori</i> if ⊕; RT for relapsed/refractory</p>
<p class="noindent1">• <b class="calibre7">Aggressive:</b> goal is cure <span class="r1">(</span><span class="r2">Am J Hematol</span> <span class="r1">2019;94:604)</span>, treatment depends on subtype</p>
<p class="noindent2">International Prognostic Index (IPI; <span class="r2">Blood</span><span class="r1"> 2007;109:1857</span>): risk factors = age &gt;60 y, stage III/IV, ≥2 extranodal sites, PS ≥2, LDH &gt;nl. 4-yr OS 55–94% based on score.</p>
<p class="noindent2"><b class="calibre7">R-CHOP</b> (<span class="underline">r</span>ituximab, <span class="underline">c</span>yclophosphamide, doxorubicin = <span class="underline">h</span>ydroxydaunorubicin, vincristine = <span class="underline">O</span>ncovin, <span class="underline">p</span>rednisone) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;346:235 &amp; 2008;359:613)</span> DLBCL 10-y PFS = 45%; overall survival = 55% <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2010;116:2040)</span></p>
<p class="noindent2">+ <b class="calibre7">Radiation</b> for localized or bulky disease</p>
<p class="noindent2">Consider <b class="calibre7">CNS prophylaxis</b> w/ intrathecal vs. systemic high-dose MTX if paranasal sinus, testicular, breast, periorbital, paravertebral, or bone marrow involved; also w/ ≥2 extranodal sites + ↑ LDH. Controversial <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2021;139:413)</span>.</p>
<p class="noindent2">Refractory/relapsed disease: salvage chemo; high-dose chemo + auto-HSCT <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2001;19:406)</span>; allo-HSCT if beyond 2<sup class="calibre19">nd</sup> relapse <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2011;29:1342)</span></p>
<p class="noindent2"><b class="calibre7">CAR-T</b> (qv): axicabtagene <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:2531)</span>, tisagenlecleucel <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:45)</span>, lisocabtagene <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2020;396:839)</span>, brexucabtagene (mantle cell; <span class="r2">NEJM</span><span class="r1"> 2020; 382:1331</span>)</p>
<p class="noindent2"><span class="underline">Mantle cell</span>: ibrutinib for relapsed/refractory disease <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:770)</span></p>
<p class="noindent1"><a id="page_5-22" class="calibre4"></a>• <b class="calibre7">Highly aggressive</b></p>
<p class="noindent2"><b class="calibre7">Burkitt:</b> dose-adjusted EPOCH-R <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:1915)</span> or CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, ifosfamide, etoposide, high-dose cytarabine rituximab) <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2008;112:2248)</span></p>
<p class="noindent2">All Pts receive CNS &amp; tumor lysis syndrome prophylaxis</p>
<p class="noindent2">Rituximab ↑ event-free survival <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:2402)</span></p>
<p class="noindent2"><b class="calibre7">High-grade B-cell lymphoma w/ rearrangements of MYC and BCL2 and/or BCL6:</b> “double-/triple-hit”, assoc. w/ poor prognosis. Often use DA-R-EPOCH.</p>
<p class="h">HIV-associated NHL <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2006;107:13)</span></p>
<p class="noindent1">• HIV ⊕ imparts 60–100× relative risk</p>
<p class="noindent1">• NHL is an AIDS-defining malignancy along with Kaposi’s, cervical CA, anal CA</p>
<p class="noindent1">• Concurrent HAART &amp; chemotherapy likely provide survival benefit</p>
<p class="noindent1">• DLBCL &amp; immunoblastic lymphoma (67%): CD4 &lt;100, EBV-associated. Burkitt lymphoma (20%): can occur with CD4 &gt;200. Generally, treat as immunocompetent, but avoid rituximab if CD4 &lt;50 (due to increased risk of death from infection).</p>
<p class="noindent1">• Primary CNS lymphoma (16%): CD4 &lt;50, EBV-assoc. (also seen in Pts w/o HIV). Rx w/ high-dose MTX-based regimen + steroid ± temozolomide ± RT, consider auto HSCT.</p>
<p class="h1cr">S<small class="calibre31">MALL</small> L<small class="calibre31">YMPHOCYTIC</small> L<small class="calibre31">YMPHOMA</small> (SLL) <small class="calibre31">OR</small> C<small class="calibre31">HRONIC</small> L<small class="calibre31">YMPHOCYTIC</small> L<small class="calibre31">EUKEMIA</small> (CLL)</p>
<p class="h">Definition <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2005;352:804;</span> <span class="r2">Blood</span> <span class="r1">2008;111:5446)</span></p>
<p class="noindent1">• Monoclonal, functionally incompetent mature B lymphocytes; CLL &amp; SLL = same disease</p>
<p class="noindent1">• <span class="underline">CLL</span>: &gt;5000/µL malignant cells; <span class="underline">SLL</span>: &lt;5000/µL malignant cells + LAN ± splenomegaly</p>
<p class="noindent1">• <span class="underline">Monoclonal B lymphocytosis</span>: resembles but does not meet CLL criteria, observe</p>
<p class="h">Epidemiology and risk factors</p>
<p class="noindent1">• ~15,000 new cases/y; median age at dx is 71 y; most common adult leukemia</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Often asx</b> &amp; identified by lymphocytosis on CBC; 10–20% p/w “B symptoms”</p>
<p class="noindent1">• <b class="calibre7">Lymphadenopathy</b> (80%) and <b class="calibre7">hepatosplenomegaly</b> (50%)</p>
<p class="noindent1">• <b class="calibre7">Autoimmune hemolytic anemia</b> (AIHA) (~10%) or <b class="calibre7">thrombocytopenia</b> (ITP) (~1–2%)</p>
<p class="noindent1">• Hypogammaglobulinemia ± neutropenia → ↑ susceptibility to <b class="calibre7">infections</b></p>
<p class="noindent1">• Bone marrow failure in ~13%; monoclonal gammopathy in ~5%</p>
<p class="noindent1">• Aggressive <b class="calibre7">Richter’s transformation</b> in ~5% into high-grade lymphoma (poor prognosis)</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• <b class="calibre7">CBC w/ diff</b>: <b class="calibre7">B-cell count</b></p>
<p class="noindent1">• <b class="calibre7">Peripheral smear: lymphocytosis</b> (predominantly mature-appearing small cells) “<b class="calibre7">smudge</b>” cells from damage to abnl lymphs from shear stress of making blood smear</p>
<p class="noindent1">• <b class="calibre7">Flow cytometry: clonality</b> with dim surface Ig; CD5+, CD19+, CD20+, CD23+</p>
<p class="noindent1">• Bone marrow (not req for dx): normo- or hypercellular; ≥30% small B lymphocytes</p>
<p class="noindent1">• <b class="calibre7">Genetics:</b> del 11q22-23 &amp; del(17p) unfavorable; trisomy 12 neutral; del 13q14 and mut <i class="calibre6">IGHV</i> favorable. Nine significantly mutated genes, including <i class="calibre6">TP53, NOTCH1</i>, <i class="calibre6">MYD88</i>, and <i class="calibre6">SF3B1.</i> Key role for spliceosome mutations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;365:2497;</span> <span class="r2">JCI</span> <span class="r1">2012;122:3432)</span>.</p>
<p class="imaget"><img src="../images/00083.jpeg" alt="" class="calibre5"/></p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:460)</span></p>
<p class="noindent1">• Observation unless “active disease”: Rai stage III/IV, Binet stage C, disease-related sx, progressive disease, AIHA or ITP refractory to steroids, recurrent infections</p>
<p class="noindent1">• <b class="calibre7">First-line:</b> w/o del(17p)/TP53 use acalabrutinib or ibrutinib (BTK inhibitors) or venetoclax + rituximab; with del(17p)/TP53 use acalabrutinib or venetoclax ± obinutuzumab; ibrutinib + venetoclax w 88% w/ CR but ↑ tox <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2095)</span></p>
<p class="noindent1">• Second-line &amp; beyond: in general, choose Rx w/ mechanism different from 1<sup class="calibre19">st</sup> line Rx. BTK inhibitors (eg, zanubrutinib), venetoclax, chemo including fludarabine, chlorambucil, or bendamustine + rituximab. Consider allo-HSCT in relapse.</p>
<p class="noindent1">• HSCT is the only curative Rx. Rx choice balances patient/disease characteristics and goals of care. Different rates of complete remission, time to progression, and toxicities.</p>
<p class="noindent1">• Rx for complications: PCP, HSV, VZV Ppx; AIHA/ITP → steroids; recurrent infxns → IVIg</p>
<h2 class="ct"><a id="h73" class="calibre8"></a><a id="page_5-23" class="calibre8"></a><a href="part0003.html#rh81" class="calibre8">PLASMA CELL DYSCRASIAS</a></h2>
<div class="cap">
<p class="caption"><a id="fig5-6" class="calibre4"></a><b class="calibre7">Figure 5-6</b> Spectrum of nonmalignant to malignant clonal plasma cell disorders</p>
<p class="imagef1"><img src="../images/00084.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Monoclonal Gammopathy of Uncertain Significance (MGUS) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:241)</span></p>
<p class="noindent1">• ✓ CBC, Ca, Cr, SPEP, serum free light chains, UPEP w/ immunofixation (to exclude MM)</p>
<p class="noindent1">• Close observation: repeat SPEP in 6 mo, then yearly thereafter if stable</p>
<p class="noindent1">• ~1%/y or ~25% lifetime risk → MM, WM, amyloidosis, or malign. lymphoproliferative dis.</p>
<p class="noindent1">• Abnormal serum free light chain ratio &amp; M protein ≥1.5 g/dL: ↑ risk of progression to MM</p>
<p class="h">Smoldering Multiple Myeloma</p>
<p class="noindent1">• Need whole-body MRI or PET-CT to rule out occult bone lesions</p>
<p class="noindent1">• Risk of prog. 10%/y, depends on [M protein], subtype, FLC ratio. No defined role for Rx yet though trials ongoing <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:438;</span> <span class="r2">Blood</span> <span class="r1">2019;134:781;</span> <span class="r2">JCO</span><span class="r1"> 2020;38:1126)</span>.</p>
<p class="h1cr">M<small class="calibre31">ULTIPLE</small> M<small class="calibre31">YELOMA</small> (MM)</p>
<p class="h">Definition and epidemiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:410)</span></p>
<p class="noindent1">• Malignant neoplasm of <b class="calibre7">plasma cells</b> producing a monoclonal Ig = “<b class="calibre7">M protein</b>”</p>
<p class="noindent1">• ~27,000 new cases/y; median age at diagnosis 69 y; more common in African Americans</p>
<p class="h">Clinical manifestations <span class="r">(CRAB criteria and other less common features)</span></p>
<p class="noindent1">• Hyper<b class="calibre7"><span class="underline">C</span></b>alcemia due to ↑ osteoclast activity</p>
<p class="noindent1">• <b class="calibre7"><span class="underline">R</span></b>enal disease: multiple mechanisms include toxic effect of filtered light chains → <i class="calibre6">renal failure</i> (cast nephropathy) or <i class="calibre6">type II RTA;</i> amyloidosis or light chain deposition disease → <i class="calibre6">nephrotic syndrome;</i> hypercalcemia, urate nephropathy, type I cryoglobulinemia</p>
<p class="noindent1">• <b class="calibre7"><span class="underline">A</span></b>nemia (normocytic) due to bone marrow involvement; rarely, may see AIHA</p>
<p class="noindent1">• Lytic <b class="calibre7"><span class="underline">B</span></b>one lesions due to ↑ osteoclast activity → pathologic fx</p>
<p class="noindent1">• Recurrent infxns due to relative hypogammaglob. (clonal plasma cells suppress nl Ig)</p>
<p class="noindent1">• Neurologic: cord compression; POEMS (<span class="underline">p</span>olyneuropathy, <span class="underline">o</span>rganomegaly, <span class="underline">e</span>ndocrinopathy, <span class="underline">M</span> protein, <span class="underline">s</span>kin changes) syndrome</p>
<p class="noindent1">• Hyperviscosity: usually when IgM &gt;4 g/dL, IgG &gt;5 g/dL, or IgA &gt;7 g/dL</p>
<p class="noindent1">• Coagulopathy: seen in amyloid due to binding &amp; depletion of Factor X</p>
<p class="noindent1">• AL amyloidosis (see “Amyloidosis”)</p>
<p class="h">Diagnostic and staging evaluation <span class="r1">(</span><span class="r2">Lancet Onc</span> <span class="r1">2014;15:e538)</span></p>
<p class="noindent1">• <b class="calibre7">Dx:</b> BM plasma cells ≥10% or bx-proven plasmacytoma &amp; ≥1 <b class="calibre7">MM-defining event</b>:</p>
<p class="noindent2">(a) myeloma-related organ or tissue impairment (<b class="calibre7">ROTI</b>) = lytic bone lesions, Ca &gt;11 mg/dL, Cr &gt;2 mg/dL, or Hb &lt;10 g/dL</p>
<p class="noindent2">(b) any of the following biomarkers: BM plasma cells ≥60%, serum free light chain (FLC) ratio ≥100:1, &gt;1 focal lesion on MRI</p>
<p class="noindent1">• <b class="calibre7">Variants</b></p>
<p class="noindent2">Solitary bone or extramedullary plasmacytoma: no periph plasmacytosis or other ROTI</p>
<p class="noindent2">Plasma cell leukemia: plasma cell count &gt;2000/µL in peripheral blood</p>
<p class="noindent2">Nonsecretory MM (~2% of MM Pts; MM without M protein)</p>
<p class="noindent1">• ✓ Peripheral smear for rouleaux (see insert), Ca, alb, Cr; ↓ anion gap, ↑ globulin, ↑ ESR</p>
<p class="noindent1">• <b class="calibre7">Protein electrophoresis and immunofixation</b></p>
<p class="noindent2"><b class="calibre7">Serum protein electrophoresis (SPEP):</b> quantitates M component; ⊕ in &gt;80% of Pts</p>
<p class="noindent2">Ddx of M component: MM, MGUS (vide supra), CLL, lymphoma, sarcoidosis, RA Polyclonal hypergam seen in inflammatory states: HIV, rheumatic diseases, cirrhosis</p>
<p class="noindent2">Urine protein electrophoresis (UPEP): detects Pts who secrete only light chains (= Bence Jones proteins), which are filtered rapidly from the blood</p>
<p class="noindent2">Immunofixation: shows component is monoclonal and identifies Ig type → IgG (50%), IgA (20%), IgD (2%), IgM (0.5%), light chain only (20%), nonsecretors (&lt;5%)</p>
<p class="noindent2"><b class="calibre7">Serum FLC assay:</b> important for dx (esp. light chain-only Pts) and f/up response to Rx</p>
<p class="noindent1">• β<sub class="calibre10">2</sub>-microglobulin (β<sub class="calibre10">2</sub>M) and LDH levels reflect tumor burden</p>
<p class="noindent1">• <b class="calibre7">BM bx cytogenetics:</b> normal karyotype better than abnl. <b class="calibre7">Standard risk</b> = hyperdiploidy or t(11;14); <b class="calibre7">high risk</b> = hypodiploidy, del. 17p13 (~10% of Pts), t(4;14) &amp; t(4;16).</p>
<p class="noindent1"><a id="page_5-24" class="calibre4"></a>• <b class="calibre7">Skeletal survey</b> (plain X-rays) to identify lytic bone lesions and areas at risk for pathologic fracture<i class="calibre6">.</i> Whole-body PET-CT (scalp to toe) or MRI often used to detect bone lesions.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre20"/>
<col class="calibre20"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Multiple Myeloma Staging Systems</b> (OS does not account for cytogenetics)</p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Stage</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">ISS Criteria<sup class="calibre27"><a id="fn114-s1" class="calibre8"></a><a href="part0011.html#rfn114-s1" class="calibre8">*</a></sup></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Durie-Salmon (DS) Criteria</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">ISS Median OS</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">I</b></p></td>
<td class="th1"><p class="tbodyc">β<sub class="calibre17">2</sub>M &lt;3.5 mg/L</p>
<p class="tbodyc"><i class="calibre6">and</i></p>
<p class="tbodyc">albumin &gt;3.5 g/dL</p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">All:</i> Hb &gt;10 g/dL; Ca ≤12 mg/dL; 0–1 lytic bone lesions; IgG &lt;5 g/dL or IgA &lt;3 g/dL or urine light chain &lt;4 g/24 h</p></td>
<td class="th1"><p class="tbodyc">62 mo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">II</b></p></td>
<td colspan="2" class="th1"><p class="tbodyc">Fulfilling criteria for neither I nor III</p></td>
<td class="th1"><p class="tbodyc">44 mo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">III</b></p></td>
<td class="th1"><p class="tbodyc">β<sub class="calibre17">2</sub>M &gt;5.5 mg/L</p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">Any:</i> Hb &lt;8.5 g/dL; Ca &gt;12 mg/dL; &gt;5 lytic bone lesions; IgG &gt;7 g/dL or IgA &gt;5 g/dL or urine light chain &gt;12 g/24 h</p></td>
<td class="th1"><p class="tbodyc">29 mo (30 mo if Cr &lt;2 mg/dL; 15 mo if Cr ≥2 mg/dL)</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn114-s1" class="calibre8"></a><a href="part0011.html#fn114-s1" class="calibre8">*</a></sup>Consider R-ISS incl chrom abnl &amp; LDH (<i class="calibre6">JCO</i> 2005;23:3412 &amp; 2015;61:2267).</p>
<p class="h">Treatment and prognosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:754 &amp; 1319; 2018;378:518 &amp; 379:1811)</span></p>
<p class="noindent1">• Decisions dictated by risk stratification and transplant eligibility; generally incurable. Stratify via ISS criteria; R-ISS which includes chrom abnl &amp; LDH <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2015;61:2267)</span>.</p>
<p class="noindent1">• Rx incl. <b class="calibre7">proteasome inhibitors:</b> bortezomib (V), carfilzomib (K), ixazomib (I); <b class="calibre7">immunomodulators:</b> lenalidomide (R), thalidomide (T), pomalidomide (P); <b class="calibre7">immunotherapy:</b> daratumumab (anti-CD38, Dara), elotuzumab (anti-SLAMF7, Elo)</p>
<p class="noindent2">Other active drugs: dexamethasone (D), melphalan, panobinostat, cyclophosphamide</p>
<p class="noindent1">• <b class="calibre7">Induction Rx</b> w/ best response rate: proteasome inhib (V or K) + immunomod (eg, R). Triplet Rx ↑ OS vs. double <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:519)</span>. RVD most common regimen in US; KRD if high-risk <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:906 &amp; 2016;374:1621)</span>. Dara-RD an option <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2104)</span>.</p>
<p class="noindent2">Quad Rx (Dara-RVD) may improve response rates <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2020;136:936)</span>.</p>
<p class="noindent1">• If <i class="calibre6">not</i> transplant eligible: <b class="calibre7">induction Rx</b> ↑ survival, not curative; consider maint chemo</p>
<p class="noindent1">• If transplant <i class="calibre6">eligible:</i> after induction chemo then <b class="calibre7">high-dose melphalan</b> + <b class="calibre7">auto-HSCT.</b> Not curative, but ↑ progression-free survival (PFS) vs. chemo alone <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:895,</span> <span class="r2">Lancet Onc</span> <span class="r1">2015;16:1617)</span>. Offer if good perf. status &amp; no prohibitive comorbid. Maint Rx w/ R improves PFS/OS <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:10)</span>. Timing of HSCT (upfront vs. relapse) debatable.</p>
<p class="noindent1">• Relapsed/refractory: HSCT (if good prior response, no prior HSCT), Elo-PD, Dara-PD, venetoclax (anti-Bcl-2) + dex in t(11;14); rarely use Allo-SCT. CAR-T w/ idecabtagene vicleucel (anti-B-cell maturation antigen) after &gt;3 prior Rx: response rates &gt;70% <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:1726 &amp; 2021;384:705)</span>.</p>
<p class="noindent1">• Local radiation for solitary or extramedullary plasmacytoma</p>
<p class="noindent1">• Adjunctive Rx: <i class="calibre6">bone:</i> <b class="calibre7">bisphosphonates</b> <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2007;25:2464)</span>, XRT for sx bony lesions</p>
<p class="noindent2"><i class="calibre6">renal:</i> avoid NSAIDs &amp; IV contrast; consider plasmapheresis for acute renal failure</p>
<p class="noindent2"><i class="calibre6">hyperviscosity syndrome:</i> plasmapheresis; <i class="calibre6">infxns:</i> consider IVIg for recurrent infections</p>
<p class="noindent1">• Common <b class="calibre7">toxicities</b> of Rx: melphalan → myelosuppression; lenalidomide → low plts &amp; thromboembolism; bortezomib → periph. neuropathy; steroids → hyperglycemia, infxn</p>
<p class="h1cr">W<small class="calibre31">ALDENSTRÖM</small>’<small class="calibre31">S</small> M<small class="calibre31">ACROGLOBULINEMIA</small> (WM)</p>
<p class="h">Definition <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2009;114:2375;</span> <span class="r2">NEJM</span><span class="r1"> 2012;367:826)</span></p>
<p class="noindent1">• B-cell neoplasm (lymphoplasmacytic lymphoma) that secretes monoclonal IgM</p>
<p class="noindent1">• 91% w/ <i class="calibre6">MYD88</i> (NF-κB pathway) L265P mut., may distinguish from MM</p>
<p class="noindent1">• <i class="calibre6">No evidence of bone lesions</i> (IgM M component + lytic bone lesions = “IgM myeloma”)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Fatigue</b> from anemia is most common sx</p>
<p class="noindent1">• <b class="calibre7">Tumor infiltration:</b> BM (cytopenias), hepatomegaly, splenomegaly, lymphadenopathy</p>
<p class="noindent1">• <b class="calibre7">Circulating monoclonal IgM</b></p>
<p class="noindent2"><b class="calibre7">Hyperviscosity syndrome</b> (~15%): <i class="calibre6">Neurologic:</i> blurred vision (“sausage” retinal veins), HA, dizziness, Δ MS. <i class="calibre6">Cardiopulmonary:</i> congestive heart failure, pulm. infiltrates.</p>
<p class="noindent2">Type I <b class="calibre7">cryoglobulinemia → Raynaud’s phenomenon</b></p>
<p class="noindent2">Platelet dysfxn → mucosal bleeding</p>
<p class="noindent1">• <b class="calibre7">IgM deposition</b> (skin, intestine, kidney); amyloidosis and glomerulopathy</p>
<p class="noindent1">• <b class="calibre7">Autoantibody activity of IgM:</b> <i class="calibre6">Chronic AIHA</i> (prominent <b class="calibre7">rouleaux;</b> 10% Coombs’ ⊕ = AIHA). <i class="calibre6">Peripheral neuropathy:</i> may be due to IgM against myelin-associated glycoprotein.</p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• SPEP + immunofixation with IgM &gt;3 g/dL; 24-h urine for UPEP (only 20% have ⊕ UPEP)</p>
<p class="noindent1">• Bone marrow biopsy: ↑ plasmacytoid lymphocytes; β<sub class="calibre10">2</sub>-microglobulin for prognostic eval</p>
<p class="noindent1">• <b class="calibre7">Relative serum viscosity:</b> ratio serum viscosity to H<sub class="calibre10">2</sub>O (nl 1.8); hyperviscosity when &gt;5–6</p>
<p class="h">Treatment</p>
<p class="noindent1">• Hyperviscosity: <b class="calibre7">plasmapheresis;</b> limit transfusions if possible (worsen hyperviscosity)</p>
<p class="noindent1">• Sx (eg, prog. anemia): ritux ± chemo (eg, bendamustine, Cy, etc.); ritux + ibrutinib <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:2399)</span>; zanubrutinib <span class="r1">(</span><span class="r2">Lancet Haem</span> <span class="r1">2020;7:e837)</span>; everolimus or HSCT in salvage</p>
<h2 class="ct"><a id="h74" class="calibre8"></a><a id="page_5-25" class="calibre8"></a><a href="part0003.html#rh82" class="calibre8">HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)</a></h2>
<p class="center"><i class="calibre6">Transplantation of donor pluripotent cells that can reconstitute all recipient blood lineages</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Categories of Stem Cell Transplantation</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Allogeneic (Allo)</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Autologous (Auto)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Donor–recipient relationship</p></td>
<td class="th1"><p class="tbodyc">Immunologically distinct</p></td>
<td class="th1"><p class="tbodyc">Donor is also recipient</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">Graft-vs.-host disease</i></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Yes</i></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7"><i class="calibre6">No</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">Graft-vs.-tumor effect</i></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Yes</i></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7"><i class="calibre6">No</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Risk of graft contam. w/ tumor</p></td>
<td class="th1"><p class="tbodyc">No</p></td>
<td class="th1"><p class="tbodyc">Yes</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Relapse risk (leukemia)</p></td>
<td class="th1"><p class="tbodyc">Lower</p></td>
<td class="th1"><p class="tbodyc">Higher</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">Transplant-related mortality</i></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Higher</i></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Lower</i></b></p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Types of Allo HSCT:</b> <i class="calibre6">based on donor/recipient matching of major HLA antigens on Chr. 6</i> (4 principal genes for serotyping: <i class="calibre6">HLA-A</i>, -<i class="calibre6">B</i>, -<i class="calibre6">C</i>, &amp; -<i class="calibre6">DR;</i> each w/ 2 alleles ∴ 8 major Ag)</p>
<p class="noindent2"><i class="calibre6">Matched related</i> (MRD, sibling 8/8 major Ag match): lowest GVHD; <b class="calibre7">preferred donor</b></p>
<p class="noindent2"><i class="calibre6">Matched unrelated (MUD):</i> ↑ risk of GVHD; ∴ matching of 10 HLA alleles (<i class="calibre6">DQ</i> also) to ↓ risk; chance of match correlates w/ ethnicity <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:339)</span></p>
<p class="noindent2"><i class="calibre6">Mismatched related</i> (eg, 1/8 Ag mismatch): ↑ available donor pool, but ↑ GVHD, rejection; ∴ need additional immunosuppression</p>
<p class="noindent2"><i class="calibre6">Haploidentical</i>: typically, between parents and young children or sibs (“half” match); early post-tx cyclophosphamide reduces GVH by destroying proliferating alloreactive T-cells</p>
<p class="noindent2"><i class="calibre6">Umbilical cord blood:</i> HSC processed at birth &amp; stored. Yields lower cell number. Need 2 cords per adult. Neonatal immune cells: HLA-mismatch tolerated better, ↓ GVHD, slow immune reconstitution → ↑ late viral infections <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2010;116:4693)</span>.</p>
<p class="noindent1">• <b class="calibre7">Graft-vs.-host disease (GVHD):</b> <i class="calibre6">undesirable</i> side effect of allo HSCT allogeneic T cells view host cells as foreign; ↑ incid. w/ mismatch or unrelated donors</p>
<p class="noindent1">• <b class="calibre7">Graft-vs.-tumor (GVT):</b> <i class="calibre6">desired</i> effect in allo-SCT; graft T cells attack host tumor cells</p>
<p class="h">Indications <span class="r1">(</span><span class="r2">BBMT</span> <span class="r1">2015;21:1863; BMT 2015;50:1037)</span></p>
<p class="noindent1">• <b class="calibre7">Malignant disease:</b></p>
<p class="noindent2"><b class="calibre7">Auto HSCT</b> allows <i class="calibre6">high-dose myeloablative chemo</i> and then rescue what would be otherwise lethal cytopenias with autologous stem cells. Used in chemosensitive diseases such as relapsed/refractory DLBCL, MM, testicular germ cell tumor.</p>
<p class="noindent2"><b class="calibre7">Allo HSCT</b> produces <b class="calibre7">graft-vs.-tumor</b> (GVT) effect, in addition to hematopoietic rescue (used for AML, ALL, MDS, CML-blast crisis, CLL, lymphoma)</p>
<p class="noindent1">• <b class="calibre7">Nonmalignant disease:</b> allo HSCT replaces abnl lymphohematopoietic system w/ one from nl donor (eg, immunodeficiencies, aplastic anemia, hemoglobinopathies)</p>
<p class="h">Transplantation procedure <span class="r">(for Allo HSCT)</span></p>
<p class="noindent1">• <b class="calibre7">Pre-Tx conditioning regimen goal:</b> immunosuppression to allow donor cell engraftment &amp; anti-tumor efficacy to ↓ relapse risk. Type and dose of agents determine this balance.</p>
<p class="noindent2"><i class="calibre6">Myeloablative conditioning</i>: high-dose chemo and/or total body irradiation. Low relapse rates, high immunosuppression, higher transplant-related morbidity.</p>
<p class="noindent2"><i class="calibre6">Reduced-intensity conditioning (“RIC”)</i>: lower dose of chemo → ↓ transplant-related morbidity/mortality, but ↑ relapse b/c it relies more on GVT effect <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2015;126:23)</span>. Allows allo HSCT for older adults (&gt;60) or Pts w/ comorbidities.</p>
<p class="noindent1">• <b class="calibre7">Sources of hematopoietic stem cells</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:1487)</span></p>
<p class="noindent2"><i class="calibre6">Bone marrow (BM):</i> original source, preferred in non-malignant disease, ↓ GVHD rates</p>
<p class="noindent2"><i class="calibre6">Peripheral blood stem cells (PBSC)</i>: easier to collect, more commonly used. BM vs. PBSC ≈ survival; BM ↓ chronic GVHD, PBSC ↓ graft failure, faster engraftment.</p>
<p class="noindent2"><i class="calibre6">Umbilical cord blood stem cells (UCB):</i> see above in Types of Allo HSCT</p>
<p class="noindent1">• <b class="calibre7">Engraftment:</b> absolute neutrophil count (ANC) recovers to 500/µL w/in ~2 wk w/ PBSC, ~2.5 wk w/ BM, ~4 wk w/ UCB. G-CSF accelerates recovery by 3–5 d in all scenarios.</p>
<p class="h">Complications</p>
<p class="noindent1">• Either <b class="calibre7">direct chemoradiotoxicities</b> associated with preparative regimen or consequences of <b class="calibre7">interaction between donor and recipient immune systems</b></p>
<p class="noindent1">• <b class="calibre7">Engraftment syndrome</b><i class="calibre6">:</i> fever, rash, noncardiogenic pulm. edema, abnl LFTs, AKI, wt gain. Dx of exclusion: r/o infection, GVHD; Rx w/ 1 mg/kg steroids, rapid taper over 3–4 d.</p>
<p class="noindent1">• <b class="calibre7">Sinusoidal obstruction syndrome (SOS):</b> incidence ~10%, mortality ~30%</p>
<p class="noindent2">Previously known as <b class="calibre7">veno-occlusive disease (VOD)</b> <span class="r1">(</span><span class="r2">BBMT</span> <span class="r1">2016;22:400)</span>. Mechanism: direct cytotoxic injury to hepatic venules → <i class="calibre6">in situ</i> thrombosis.</p>
<p class="noindent2">Symptoms: tender hepatomegaly, ascites, jaundice, fluid retention with severe disease → liver failure, encephalopathy, hepatorenal syndrome</p>
<p class="noindent2">Diagnosis: ↑ ALT/AST, ↑ bilirubin; ↑ PT with severe disease; Doppler U/S <i class="calibre6">may</i> show reversal of portal vein flow; ↑ hepatic wedge pressure; abnl liver bx</p>
<p class="noindent2">Treatment: supportive; prophylaxis with <b class="calibre7">ursodiol;</b> treat w/ defibrotide <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2016;127:1656)</span></p>
<p class="noindent1"><a id="page_5-26" class="calibre4"></a>• <b class="calibre7">Idiopathic pneumonia syndrome (IPS):</b> 5–25% of Pts, &gt;50% mortality <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2003;102:2777)</span></p>
<p class="noindent2">Alveolar injury 2/2 direct toxicity → fever, hypoxia, diffuse infiltrates; occult infxn frequent</p>
<p class="noindent1">• <b class="calibre7">Bleeding</b>: incidence ~25%, 2/2 ↓↓ plts; sites: CNS, GI, pulm.; Ppx w plt transfusions</p>
<p class="noindent1">• <b class="calibre7">Diffuse alveolar hemorrhage (DAH):</b> Dx: bronchoscopy to exclude infection; ↑ bloody lavage fluid. Rx: 500–1000 mg Solu-Medrol × 3 d ± etanercept <span class="r1">(</span><span class="r2">BBMT</span> <span class="r1">2015;1:67)</span>.</p>
<p class="noindent1">• <b class="calibre7">Acute GVHD</b> (usually within 6 mo of transplant; <span class="r2">NEJM</span> <span class="r1">2017;377:2167</span>)</p>
<p class="noindent2">Clinical grades I–IV based on scores for <b class="calibre7">skin</b> (severity of maculopapular rash), <b class="calibre7">liver</b> (bilirubin level) and <b class="calibre7">GI</b> (volume of diarrhea); bx supports diagnosis</p>
<p class="noindent2">Prevention: <b class="calibre7">immunosuppression</b> (MTX + cyclosporine, or tacrolimus), T-cell depletion of graft, post-Tx cyclophos. for haploidentical, some high-risk allo <span class="r1">(</span><span class="r2">BBMT</span> <span class="r1">2008;14:641)</span></p>
<p class="noindent2">Treatment: grade I → topical Rx; grades II–IV → associated with ↓ survival and ∴ treated with immunosuppressants (corticosteroids, CsA, tacrolimus, rapamycin, MMF)</p>
<p class="noindent1">• <b class="calibre7">Chronic GVHD</b> (developing or persisting &gt;3 mo posttransplant; <span class="r2">NEJM</span><span class="r1"> 2017;377:2565</span>)</p>
<p class="noindent2">Clinical: malar rash, sicca syndrome, arthritis, obliterative bronchiolitis, bile duct degeneration, cholestasis, and many others. More common w/ PBSC than BM.</p>
<p class="noindent2">Treatment: immunosuppression; rituximab; photopheresis; ibrutinib <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2017;130:21)</span>, ruxolitinib <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021; 385:228)</span>, belumosudil <span class="r1">(</span><span class="r2">Blood</span> <span class="r1">2021;138:2278)</span></p>
<p class="noindent1">• <b class="calibre7">Graft failure</b></p>
<p class="noindent2">Primary = persistent neutropenia without evidence of engraftment</p>
<p class="noindent2">Secondary = delayed pancytopenia after initial engraftment; either immune mediated via immunocompetent host cells (<b class="calibre7">graft rejection</b>) or non–immune mediated (eg, CMV)</p>
<p class="noindent1">• <b class="calibre7">Infectious complications</b></p>
<p class="noindent2">due to regimen-induced pancytopenia and immunosuppression</p>
<p class="noindent2">auto HSCT recipients: no immunosuppression ∴ at ↑ risk only pre-/postengraftment</p>
<p class="noindent2">both primary infections and reactivation events occur (eg, CMV, HSV, VZV)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre20"/>
<col class="calibre23"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Timing of Complications Following Allogeneic HSCT</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td colspan="2" class="th1"><p class="tbodyc"><b class="calibre7">Time After Transplant and Associated Risk Factors</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Days 0–30</b> Mucositis; organ dysfunction; neutropenia</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Days 30–90</b> Acute GVHD; ↓ cell immunity</p></td>
<td class="th1"><p class="tbodyc">&gt;<b class="calibre7">90 Days</b> Chronic GVHD; ↓ cellular &amp; humoral immunity</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbodyh"><b class="calibre7">Viral infection</b></p></td>
<td class="th1" colspan="3"><p class="tbodyc">Respiratory and enteral viruses, BK virus</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">HSV<sup class="calibre27"><a id="fn116-s1" class="calibre8"></a><a href="part0011.html#rfn116-s1" class="calibre8">*</a></sup></p></td>
<td class="th1" colspan="2"><p class="tbodyc">CMV<sup class="calibre27"><a href="part0011.html#rfn116-s1" class="calibre8">*</a></sup>, HHV 6 &amp; 7</p></td>
</tr>
<tr class="calibre15">
<td class="th"><p class="tbody"> </p></td>
<td class="th1" colspan="2"><p class="tbodyc">EBV-related lymphoma</p></td>
</tr>
<tr class="calibre15">
<td class="th"><p class="tbody"> </p></td>
<td class="th"><p class="tbodyh"> </p></td>
<td class="th1"><p class="tbodyc">VZV<sup class="calibre27"><a href="part0011.html#rfn116-s1" class="calibre8">*</a></sup>, JC</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bacterial infection</b></p></td>
<td class="th1" colspan="2"><p class="tbodyc">Gram ⊕ cocci (<i class="calibre6">Staph.</i>, <i class="calibre6">Strep. viridans</i>)</p>
<p class="tbodyc">GNRs (Enterobacteriaceae, <i class="calibre6">Pseudomonas, Legionella, S. maltophilia</i>)</p></td>
<td class="th1"><p class="tbodyc">Encapsulated bacteria</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbodyh"><b class="calibre7">Fungal infection</b></p></td>
<td class="th1" colspan="2"><p class="tbodyc"><i class="calibre6">Candida</i> spp.</p></td>
<td class="th"><p class="tbodyh"> </p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbodyc"><i class="calibre6">Aspergillus</i> spp.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Parasitic infection</b></p></td>
<td class="th"><p class="tbodyh"> </p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">T. gondii</i></p>
<p class="tbodyc"><i class="calibre6">P. carinii</i></p>
<p class="tbodyc"><i class="calibre6">S. stercoralis</i></p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">T. gondii</i></p>
<p class="tbodyc"><i class="calibre6">P. carinii</i></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="7"><p class="tbodyh"><b class="calibre7">Regimen-related</b></p></td>
<td class="th1"><p class="tbodyc">Pancytopenia</p></td>
<td rowspan="6" class="th"><p class="tbodyh"> </p></td>
<td class="th1"><p class="tbodyc">Growth failure</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Mucositis, rash, alopecia</p></td>
<td class="th1"><p class="tbodyc">Hypogonadism/infertility</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Nausea, vomiting, diarrhea</p></td>
<td class="th1"><p class="tbodyc">Hypothyroidism</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Peripheral neuropathies</p></td>
<td class="th1"><p class="tbodyc">Cataracts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Hemorrhagic cystitis</p></td>
<td class="th1"><p class="tbodyc">Avascular necrosis of bone</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Veno-occlusive disease</p></td>
<td class="th1"><p class="tbodyc">2<sup class="calibre27">nd</sup> malignancy</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbodyc">IPS/Interstitial pneumonitis</p></td>
<td class="th1"><p class="tbodyh"> </p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbodyh"><b class="calibre7">Immune-mediated</b></p></td>
<td class="th1" colspan="2"><p class="tbodyc">Acute GVHD</p></td>
<td class="th1"><p class="tbodyc">Chronic GVHD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Primary graft failure</p></td>
<td class="th1" colspan="2"><p class="tbodyc">Secondary graft failure</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn116-s1" class="calibre8"></a><a href="part0011.html#fn116-s1" class="calibre8">*</a></sup>Primarily among persons who are seropositive before transplant.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td colspan="3" class="th"><p class="tbodyc"><b class="calibre7">Prophylaxis/Supportive Medications During HSCT</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Medication</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Prophylaxis Against</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Duration</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fluconazole or posaconazole</p></td>
<td class="th1"><p class="tbodyc"><i class="calibre6">Candida</i></p></td>
<td class="th1"><p class="tbodyc">75 d</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Acyclovir</p></td>
<td class="th1"><p class="tbodyc">HSV/VZV</p></td>
<td class="th1"><p class="tbodyc">365 d</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Valganciclovir, ganciclovir, or letermovir if CMV ⊕</p></td>
<td class="th1"><p class="tbodyc">CMV</p></td>
<td class="th1"><p class="tbodyc">100 d or when no longer immunosuppressed</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Antibiotics (eg, fluoroquinolone)</p></td>
<td class="th1"><p class="tbodyc">Bacterial infxn</p></td>
<td class="th1"><p class="tbodyc">While neutropenic</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">TMP-SMX or atovaquone</p></td>
<td class="th1"><p class="tbodyc">PCP</p></td>
<td class="th1"><p class="tbodyc">365 d or when off immunosupp.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Allopurinol</p></td>
<td class="th1"><p class="tbodyc">Hyperuricemia</p></td>
<td class="th1"><p class="tbodyc">Until d –1</p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h75" class="calibre8"></a><a id="page_5-27" class="calibre8"></a><a href="part0003.html#rh83" class="calibre8">LUNG CANCER</a></h2>
<p class="h">Epidemiology and risk factors</p>
<p class="noindent1">• Most common cause of cancer-related death for both men and women in the U.S.</p>
<p class="noindent1">• Two main types: <b class="calibre7">non-small cell</b> (NSCLC, ~85% of cases); <b class="calibre7">small cell</b> (SCLC, ~15%)</p>
<p class="noindent1">• <b class="calibre7">NSCLC</b> comprised of <b class="calibre7">adeno</b> (40%), <b class="calibre7">squamous cell</b> (SCC, 20%), &amp; large cell (5%) carcinomas, as well as other / not classified (20%)</p>
<p class="noindent1">• <b class="calibre7">Cigarette smoking:</b> 85% of lung cancers occur in smokers; risk ∝ total pack-yrs, ↓ risk after quitting/reducing but not to baseline <span class="r1">(</span><span class="r2">Int J Cancer</span> <span class="r1">2012;131:1210)</span>.</p>
<p class="noindent2">SCC &amp; SCLC almost exclusively in smokers, adeno most common type in nonsmokers.</p>
<p class="noindent1">• Asbestos: when combined with smoking, synergistic ↑ in risk of lung cancer</p>
<p class="noindent1">• Other: RT (for other cancer); HIV; environ. toxins (radon, 2<sup class="calibre19">nd</sup>-hand smoke); pulm. fibrosis</p>
<p class="h">Screening <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:962)</span></p>
<p class="noindent1">• <b class="calibre7">Annual low-dose chest CT</b> in ≥20 pack-year current or former (quit w/in 15 y) smokers, age 50–80 y → 20% ↓ lung cancer-related mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:503)</span></p>
<p class="noindent1">• High rates of screen-detected nodules. Multidisciplinary mgmt recommended (pulm., med onc, thoracic radiology &amp; surgery; <span class="r2">NCCN Guidelines: Lung Cancer Screening</span> <span class="r1">v.1.2022</span>).</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• ~10% asymptomatic at dx, detected incidentally (only 16% w/ localized dis. at presentation)</p>
<p class="noindent1">• <b class="calibre7">Endobronchial growth</b> of 1° tumor: <b class="calibre7">cough</b>, <b class="calibre7">hemoptysis</b>, <b class="calibre7">dyspnea</b>, pain, wheezing, post-obstructive pneumonia; more common with squamous or small cell (central location)</p>
<p class="noindent1">• <b class="calibre7">Regional spread</b>: can cause dysphagia (esophageal compression), stridor (tracheal obstruction), hoarseness (recurrent laryngeal nerve palsy). Pleural effusions &amp; pleural metastases specifically = metastatic disease = Stage IV.</p>
<p class="noindent2"><b class="calibre7">Pancoast’s syndrome:</b> apical tumor → brachial plexus involvement (C8, T1, T2) → Horner’s syndrome, shoulder pain, rib destruction, atrophy of hand muscles</p>
<p class="noindent2"><b class="calibre7">SVC syndrome</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2007;356:1862)</span>: central tumor → SVC compression → face/arm swelling (&gt;80%), neck/chest vein distention (~60%), SOB/cough (~50%), HA (~10%); Rx = steroids, diuretics, RT ± chemo, SVC stent if severe sx, anticoag if clot</p>
<p class="noindent1">• <b class="calibre7">Extrathoracic metastases:</b> brain (~25% of patients at dx), bone, liver, adrenal</p>
<p class="noindent1">• <b class="calibre7">Paraneoplastic syndromes</b></p>
<p class="noindent2"><i class="calibre6">Endo:</i> <b class="calibre7">SIADH</b> (SCLC); ACTH (SCLC) → <b class="calibre7">Cushing’s;</b> PTH-rP (SCC) → <b class="calibre7">hyperCa</b></p>
<p class="noindent2"><i class="calibre6">Skeletal:</i> digital clubbing (NSCLC), <b class="calibre7">hypertrophic pulm. osteoarthropathy</b> (adenocarcinoma) = symmetric polyarthritis and proliferative periostitis of long bones</p>
<p class="noindent2"><i class="calibre6">Neuro</i> (SCLC): <b class="calibre7">Eaton-Lambert</b> (anti-P/Q-type voltage-gated Ca<sup class="calibre19">2+</sup> channel Abs), peripheral neuropathy (anti-Hu, anti-PCA-2, anti-CRMP5), cerebellar degeneration (anti-Hu, anti-Yo, anti-Ri, anti-Tr), encephalomyelitis (anti-Hu, anti-Ma1/2, anti-CRMP5)</p>
<p class="noindent2"><i class="calibre6">Hematologic:</i> hypercoagulable state (adenocarcinoma), DIC</p>
<p class="h">Diagnostic and staging evaluation <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v.7.2021)</span></p>
<p class="noindent1">• <b class="calibre7">Staging:</b> based on tumor size and extent of invasion (T), regional LN involvement [N: N0 (none), N1 (ipsilat. hilar), N2 (ipsilat. mediast.), N3 (contralat., supraclav.)] and presence of metastases (M) <span class="r1">(</span><span class="r2">Chest</span><span class="r1"> 2017;151:193)</span>. Pleural effusions/implants = Stage IV.</p>
<p class="noindent2">5-y survival: ~70–90% for stage I, 50–60% stage II, 15–35% stage III, 0–10% stage IV <span class="r1">(</span><span class="r2">J Thorac Oncol</span> <span class="r1">2016;11:39)</span>; survival improving with newer therapies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:640)</span>.</p>
<p class="noindent1">• <b class="calibre7">Imaging: CT w/ contrast</b> of chest &amp; abd/pelvis to assess for mets (adrenal, liver, bones).</p>
<p class="noindent2"><b class="calibre7">PET-CT</b> more Se than CT alone for detecting mediastinal and distant mets as well as</p>
<p class="noindent2">bone mets <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;361:32)</span>. <b class="calibre7">Brain MRI</b> for all Pts except stage IA.</p>
<p class="noindent1">• <b class="calibre7">Pathology:</b> via<b class="calibre7"> bronchoscopy</b> (central lesions) or <b class="calibre7">CT-guided needle bx</b> (peripheral lesions or accessible sites of suspected metastasis); mediastinoscopy (LN bx / eval), VATS (eval. of pleural peripheral lesions), thoracentesis if pleural effusion (cytology).</p>
<p class="noindent1">• <b class="calibre7">Genetics</b> (usually just in adv/metastatic disease)<b class="calibre7">:</b> ✓ <i class="calibre6">EGFR</i> (include in stage IIA-IIIB), <i class="calibre6">ALK, ROS1, MET, KRAS, RET, BRAF, NTRK</i> fusion for all non-squamous disease (incidence lower in SCC but still consider testing); PD-L1 expression</p>
<p class="noindent1">• PFTs w/ quant V/Q if Rx includes resection; need 30% nl predicted lung fxn <i class="calibre6">after</i> resection</p>
<p class="h">NSCLC Treatment <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v.7.2021;</span> <span class="r2">Lancet</span> <span class="r1">2021;398:535)</span></p>
<p class="noindent1">• Localized disease: surgery if possible; RT (eg, stereotactic ablative radiotherapy [SABR]) vs. chemo/RT if not (see <a href="part0011.html#fig5-7" class="calibre4">Figure 5-7</a>)</p>
<p class="noindent1">• Metastatic disease: &gt;20 new Rx since 2015. Some targeted Rx substantially improves survival &amp; are better tolerated (see Stage IV Rx table); however, 5-y survival still poor.</p>
<p class="noindent3">First-line immunotherapy (IO) ± chemo for most Pts w/o targetable mutations.</p>
<p class="noindent3">Pemetrexed + pembrolizumab often continued as maintenance when used.</p>
<p class="noindent3">Palliative care ↑ survival <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:733)</span>; palliative RT for local sx from tumor/mets.</p>
<p class="noindent1">• Avoid combining IO &amp; targeted Rx, ↑↑ tox (eg, rash/diarrhea, lung/liver injury [can be fatal])</p>
<p class="noindent1">• Solitary brain metastasis (oligomet): surgical resection + brain radiation may ↑ survival</p>
<div class="cap">
<p class="caption"><a id="page_5-28" class="calibre4"></a><a id="fig5-7" class="calibre4"></a><b class="calibre7">Figure 5-7</b> Localized NSCLC treatment algorithm</p>
<p class="imagef1"><img src="../images/00085.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">(<i class="calibre6">NCCN Guidelines</i> v7.2021; <i class="calibre6">NEJM</i> 2017:377:1919, 2018;378:113, &amp; 2020;383:1711; <i class="calibre6">Lancet</i> 2021;398:1344)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre12"/>
<col class="calibre25"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Stage IV NSCLC Treatment</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Genetics</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">%</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="11"><p class="tbody"><b class="calibre7">Adeno or Other</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">EGFR</i></p></td>
<td class="th1"><p class="tbodyc">~15</p></td>
<td class="th1"><p class="tbody">1<sup class="calibre27">st</sup> line: osimertinib if L858R, ex19del <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:113)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">EGFR</i> ex20 insertion</p></td>
<td class="th1"><p class="tbodyc">2–3</p></td>
<td class="th1"><p class="tbody">Subsequent Rx w/ amivantamab <span class="sm">(<i class="calibre6">JCO</i> 2021;39:3391)</span> or mobocertinib <span class="sm">(<i class="calibre6">JAMA Onc</i> 2021;7:e214761)</span> after platinum chemo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">ALK</i></p></td>
<td class="th1"><p class="tbodyc">~4</p></td>
<td class="th1"><p class="tbody">1<sup class="calibre27">st</sup> line: alectinib pref. b/c CNS activity <span class="sm">(<i class="calibre6">NEJM</i> 2017;377:829)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">ROS</i>1</p></td>
<td class="th1"><p class="tbodyc">2</p></td>
<td class="th1"><p class="tbody">Crizotinib pref. <span class="sm">(<i class="calibre6">JCO</i> 2017;35:2613)</span>; entrectinib <span class="sm">(<i class="calibre6">Lancet Onc</i> 2020;21:261)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">MET</i> ex14 skip or amplif.</p></td>
<td class="th1"><p class="tbodyc">3</p></td>
<td class="th1"><p class="tbody">Capmatinib <span class="sm">(<i class="calibre6">NEJM</i> 2020;383:944)</span> or tepotinib <span class="sm">(<i class="calibre6">NEJM</i> 2020;383:931)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">RET</i></p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbody">Selpercatinib <span class="sm">(<i class="calibre6">NEJM</i> 2020;383:813)</span> or pralsetinib <span class="sm">(<i class="calibre6">Lancet Onc</i> 2021;22: 959-969)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">BRAF</i> V600E</p></td>
<td class="th1"><p class="tbodyc">1–3</p></td>
<td class="th1"><p class="tbody">Dabrafenib + trametinib <span class="sm">(<i class="calibre6">Lancet Onc</i> 2016;17:984)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">NTRK</i> fusions</p></td>
<td class="th1"><p class="tbodyc">&lt;1</p></td>
<td class="th1"><p class="tbody">Larotrectinib <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:731)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">KRAS</i> G12C</p></td>
<td class="th1"><p class="tbodyc">~13</p></td>
<td class="th1"><p class="tbody">Subsequent Rx w/ sotorasib <span class="sm">(<i class="calibre6">NEJM</i> 2021;384:2371)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PD-L1≥50%</p></td>
<td class="th1"><p class="tbodyc">30</p></td>
<td class="th1"><p class="tbody">Pembrolizumab or chemo + pembro <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:2078)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">No targets &amp; PD-L1 &lt;50%</p></td>
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody">Chemo (carbo/pemetrexed) + pembro <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:2078)</span> <i class="calibre6">or</i> carbo/paclitaxel + anti-VEGF Ab (bevacizumab) + atezo <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:2288)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Squam</b></p></td>
<td class="th1"><p class="tbody">PD-L1 ≥50%</p></td>
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody">Pembrolizumab or chemo/pembro <span class="sm">(<i class="calibre6">NEJM</i> 2016;375:1823)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody">PD-L1 &lt;50%</p></td>
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody">Chemo [carbo/paclitaxel] + pembro <span class="sm">(<i class="calibre6">NEJM</i> 2018;379:2040)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn">Many are specific tyrosine kinase inhibitors (‘tinibs) directed against EGFR, ALK, etc. Amivantamab is an EGFR- MET bispecific mAb. Pembrolizumab is a mAb against PD-1 on lymphocytes (ie, an immune checkpoint inhibitor).</p>
<p class="h">SCLC staging and treatment <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v.1.2022)</span></p>
<p class="noindent1">• SCLC usually disseminated at presentation; poor overall survival</p>
<p class="noindent1">• Can be very responsive to chemotherapy, but rapidly develop resistance</p>
<p class="noindent1">• <b class="calibre7">Diagnosis:</b> all have Rb &amp; p53 mutations <span class="r1">(</span><span class="r2">Nature</span> <span class="r1">2015;524:47)</span>; 90% w/ neuroendo markers</p>
<p class="noindent1">• <b class="calibre7">Treatment:</b> primarily chemo (platinum + etoposide); adding anti-PD-L1 Ab (atezolizumab)</p>
<p class="noindent2">↑ survival <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:2220)</span>, as does concurrent thoracic RT in limited-stage disease</p>
<p class="imaget"><img src="../images/00086.jpeg" alt="" class="calibre5"/></p>
<p class="noindent1">• <b class="calibre7">Prophylactic cranial irradiation</b> (PCI) controversial. Offered to potentially ↑ survival for LS-SCLC in complete remission <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1999;341:476).</span> Role in ES-SCLC being studied.</p>
<p class="noindent1">• <b class="calibre7">Second line</b>: low response rates, short survival. Options: lurbinectedin, single-agent chemo (eg, topotecan, docetaxel), reRx w/ platinum doublet, anti-PD-1 (eg, nivo).</p>
<h2 class="ct"><a id="h76" class="calibre8"></a><a id="page_5-29" class="calibre8"></a><a href="part0003.html#rh84" class="calibre8">BREAST CANCER</a></h2>
<p class="h">Epidemiology</p>
<p class="noindent1">• In U.S., most common cancer in women; 2<sup class="calibre19">nd</sup> leading cause of cancer death in women</p>
<p class="noindent1">• <b class="calibre7">Genetic risk:</b> 15–20% ⊕ FHx → 2× ↑ risk; ~45% familial cases a/w germline mutation.</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">BRCA1/2</i>:</b> 35–85% lifetime risk of breast ca. Germline loss-of-function mutations in <b class="calibre7"><i class="calibre6">PALB2</i></b> a/w 35% ↑ risk breast cancer by age 70. Moderate risk mutations <b class="calibre7"><i class="calibre6">CHEK2</i></b> and <b class="calibre7"><i class="calibre6">BARD1</i></b> a/w 15–30% lifetime risk of breast cancer <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:428)</span>.</p>
<p class="noindent1">• <b class="calibre7">Estrogen:</b> ↑ risk with early menarche, late menopause, late parity or nulliparity <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;354:270)</span>; ↑ risk with prolonged HRT (RR = 1.24 after 5.6 y; <span class="r2">JAMA</span><span class="r1"> 2003;289:3243</span>); OCP use a/w extremely low to no ↑ risk <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017:317:2228;</span> <span class="r2">JAMA Oncol</span> <span class="r1">2018;4:516)</span></p>
<p class="noindent1">• Benign breast conditions: ↑ risk if atypia (atypical ductal or lobular hyperplasia; <span class="r2">NEJM</span><span class="r1"> 2015;372:78</span>) or proliferative (ductal hyperplasia, papilloma, radial scar, or sclerosing adenosis) features; <i class="calibre6">no</i> ↑ risk w/ cysts, simple fibroadenoma, or columnar changes</p>
<p class="noindent1">• ↑ risk with h/o ionizing radiation to chest for treatment of Hodgkin lymphoma</p>
<p class="h">Prevention <span class="r">(if high-risk: eg, FHx, LCIS, atypical hyperplasia)</span></p>
<p class="noindent1">• Tamoxifen (contraindic. in preg): ↓ risk contralateral breast ca as adjuvant Rx. Approved for 1° prevent. if ↑ risk: ↓ invasive breast cancer, but ↑ DVT &amp; uterine ca.</p>
<p class="noindent1">• Raloxifene (only if post-menopausal): ↓ risk of invas breast ca, vertebral fx, &amp; uterine ca, ↑ risk stroke &amp; DVT/PE <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;355:125)</span>; less effective than tamoxifen for prevention.</p>
<p class="noindent1">• Aromatase inhib. (post-menopausal): ↓ risk &gt;50% <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2014;383:1041)</span>, ↑ osteoporosis</p>
<p class="noindent1">• <i class="calibre6">BRCA1/2</i> ⊕: intensified surveillance vs. prophylactic bilat. mastectomy which ↓ risk ~90%; bilat. salpingo-oophorectomy ↓ risk of ovarian <i class="calibre6">and</i> breast cancer <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:454)</span></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Breast mass (hard, irregular, fixed, nontender), nipple discharge (higher risk if unilateral, limited to 1 duct, bloody, associated with mass)</p>
<p class="noindent1">• Special types: <b class="calibre7">Paget</b> disease → unilateral nipple eczema + nipple discharge; <b class="calibre7">inflammatory</b> breast cancer → skin erythema and edema <i class="calibre6">(peau d’orange)</i></p>
<p class="noindent1">• Metastases: lymph nodes, bone, liver, lung, brain</p>
<p class="h">Screening <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2015;314:1599;</span> <span class="r2">Annals</span> <span class="r1">2019;170:547)</span></p>
<p class="noindent1">• <b class="calibre7">Mammography:</b> ~20–30% ↓ <b class="calibre7">in breast cancer mortality</b>, smaller abs. benefit in women &lt;50 y <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2018;319:1814)</span>; digital breast tomosynthesis (3-D) ↑ specificity <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> Oncol 2019;5:635)</span>; suspicious findings: clustered <b class="calibre7">microcalcifications</b>, <b class="calibre7">spiculated</b>, <b class="calibre7">enlarging</b></p>
<p class="noindent1">• ACS: annual mammo starting at 45 (consider biennial after 54), cont. if life expect ≥10 y</p>
<p class="noindent1">• USPSTF: screen biennially ages 50–75 (some may want to begin at 40)</p>
<p class="noindent1">• ↑ risk: screen earlier w/ exam and mammo (age 25 in <i class="calibre6">BRCA1/2</i> carrier, 5–10 y before earliest FHx case, 8–10 y after thoracic RT, upon dx of ↑ risk benign disease)</p>
<p class="noindent1">• <b class="calibre7">MRI:</b> superior to mammo in high-risk and young Pts; consider annually if &gt;20% lifetime risk (eg, ⊕ FHx, <i class="calibre6">BRCA1/2</i>, prior chest RT) <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2011;378:1804)</span></p>
<p class="noindent1">• <b class="calibre7">Germline genetic testing:</b> if metastatic, TNBC, ♂, age ≤45y, or by FHx <span class="r1">(</span><span class="r2">NCCN</span> <span class="r1">v1.2022)</span></p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• <b class="calibre7">Palpable breast mass:</b> age &lt;30 y → observe for resolution over 1–2 menstrual cycles; age &lt;30 y, unchanging mass → <b class="calibre7">U</b>/<b class="calibre7">S</b> → aspiration if mass not simple cyst;</p>
<p class="noindent2">age &gt;30 y <i class="calibre6">or</i> solid mass on U/S <i class="calibre6">or</i> bloody aspirate <i class="calibre6">or</i> recurrence after aspiration → <b class="calibre7">mammo</b> (detect other lesions) <i class="calibre6">and</i> either <b class="calibre7">fine-needle asp.</b> or <b class="calibre7">core-needle bx</b></p>
<p class="noindent2">clearly cancerous on exam or indeterminate read or atypia on bx → <b class="calibre7">excisional bx</b></p>
<p class="noindent1">• <b class="calibre7">Suspicious mammogram</b> with normal exam: stereotactically guided bx</p>
<p class="noindent1">• MRI: detects contralateral cancer in 3% of Pts w/ recently dx breast cancer &amp; contra-lateral mammo (but PPV only 21%) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2007;356:1295)</span>; utility remains unclear</p>
<p class="h">Staging</p>
<p class="noindent1">• <b class="calibre7">Anatomic:</b> tumor size, chest wall invasion, axillary LN mets (<i class="calibre6">strongest prognostic factor</i>)</p>
<p class="noindent1">• <b class="calibre7">Histopathologic:</b> type (little prognostic relevance) &amp; grade; lymphatic/vascular invasion</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">In situ</i></b> carcinoma: no invasion of surrounding stroma</p>
<p class="noindent2"><b class="calibre7">Ductal</b> (DCIS): ↑ risk of invasive cancer in <i class="calibre6">ipsilateral</i> breast (~30%/10 y)</p>
<p class="noindent2"><b class="calibre7">Lobular</b> (LCIS): benign entity; marker of ↑ risk of inv. cancer in <i class="calibre6">either</i> breast (~1%/y)</p>
<p class="noindent2"><b class="calibre7">Invasive</b> carcinoma: infiltrating ductal (70–80%); invasive lobular (5–10%); tubular, medullary and mucinous (10%, better prognosis); papillary (1–2%); other (1–2%)</p>
<p class="noindent2"><b class="calibre7">Inflammatory breast cancer</b> (see above): not a histologic type but a clinical reflection of tumor invasion of dermal lymphatics; very poor prognosis</p>
<p class="noindent2"><b class="calibre7">Paget disease</b> (see above)<b class="calibre7">:</b> ductal cancer invading nipple epidermis ± associated mass</p>
<p class="noindent1">• <b class="calibre7">Tissue biomarkers:</b> estrogen and progesterone receptor (ER/PR), HER2</p>
<p class="noindent1">• Oncotype DX 21-gene expression recurrence score predicts which ER ⊕, HER2 ⊖ will have minimal benefit from adjuvant chemo in LN ⊖ <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:111)</span> and LN ⊕ (1–3) disease <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;385:2336)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre34"/>
<col class="calibre12"/>
<col class="calibre25"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><a id="page_5-30" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Simplified Staging &amp; 5-y Dis. Specific Survival</b> <span class="sm">(<i class="calibre6">CA Cancer J Clin</i> 2017;67:290; <i class="calibre6">SEER</i> 2017)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Stage</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Characteristics</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Description</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">5-y DSS</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">I</p></td>
<td class="th1"><p class="tbody">Tumor ≤2 cm</p></td>
<td rowspan="3" class="th1"><p class="tbody">Operable</p>
<p class="tbody">locoregional</p></td>
<td class="th1"><p class="tbodyc">99%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">IIA</p></td>
<td class="th1"><p class="tbody">Tumor &gt;2 cm or <i class="calibre6">mobile</i> axillary nodes</p></td>
<td class="th1"><p class="tbodyc">98%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">IIB</p></td>
<td class="th1"><p class="tbody">Tumor &gt;5 cm or 2–5 cm w/ mobile nodes</p></td>
<td class="th1"><p class="tbodyc">96%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">IIIA</p></td>
<td class="th1"><p class="tbody">Internal mammary or <i class="calibre6">fixed</i> axillary nodes</p></td>
<td class="th1"><p class="tbody">Locally advanced</p></td>
<td class="th1"><p class="tbodyc">95%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">IIIB/C</p></td>
<td class="th1"><p class="tbody">Chest wall, skin, infra or supraclavic. nodes</p></td>
<td class="th1"><p class="tbody">Inoperable</p></td>
<td class="th1"><p class="tbodyc">80–85%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">IV</p></td>
<td class="th1"><p class="tbody">Distant metastases</p></td>
<td class="th1"><p class="tbody">Metastatic</p></td>
<td class="th1"><p class="tbodyc">27%</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre42"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">General Approach to Treatment</b> <span class="sm">(<i class="calibre6">JAMA</i> 2019;321:288 &amp; 1716)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">DCIS</b></p></td>
<td class="th1"><p class="tbody">Mastectomy or lumpectomy ± RT ± chemoprevention <span class="sm">(<i class="calibre6">Lancet</i> 2016;387:849 &amp; 866)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">I</b></p></td>
<td class="th1"><p class="tbody">Surgery + RT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">II</b></p></td>
<td class="th1"><p class="tbody">+ adjuv. chemo if ↑ risk: tumor &gt;2 cm <i class="calibre6">or</i> ⊕ LN <i class="calibre6">or</i> triple ⊖ <i class="calibre6">or</i> Oncotype DX-guided</p>
<p class="tbody">+ hormonal Rx for ER/PR ⊕: add ovarian suppression if ↑ risk <span class="sm">(<i class="calibre6">NEJM</i> 2018; 379:122)</span></p>
<p class="tbody">+ anti-<i class="calibre6">HER2</i> Rx and chemo if <i class="calibre6">HER2</i> ⊕ and tumor ≥1 cm or ⊕ LN</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">III</b></p></td>
<td class="th1"><p class="tbody">Neoadjuvant chemo → surgery + RT ± adjuvant chemotherapy</p>
<p class="tbody">+ hormonal Rx for ER/PR ⊕: add ovarian suppression if premenopausal</p>
<p class="tbody">+ anti-<i class="calibre6">HER2</i> Rx for <i class="calibre6">HER2</i> ⊕: usually trastuzumab + pertuzumab</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IV</b></p></td>
<td class="th1"><p class="tbody">ER/PR ⊕: combined aromatase &amp; CDK4/6 inhibitors <span class="sm">(<i class="calibre6">NEJM</i> 2016; 375:1925)</span></p>
<p class="tbody">ER/PR ⊖<i class="calibre6">/HER2</i> ⊕: chemo + anti-<i class="calibre6">HER2</i> therapy</p>
<p class="tbody">Triple ⊖: chemo ± immune checkpoint inhibitor</p>
<p class="tbody">Bony mets: bisphosphonates &amp; denosumab ↓ fractures <span class="sm">(<i class="calibre6">Cochrane</i> 2017;CD003474)</span></p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td colspan="2" class="th"><p class="tbodyc"><b class="calibre7">Surgery and Radiation for Local Control</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Intervention</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Indication</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Breast conserving</p></td>
<td class="th1"><p class="tbody">Stage I–II, lumpectomy + sentinel lymph node biopsy<sup class="calibre27"><a id="fn121-s1" class="calibre8"></a><a href="part0011.html#rfn121-s1" class="calibre8">*</a></sup> + RT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Modified radical</p>
<p class="tbody">mastectomy</p></td>
<td class="th1"><p class="tbody">Large tumor relative to breast, multicentric dis., prior chest</p>
<p class="tbody">RT, diffuse microcalcifications, ⊕ margins after lumpectomy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Post mastectomy</p>
<p class="tbody">Radiation</p></td>
<td class="th1"><p class="tbody">≥4 ⊕ LN, tumor &gt;5 cm, ⊕ surgical margins, chest wall or skin</p>
<p class="tbody">involvement <span class="sm">(<i class="calibre6">Lancet</i> 2014;384:1848)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn121-s1" class="calibre8"></a><a href="part0011.html#fn121-s1" class="calibre8">*</a></sup>Axillary lymph node dissection indicated for palpable axillary LNs</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre25"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Systemic Therapy</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Indic.</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Class</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Examples</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbody">ER/PR ⊕</p>
<p class="tbody"><span class="sm">(<i class="calibre6">Lancet</i> 2017;389: 2403)</span></p></td>
<td class="th1"><p class="tbody">Endo <span class="sm">(<i class="calibre6">NEJM</i> 2019;380: 1226)</span></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Tamoxifen:</b> adjuvant Rx for low-risk pre-meno; ↓ recurrence &amp; ↓ mortality; 10 y superior to 5 y <span class="sm">(<i class="calibre6">Lancet</i> 2011;378:771 &amp; 2013;381:805)</span></p>
<p class="tbodyh"><b class="calibre7">Aromatase inhib</b> (AI; anastrozole, letrozole, exemestane): adjuvant Rx for post-meno; ↑ OS vs. tam. <span class="sm">(<i class="calibre6">Lancet</i> 2015;386:1341)</span>; 7 y of Rx ↑ DFS vs. 5 y of Rx <span class="sm">(<i class="calibre6">NEJM</i> 2021;385:395)</span></p>
<p class="tbodyh">Adding selective ER degrader (fulvestrant) to AI ↑ OS if mets</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ovarian suppress.</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">LHRH agonists</b> (eg, leuprolide) or oophorectomy: adjuvant Rx for high-risk pre-meno combined with tam. or AI <span class="sm">(<i class="calibre6">NEJM</i> 2018;379:122)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cell prolif.</p>
<p class="tbody"><span class="sm">(<i class="calibre6">NEJM</i> 2012;366: 520)</span></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">CDK 4/6 inhib</b> (eg, palbociclib, abemaciclib, ribociclib): + AI (1<sup class="calibre27">st</sup>-line metastatic Rx) or fulvestrant ↑ PFS (&amp; OS for ribociclib) in stage IV vs. AI alone <span class="sm">(<i class="calibre6">NEJM</i> 2018;379:1926; <i class="calibre6">JCO</i> 2017;35:3638)</span>; + AI for adjuvant <span class="sm">(<i class="calibre6">Ann Onc</i> 2021;32:1571)</span></p>
<p class="tbodyh"><b class="calibre7">mTOR inhib</b> (everolimus): + AI (exemestane) ↑ OS in stage IV</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PIK3CA ⊕</p></td>
<td class="th1"><p class="tbody">PI3K inhib</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Alpelisib</b> + fulvestrant ↑ PFS in met HR⊕ <span class="sm">(<i class="calibre6">NEJM</i> 2019;380:1929)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">HER2 ⊕</p>
<p class="tbody"><span class="sm">(<i class="calibre6">Lancet</i> 2017;389: 2415)</span></p></td>
<td class="th1"><p class="tbody">HER2- targeted</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Trastuzumab</b> (anti-HER2): 1<sup class="calibre27">st</sup>-line Rx combined w/ chemo</p>
<p class="tbodyh"><b class="calibre7">Trastuzumab emtansine</b> (mAb linked to chemo): ↓ risk of recurrence/death if residual disease post neoadj. Rx <span class="sm">(<i class="calibre6">NEJM</i> 2019;380:617)</span>; preferred 2<sup class="calibre27">nd</sup> line Rx for met. disease</p>
<p class="tbodyh"><b class="calibre7">Trastuzumab deruxtecan</b> (mAb linked to chemo): emerging data as 2<sup class="calibre27">nd</sup> line Rx for met disease, ↓ risk disease progression vs. trastuzumab emtansine, ↑ lung toxicity <span class="sm">(<i class="calibre6">NEJM</i> 2022;386:1143)</span></p>
<p class="tbodyh"><b class="calibre7">Margetuximab</b> (anti-HER2): combined w/ chemo preferred after 2+ lines of Rx <span class="sm">(<i class="calibre6">JAMA Oncol</i> 2021;7:573)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Stage I–III (above)</p></td>
<td class="th1"><p class="tbody">Chemo</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Neoadjuvant:</b> to conserve breast &amp; evaluate Rx efficacy, equivalent OS as adjuvant <span class="sm">(<i class="calibre6">JCO</i> 2008;26:778)</span></p>
<p class="tbodyh"><b class="calibre7">Adjuvant:</b> use anthracycline ± taxane. Nb, endocrine only for some ER/PR ⊕ based on oncotype Dx (see staging).</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbody">Triple ⊖</p></td>
<td class="th1"><p class="tbody">Immune</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Pembrolizumab</b> (anti-PD-1 mAb) + chemo 1<sup class="calibre27">st</sup>-line for early stage <span class="sm">(<i class="calibre6">NEJM</i> 2020;382:810)</span> &amp; PD-L1 ⊕ met dis. <span class="sm">(<i class="calibre6">Lancet</i> 2020;396:1817)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ab-drug conjugate</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Sacituzumab govitecan</b>: anti-trop-2 Ab linked to chemo ↑ PFS &amp; OS in heavily pre-Rx’d metastatic disease <span class="sm">(<i class="calibre6">NEJM</i> 2019;380:741)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">BRCA ⊕</p></td>
<td class="th1"><p class="tbody">PARP inh</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Olaparib &amp; talazoparib</b> <span class="sm">(<i class="calibre6">NEJM</i> 2017;377:523 &amp; 2018;379:753)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn">DFS, disease-free survival; OS, overall survival; PFS, progression-free survival</p>
<h2 class="ct"><a id="h77" class="calibre8"></a><a id="page_5-31" class="calibre8"></a><a href="part0003.html#rh85" class="calibre8">PROSTATE CANCER</a></h2>
<p class="h">Epidemiology and risk factors <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:366)</span></p>
<p class="noindent1">• Most common cancer in U.S. men; 2<sup class="calibre19">nd</sup> most common cause of cancer death in men</p>
<p class="noindent1">• Lifetime risk of prostate cancer dx ~16%; lifetime risk of dying of prostate cancer ~3%</p>
<p class="noindent1">• ↑ risk with ↑ age (rare if &lt;45 y), in African Americans, ⊕ FHx, BRCA mutations</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Most prostate cancers (78%) are asymptomatic and localized at diagnosis</p>
<p class="noindent1">• Metastatic dis. sx primarily from bone mets: bone pain, spinal cord compression, cytopenias</p>
<p class="h">Screening <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;311:1143;</span> <span class="r2">Lancet</span> <span class="r1">2014;384:2027)</span></p>
<p class="noindent1">• <b class="calibre7">PSA:</b> 4 ng/mL cut point neither Se nor Sp; can ↑ with BPH, prostatitis, acute retention, after bx or TURP, and ejaculation (<i class="calibre6">no significant</i> ↑ <i class="calibre6">after DRE, cystoscopy</i>); 15% of men &gt;62 y w/ PSA &lt;4 &amp; nl DRE have bx-proven T1 cancer <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2004;350:2239)</span></p>
<p class="noindent1">• Digital rectal exam no longer recommended due to limitations, no mortality benefit</p>
<p class="noindent1">• ACS rec: ≥50 y (or ≥45 y AA or ⊕ FHx) discuss PSA screening, informed decision making</p>
<p class="noindent1">• USPSTF <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2018;319:1901)</span> rec discuss pros/cons w/ Pt (no ↓ in prostate ca-related mort.)</p>
<p class="h">Diagnostic evaluation, staging, and treatment <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v1.2022)</span></p>
<p class="noindent1">• <b class="calibre7">Transrectal ultrasound</b> (TRUS) <b class="calibre7">guided biopsy</b> (6–12 cores)</p>
<p class="noindent1">• Multiparametric MRI (± endorectal coil): improves detection <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1767)</span></p>
<p class="noindent1">• <b class="calibre7">Gleason score &amp; grade group (histology):</b> Gleason score determines Grade Group. 1 = best → 5 = worst. Group 1: 3+3=6 (most common histologic pattern is 1<sup class="calibre19">st</sup> #, next is 2<sup class="calibre19">nd</sup> #), Group 2: 3+4=7, Group 3: 4+3=7, Group 4: 4+4=8, Group 5: all higher.</p>
<p class="imaget"><img src="../images/00087.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn122-s1" class="calibre8"></a>*</sup>In asx Pts w/ life expect ≤5 y &amp; very low-to-intermed risk dis., no w/up or Rx until sx. <i class="calibre6">NCCN Guidelines</i> v1.2022</p>
<p class="tfn"><sup class="calibre22">†</sup>RP more short-term impotence (unless ADT) &amp; incont than RT; over yrs → similar (<i class="calibre6">NEJM</i> 2016;375:1425)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Treatment of Metastatic Prostate Cancer</b> <span class="sm">(<i class="calibre6">NCCN Guidelines</i> v1.2022)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Androgen deprivation therapy (ADT)</b></p></td>
<td class="th1"><p class="tbodyh">Prostate ca requires androgen signaling for growth. ADT backbone of Rx.</p>
<p class="tbodyh">Med: 1. Luteinizing hormone-releasing hormone (LHRH) agonist (eg, leuprolide) ± 1<sup class="calibre27">st</sup>-gen anti-androgen (nilutamide, bicalutamide), <i class="calibre6">or</i></p>
<p class="tbodyh">2. LHRH antagonist (degarelix)</p>
<p class="tbodyh">Surgery: bilateral orchiectomy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Hormone- sensitive prostate cancer (HSPC)</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Def:</b> ADT sensitive (ie, PSA ↓ w/ Rx): all prostate ca initially sensitive</p>
<p class="tbodyh"><b class="calibre7">Workup/testing:</b> PEx &amp; PSA q 3–6 mos; sx-guided imaging</p>
<p class="tbodyh"><b class="calibre7">Rx:</b> 1. ADT alone (only if minimal disease, eg, rising PSA); <i class="calibre6">or</i></p>
<p class="tbodyh">2. ADT + abiraterone/pred or enza/apalutamide (↑ OS vs. ADT alone); <i class="calibre6">or</i></p>
<p class="tbodyh">3. Docetaxel + ADT (↑ OS vs. ADT alone, espec. in high-volume disease)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Castration-resistant prostate cancer (CRPC)</b></p>
<p class="tbodyc"><i class="calibre6">Always continue ADT</i></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Def:</b> All met. HSPC eventually becomes CRPC (ie, progression despite castration androgen levels on ADT), due to re-estab. of androgen signaling via other mech. ∴ more potent anti-androgens are needed.</p>
<p class="tbodyh"><b class="calibre7">Rx:</b> New-gen. anti-androgens: abiraterone (biosynth inhib.) + pred, or enza/daro/apalutamide (receptor blocker) ↑ PFS &amp; OS</p>
<p class="tbodyh"><b class="calibre7">Targeted:</b> <i class="calibre6">BRCA</i>1<i class="calibre6">/2, ATM</i> (homologous recomb genes, ~20%): olaparib; <i class="calibre6">MSI-H/</i>Lynch syndrome (2–5%): pembro<i class="calibre6">; Cancer vaccine:</i> Sipuleucel-T</p>
<p class="tbodyh"><b class="calibre7">Chemo:</b> doce/cabazitaxel +pred/dex+Luetitium-177 <span class="sm">(<i class="calibre6">NEJM</i> 2021;385:1091)</span></p>
<p class="tbodyh"><b class="calibre7">Bone-active agents:</b> 1. denosumab or zoledronic acid ↓ skeletal-related events (SREs); 2. radium-223 used in bone-only dis, ↓ SREs &amp; ↑ OS</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">NEJM</i> 2017;377:338 &amp; 352; 2019;381:121; 2019;381:13; <i class="calibre6">Lancet</i> 2016;387:1163)</p>
<p class="h">Prognosis and monitoring</p>
<p class="noindent1">• PSA level, Gleason score/grade group and age are predictors of metastatic disease</p>
<p class="noindent1">• In surgically treated Pts, 5-y relapse-free survival &gt;90% (excellent) if disease confined to organ, ~75% if extension through capsule, and ~40% if seminal vesicle invasion</p>
<p class="noindent1">• PSA q6mo for 5 y if curative Rx; consider PET Axumin scan if ↑ PSA ± equivocal bone scan</p>
<h2 class="ct"><a id="h78" class="calibre8"></a><a id="page_5-32" class="calibre8"></a><a href="part0003.html#rh86" class="calibre8">COLORECTAL CANCER (CRC)</a></h2>
<p class="h">Epidemiology and risk factors <span class="r1">(</span><span class="r2">CA Cancer J Clin</span> <span class="r1">2018;68:7)</span></p>
<p class="noindent1">• 4<sup class="calibre19">th</sup> most common cancer in U.S. men &amp; women; 2<sup class="calibre19">nd</sup> leading cause of all cancer death</p>
<p class="noindent1">• 90% of cases occur after age 50. ~75% are sporadic.</p>
<p class="noindent1">• IBD a/w ~0.3%/y ↑ risk of CRC. ↑ risk w/ ↑ extent and duration of disease.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre28"/>
<col class="calibre33"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Heritable Genetic Syndromes</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Disorder</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">CRC risk</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Pathophysiology</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Assoc Cancers</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Hereditary nonpolyposis colorectal cancer (HNPCC or Lynch)</b></p></td>
<td class="th1"><p class="tbodyc">~80%</p>
<p class="tbodyc">lifetime</p></td>
<td class="th1"><p class="tbody">Most common hered. CRC (~3%). Mismatch repair mut (eg, <i class="calibre6">MSH2</i>, <i class="calibre6">MLH</i>1). Dx: ≥3 family HNPCC cancer, 1 dx before 50 y, involves 2 gen. Typically <b class="calibre7">right-sided</b>.</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Endometrial</b>, ovarian, stomach, urothelial, small bowel &amp; pancreas</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Familial adeno polyposis (FAP)</b></p></td>
<td class="th1"><p class="tbodyc">100% lifetime</p></td>
<td class="th1"><p class="tbody">Mutation in <i class="calibre6">APC</i> gene → 1000s of polyps at young age</p></td>
<td class="th1"><p class="tbody">Thyroid, stomach, small bowel</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">MUTYH-assoc. polyposis (MAP)</b></p></td>
<td class="th1"><p class="tbodyc">40–100% lifetime</p></td>
<td class="th1"><p class="tbody">Autosomal <i class="calibre6">recessive;</i> consider if mult. polyps but ⊖ for FAP</p></td>
<td class="th1"><p class="tbody">Duodenal, ovarian, bladder, skin</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• ASA rec for 1° prev. if 50–59 y &amp; ≥10% 10-y CRC risk. Must take for at least 10 years.</p>
<p class="h">Screening <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:1965)</span></p>
<p class="noindent1">• <i class="calibre6">Average-risk Pts</i>: start at age 45, repeat q1–10y based on screening modality</p>
<p class="noindent1">• ↑<i class="calibre6"> risk Pts</i>: ⊕ FHx: screen age 40 or 10 y before index dx, then q5y. IBD: colo 8–10 y after dx, then q1–2y. Suspect familial syndrome: genetic counsel, screen age 20–25, yearly.</p>
<p class="noindent1">• <b class="calibre7">Colonoscopy:</b> <i class="calibre6">preferred</i>; 90% Se for lesions &gt;1 cm. If polyp, re ✓ in 3–5 y. Adenomatous polyp removal a/w ↓ CRC mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;366:687)</span>. <i class="calibre6">Adenoma</i><span class="r">:</span> ↑ risk of malig. if &gt;2.5 cm, villous, or sessile; can progress to CRC over ~10 y interval (sporadic &amp; familial).</p>
<p class="noindent1">• <b class="calibre7">Sigmoidoscopy:</b> benefit w/ 1-time flex-sig <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:1299)</span>; less Se than colo or CTC</p>
<p class="noindent1">• <b class="calibre7">CT colonography (CTC):</b> ~90% Se for lesions ≥1 cm but less if smaller <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2008;359:1207)</span>. If high-risk, Se only 85% for neoplasia ≥6 mm <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2009;301:2453)</span>.</p>
<p class="noindent1">• <b class="calibre7">Combo DNA</b> +<b class="calibre7"> Hb immunoassay</b> w/ ~90% Se &amp; Sp <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1287)</span></p>
<p class="noindent1">• Occult blood (FOBT): use 3-card home testing (Se 24%) yearly</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Distal colon: Δ <b class="calibre7">bowel habits/ caliber</b>, <b class="calibre7">obstruction</b>, colicky abd. pain, <b class="calibre7">hematochezia</b></p>
<p class="noindent1">• Proximal colon: <b class="calibre7">iron defic. anemia</b>, dull vague abd pain, liquid stool</p>
<p class="noindent1">• Associated with <i class="calibre6">Streptococcus bovis</i> bacteremia and <i class="calibre6">Clostridium septicum</i> sepsis</p>
<p class="h">Cancer genetics <span class="r1">(</span><span class="r2">Nature</span> <span class="r1">2014;513:382)</span></p>
<p class="noindent1">• <b class="calibre7">Microsatellite stable (MSS) vs. high instability (MSI-H):</b> latter sign of mismatch repair gene failure, accounts for 15% CRC, presents more often as early stage, ~5% of met dis.</p>
<p class="noindent1">• <b class="calibre7">Mutations:</b> <i class="calibre6">APC</i> (~80%); <i class="calibre6">KRAS</i> (~40%); <i class="calibre6">TP53</i> (50–70%); <i class="calibre6">DCC</i>, <i class="calibre6">SMAD4</i>, <i class="calibre6">BRAF</i> (~15%), <i class="calibre6">HER2</i> amplification (&lt;5%)</p>
<p class="h">Staging and treatment <span class="r1">(</span><span class="r2">NCCN Clin Pract Guidelines;</span> <span class="r1">version 3.2021)</span></p>
<p class="noindent1">• TNM staging, including CT chest and abdomen/pelvis with contrast ± MRI pelvis for rectal</p>
<p class="noindent1">• Baseline <b class="calibre7">CEA</b>: monitor post resection or follow response; <i class="calibre6">not</i> for screening</p>
<p class="noindent1">• <b class="calibre7">Chemo options</b> <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2014;383:1490)</span>: 5-FU/leucovorin (LV) foundation. 5-FU/LV + oxaliplatin &amp;/or irinotecan (FOLFOX, FOLFIRI, FOLFOXIRI, resp). Capecitabine oral 5-FU prodrug. TAS102 (trifluridine + tipiracil) in progressive disease <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:1909)</span>.</p>
<p class="noindent2"><i class="calibre6">Anti-VEGF</i> (bevacizumab) added to chemo ↑ OS in all subsets of mCRC.</p>
<p class="noindent1">• <b class="calibre7">Targeted therapy:</b> <i class="calibre6">anti-EGFR mAb</i> (cetuximab or panitumumab) in unmutated <i class="calibre6">KRAS/NRAS/BRAF</i> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:1023)</span>, better for L-sided disease; encorafienib + cetuximab + binimetinib in <i class="calibre6">BRAF</i> V600E <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;381:1632)</span></p>
<p class="noindent1">• <b class="calibre7">ImmunoRx</b>: anti PD-1 <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:2207)</span> ± CTLA-4 in MSI-H/ MMRd met CRC</p>
<p class="noindent1">• <b class="calibre7">Radiation:</b> loc. adv. rectal (T3/N+) &amp; colon (unresectable); consider for oligo-mets</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre20"/>
<col class="calibre28"/>
<col class="calibre26"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbodyc"><b class="calibre7">TNM</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Path. Criteria</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">5-y Surv.</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">I</b></p></td>
<td class="th1"><p class="tbody">Submucosa/muscularis</p></td>
<td class="th1"><p class="tbodyc">94–97%</p></td>
<td class="th1"><p class="tbody">Surgery alone (resect &amp; analyze ≥12 LN)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IIA</b></p></td>
<td class="th1"><p class="tbody">Serosa</p></td>
<td class="th1"><p class="tbodyc">83%</p></td>
<td rowspan="3" class="th1"><p class="tbody">Surgery. Consider adjuvant chemo for high-risk Stage II: obstruction, perf, adherence, inadequate LN sampling (&lt;12 LNs).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IIB</b></p></td>
<td class="th1"><p class="tbody">Peritoneum</p></td>
<td class="th1"><p class="tbodyc">74%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IIC</b></p></td>
<td class="th1"><p class="tbody">Direct invasion</p></td>
<td class="th1"><p class="tbodyc">56%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IIIA</b></p></td>
<td class="th1"><p class="tbody">≤6 ⊕ LNs</p></td>
<td class="th1"><p class="tbodyc">86%</p></td>
<td rowspan="3" class="th1"><p class="tbodyh">Surgery + FOLFOX (6 mo)<br class="calibre1"/>or CAPOX (3–6 mo) <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:13)</span></p>
<p class="tbody">Pre RT ± chemo if rectal <span class="sm">(<i class="calibre6">NEJM</i> 2006;355:1114)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IIIB</b></p></td>
<td rowspan="2" class="th1"><p class="tbody">Varying # ⊕ LNs &amp; local invasion</p></td>
<td class="th1"><p class="tbodyc">51–77%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IIIC</b></p></td>
<td class="th1"><p class="tbodyc">15–47%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">IV</b></p></td>
<td class="th1"><p class="tbody">Distant metastases<sup class="calibre27"><a id="fn125-s1" class="calibre8"></a><a href="part0011.html#rfn125-s1" class="calibre8">*</a></sup> <span class="sm">(<i class="calibre6">NEJM</i> 2014;371:1609)</span></p></td>
<td class="th1"><p class="tbodyc">5%</p></td>
<td class="th1"><p class="tbody">Chemo (FOLFOXIRI if high-risk) ± anti-PD-1 (MSI-H only) ± resect isolated mets</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn125-s1" class="calibre8"></a><a href="part0011.html#fn125-s1" class="calibre8">*</a></sup>Oligometastatic dis (few, limited mets) sometimes still curable w/ chemo + metastatectomy/radiation</p>
<h2 class="ct"><a id="h79" class="calibre8"></a><a id="page_5-33" class="calibre8"></a><a href="part0003.html#rh87" class="calibre8">PANCREATIC TUMORS</a></h2>
<p class="h">Genetics and path <span class="r1">(</span><span class="r2">Nat Rev Dis Primers</span> <span class="r1">2016;2:16022)</span></p>
<p class="noindent1">• Histologic types: <b class="calibre7">adenocarcinoma</b> (~85%), acinar cell carcinoma, endocrine tumors, cystic neoplasms (&lt;10%); rarely, mets to pancreas (eg, lung, breast, renal cell)</p>
<p class="noindent1">• Location: ~60% in head, 15% in body, 5% in tail; in 20% diffuse infiltration of pancreas</p>
<p class="noindent1">• Adeno. mut.: <i class="calibre6">KRAS</i> (&gt;90%), <i class="calibre6">p16</i> (80–95%), <i class="calibre6">p53</i> (50–75%), <i class="calibre6">SMAD4</i> (~55%), <i class="calibre6">BRCA</i> (10%)</p>
<p class="h">Epidemiology and risk factors <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:73)</span></p>
<p class="noindent1">• 4<sup class="calibre19">th</sup> leading cause of cancer death in U.S.; 80% panc adeno in ages 60–80 y; M&gt;F (1.3:1)</p>
<p class="noindent1">• Acquired risk factors: <b class="calibre7">smoking</b> (RR ~1.5; 25% cases), obesity, chronic pancreatitis, T2DM</p>
<p class="noindent1">• Hereditary (5–10%): familial breast/ovarian CA (<i class="calibre6">BRCA2</i>); <i class="calibre6">hereditary chronic pancreatitis</i> (mutation in cationic trypsinogen gene (<i class="calibre6">PRSS1</i>, <i class="calibre6">SPINK1</i>);<i class="calibre6"> familial cancer syndromes:</i> atypical multiple mole melanoma (<i class="calibre6">CDKN2A/p16</i>), Peutz-Jeghers (<i class="calibre6">LKB1</i>), ataxia-telang.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Painless jaundice</b> (w/ pancreatic head mass), <b class="calibre7">pain</b> radiates to back, ↓ <b class="calibre7">weight</b> &amp; appetite</p>
<p class="noindent1">• New-onset atypical DM (25%); migratory thrombophlebitis (Trousseau’s syndrome)</p>
<p class="noindent1">• Exam: jaundice, RUQ/epigastric nontender mass, palpable gallbladder (Courvoisier’s sign); hepatomegaly; ascites; L supraclavicular node (Virchow’s)</p>
<p class="noindent1">• Laboratory tests may show ↑ bilirubin, ↑ alk phos, anemia</p>
<p class="h">Diagnostic and staging evaluation <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v.2.2021)</span></p>
<p class="noindent1">• <b class="calibre7">Pancreatic protocol CT scan</b> (I<sup class="calibre19">+</sup> w/ arterial &amp; venous phase imaging) or <b class="calibre7">MRI w/ contrast</b></p>
<p class="noindent1">• <i class="calibre6">If no lesion seen but concerning signs &amp; sx as above</i> → EUS, ERCP, or MRCP</p>
<p class="noindent1">• <b class="calibre7">Biopsy pancreatic lesion</b> via EUS-guided FNA (pref. for surgical candidates) or CT-guided (risk of seeding); if possible metastases, biopsy those for staging <i class="calibre6">and</i> dx.</p>
<p class="noindent1">• ✓ <b class="calibre7">CA19-9</b> preop (nb, can be ↑ in benign liver/biliary dis.); may be useful to trend postop</p>
<p class="noindent1">• <b class="calibre7">Germline genetic testing</b> for all Pts with pancreatic cancer</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Clinical (Radiologic) Staging Pancreatic Adenocarcinoma</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Resectable</b></p></td>
<td class="th1"><p class="tbody">No extrapanc. dis. or bulky LAN; no <b class="calibre7">arterial</b> tumor contact [celiac axis (CA), SMA, common hepatic (CHA)]; and no <b class="calibre7">venous</b> contact [SMV, portal vein (PV)] or ≤180<b class="calibre7">°</b> + patent veins (ie, no tumor thrombus)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Borderline resectable</b></p></td>
<td class="th1"><p class="tbody">No extrapanc dis. or bulky LAN. <b class="calibre7">Head/uncinate:</b> contact w/ CHA (no extension to CA or HA bifurcation), SMA contact ≤180<b class="calibre7">°</b>, variant anatomy.</p>
<p class="tbody"><b class="calibre7">Body/tail:</b> contact CA ≤180<b class="calibre7">°</b> or &gt;180<b class="calibre7">°</b> but w/o gastro-duodenal art. or aortic. <b class="calibre7">Venous:</b> SMV &amp; PV contact ≤180<b class="calibre7">°</b> w/ contour irreg; contact w/ IVC.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Unresect.</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Distant mets</b>; or <b class="calibre7">head/uncinate:</b> contact &gt;180<b class="calibre7">°</b> SMA, CA; or</p>
<p class="tbody"><b class="calibre7">Body/tail:</b> contact &gt;180<b class="calibre7">°</b> SMA or CA; CA &amp; aortic involvement; or</p>
<p class="tbody"><b class="calibre7">Venous:</b> SMV/PV involvement/not reconstructible</p></td>
</tr>
</tbody>
</table>
<p class="h">Treatment of pancreatic adenocarcinoma <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:73)</span></p>
<p class="noindent1">• <b class="calibre7">Resectable:</b> pancreaticoduodenectomy (<b class="calibre7">Whipple procedure</b>) + adjuvant chemo:</p>
<p class="noindent2">modified FOLFIRINOX (5-FU + leucovorin, irinotecan, oxaliplatin) if ECOG 0-1</p>
<p class="noindent2"><span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:2395)</span>, o/w gemcitabine + capecitabine <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:1011)</span>. Gemcitabine</p>
<p class="noindent2">monoRx recently standard, but now w/ ↓ role. Role of RT is controversial.</p>
<p class="noindent1">• <b class="calibre7">Borderline:</b> goal to ↓ tumor to allow complete resection (R0 – neg margin at histology) using neoadjuvant Rx (various approaches tested). General schema:<b class="calibre7"> chemo</b> ±<b class="calibre7"> RT</b> → <b class="calibre7">restage &amp; potential resection</b> depending on response<b class="calibre7">.</b> May need vasc. reconstruction during resection. Regimens include: FOLFIRINOX; gemcitabine + nab-paclitaxel.</p>
<p class="noindent1">• <b class="calibre7">Locally advanced</b> (ie, unresectable): Rx is typically palliative. However, in highly select Pts recent trend toward Rx w/ FOLFIRINOX plus XRT followed by laparotomy for response assessment (imaging can be unreliable) and potential resection.</p>
<p class="noindent1">• <b class="calibre7">Metastatic:</b> <i class="calibre6">clinical trials preferred;</i> Rx based on performance status (PS)</p>
<p class="noindent2"><i class="calibre6">Good PS:</i> <b class="calibre7">FOLFIRINOX</b>, <b class="calibre7">gemcitabine</b> + nab-paclitaxel <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:1691)</span>; germline <i class="calibre6">BRCA1/2</i> mut: maintenance olaparib <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;381:317)</span> also ↑ response to platinum combination chemo (eg, cisplatin w/ gemcitabine), ICI for MSI-high.</p>
<p class="noindent2"><i class="calibre6">Poor PS:</i> gemcitabine; capecitabine; continuous infusion 5-FU</p>
<p class="noindent1">• <b class="calibre7">Palliative care:</b> <i class="calibre6">Biliary/gastric outlet obstruct</i>.<i class="calibre6">:</i> endoscopic stenting, IR drain, surg bypass. <i class="calibre6">Pain:</i> opiates, celiac plexus neurolysis, XRT. <i class="calibre6">Wt loss:</i> enzyme replacement.</p>
<p class="h">Prognosis</p>
<p class="noindent1">• Resectable: if Rx’d w/ adjuvant FOLFIRINOX, 50+ mos, o/w ~30 mos</p>
<p class="noindent1">• Unresectable: if locally advanced ~1–2 y; if metastatic, ~1 y</p>
<p class="h">Cystic lesions of the pancreas <span class="r1">(</span><span class="r2">Am J Gastroenterol</span> <span class="r1">2018;113:464)</span></p>
<p class="noindent1">• <b class="calibre7">Serous cystadenoma:</b> usually benign; central scar or honeycomb appearance on imaging</p>
<p class="noindent1">• <b class="calibre7">Mucinous cystic neoplasm</b> (MCN): predominantly young females; multiloculated tumors in body or tail w/ ovarian-type stroma and mucin-rich fluid w/ ↑ CEA levels; precancerous</p>
<p class="noindent1">• <b class="calibre7">Intraductal papillary mucinous neoplasm</b> (IPMN): arises in main panc duct or branch</p>
<h2 class="ct"><a id="h80" class="calibre8"></a><a id="page_5-34" class="calibre8"></a><a href="part0003.html#rh88" class="calibre8">OTHER SOLID TUMORS</a></h2>
<p class="h1cr">H<small class="calibre31">EPATOCELLULAR</small> C<small class="calibre31">ARCINOMA</small> (HCC)</p>
<p class="h">Risk factors <span class="r">(globally, 3<sup class="calibre19">rd</sup> leading cause of cancer death, espec. in Africa &amp; Asia)</span></p>
<p class="noindent1">• <b class="calibre7">Cirrhosis:</b> present in 70–90% HCC cases</p>
<p class="noindent1">• <b class="calibre7">Infectious:</b> HCV &amp; HBV (~75%), HBV/HDV coinfection; HBV can cause HCC w/o cirrhosis</p>
<p class="noindent1">• <b class="calibre7">Toxic:</b> EtOH (⅓ cases in U.S.), tobacco, aflatoxin from <i class="calibre6">Aspergillus</i></p>
<p class="noindent1">• <b class="calibre7">Metabolic disorders:</b> NASH, DM, autoimmune hepatitis, hemochromatosis</p>
<p class="h">Screening <span class="r">(screen high-risk Pts: cirrhosis, chronic HBV)</span></p>
<p class="noindent1">• <b class="calibre7">Ultrasonography</b> (U/S) + AFP q 6 mos; if high-risk may alternate U/S w/ <b class="calibre7">MRI</b></p>
<p class="noindent1">• If lesion found or increasing AFP, perform <b class="calibre7">3-phase contrast CT</b> or<b class="calibre7"> MRI</b></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Exam: nonspec. c/w liver dysfxn (eg, hepatomegaly, ascites, jaundice, encephalopathy)</p>
<p class="noindent1">• Labs: coagulopathy, low albumin, elevated LFTs; r/o other etiologies of liver dysfxn</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Can diagnose w/o biopsy in high-risk Pts with <b class="calibre7">3-phase contrast CT</b> or<b class="calibre7"> MRI</b></p>
<p class="noindent1">• Only 15% of liver masses are HCC; liver metastases from other 1° more common</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:1450)</span></p>
<p class="noindent1">• Localized disease (goal = cure) → <b class="calibre7">resection</b> if feasible (preferred), ablation, transarterial chemoembolization, or radiotherapy (SBRT) also options. Inadequate hepatic reserve → <b class="calibre7">liver transplant</b> if able <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1996;334:693)</span>; non-surgical local and/or systemic Rx if not.</p>
<p class="noindent1">• Systemic Rx: atezolizumab (anti-PD-L1) + bevacizumab preferred <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:1894)</span>, 2<sup class="calibre19">nd</sup> line: kinase (lenvatinib, sorafenib) or PD-(L)1 inhib <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:2492 &amp; 2018;391:1163)</span></p>
<p class="h1cr">G<small class="calibre31">ASTRIC</small>/E<small class="calibre31">SOPHAGEAL</small> C<small class="calibre31">ANCER</small></p>
<p class="h">Epidemiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;390:2383 &amp; 2020;29:635)</span></p>
<p class="noindent1">• <b class="calibre7">Esophageal:</b> Predominantly adenocarcinoma in U.S. (&gt;60%), squamous cell (SCC) more common globally. Risk factors: GERD → Barrett’s esoph (adeno), smoking/EtOH (SCC)</p>
<p class="noindent1">• <b class="calibre7">Gastric:</b> Predominantly adenocarcinoma. Risk factors include <i class="calibre6">H. pylori</i>, FHx &amp; cancer syndromes (eg, Lynch syndrome), nitrosamines in diet, smoking/EtOH.</p>
<p class="h">Screening</p>
<p class="noindent1">• <b class="calibre7">Esophageal:</b> screen for Barrett’s w/ endoscopy if multiple risk factors (eg, hiatal hernia, age ≥50, male, chronic GERD, obese, smoking, FHx). Repeat q3–5y if Barrett’s.</p>
<p class="noindent1">• <b class="calibre7">Gastric:</b> typically not screened in U.S. More common in regions w/ higher incidence (eg, Japan, Korea, Chile) w/ endoscopy or barium radiographs.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Dysphagia, wt loss, early satiety, nausea, typically occult GI bleed, vague abd discomfort</p>
<p class="noindent1">• Exam: diffuse seborrheic keratoses (Leser-Trélat sign, though non-specific)</p>
<p class="h">Diagnosis and staging</p>
<p class="noindent1">• Both diagnosed w/ <b class="calibre7">endoscopic biopsy</b>. CT chest/abd/pelvis for staging. If no mets → PET/CT (occult mets). If neg → endoscopic ultrasound for locoregional assessment.</p>
<p class="noindent1">• Staging laparoscopy needed for gastric cancer</p>
<p class="noindent1">• Molecular: ✓ HER2, PD-L1, microsatellite instability &amp; mismatch repair</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v5.2021 Gastric &amp; v4.2021 Esophageal)</span></p>
<p class="noindent1">• If localized disease and good performance status/fit, goal is cure with surgery</p>
<p class="noindent1">• <b class="calibre7">Localized</b>: resection. Periop or neoadjuvant chemo/chemoRT if stage IB or higher <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;366:2074)</span>. Adjuvant nivolumab <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:1191)</span>.</p>
<p class="noindent1">• <b class="calibre7">Advanced</b>: sequential chemo w/ platinum/fluoropyrimidine (+ trastuzumab if HER2⊕, + nivolumab if PD-L1⊕), ramucirumab (VEGF, 2<sup class="calibre19">nd</sup> line), nivolumab/pembrolizumab (PD-1, 3<sup class="calibre19">rd</sup> line)</p>
<p class="noindent1">• <b class="calibre7">Supportive care</b>: pain/nausea mgmt. Consider G/G-J tube if obstruction, IVF prn.</p>
<p class="h1cr">M<small class="calibre31">ELANOMA</small></p>
<p class="h">Clinical presentation and workup <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v1.2022)</span></p>
<p class="noindent1">• Suspicious skin lesion (ABCDE: asymm, border, color, diameter &gt;6 mm, evolution) → bx</p>
<p class="noindent1">• <b class="calibre7">Staging:</b> I &amp; II = no regional/distant mets. III = regional LN ⊕ or in-transit/satellite mets. Ulceration &amp; thickness confer substage within I–III. IV = distant mets.</p>
<p class="noindent1">• <b class="calibre7">Prognosis:</b> excellent if localized dis., ≤1 mm thickness. Varies widely stage IIIA–IIID based on nodal burden (5yr OS 20–70%; ulceration, mitotic rate, &amp; invasion depth predictive).</p>
<p class="noindent1">• Molecular diagnostics: check for <i class="calibre6">BRAF</i> V600E (present in ~50% of melanomas)</p>
<p class="h"><a id="page_5-35" class="calibre4"></a>Treatment <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v1.2022;</span> <span class="r2">NEJM</span><span class="r1"> 2021;384:2229)</span></p>
<p class="noindent1">• Wide surgical excision + sentinel node mapping (unless <i class="calibre6">in situ</i> or low risk of node ⊕).</p>
<p class="noindent2">If sentinel node ⊕, nodal dissection vs. observation. No difference in survival w/ observation <span class="r1">(</span><span class="r2">Lancet Oncol</span> <span class="r1">2016;17:757,</span> <span class="r2">NEJM</span><span class="r1"> 2017;376:2211)</span>.</p>
<p class="noindent1">• <b class="calibre7">Checkpoint inhibitors</b> (CPI = pembrolizumab, nivolumab, nivolumab/ipilimumab)</p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">BRAF/MEK</i> inhibitors</b> (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) if activating <i class="calibre6">BRAF V600E</i> mutation present</p>
<p class="noindent1">• Adjuvant for high-risk node ⊕ disease: CPI (↑ RFS, <span class="r2">Lancet Onc</span> <span class="r1">2020;21:1465 &amp;</span> <span class="r2">JCO</span><span class="r1"> 2020;38:3925</span>) or dabrafenib/trametinib (BRAF ⊕, ↑ OS, <span class="r2">NEJM</span><span class="r1"> 2020;383:1139</span>)</p>
<p class="noindent1">• Metastatic: CPI mono vs. dual (ipi+nivo a/w improved response rate especially for intracranial mets, <span class="r2">NEJM</span><span class="r1"> 2018;379:722</span>). Consider targeted Rx if BRAF ⊕.</p>
<p class="h1cr">O<small class="calibre31">VARIAN</small> C<small class="calibre31">ANCER</small></p>
<p class="h">Histopathology</p>
<p class="noindent1">• Epithelial ovarian carcinoma (EOC, 95%): high-grade serous (most common, often dx at late stage, poor prognosis), low-grade serous, endometroid, clear cell, mucinous</p>
<p class="noindent1">• Non-epithelial (~5%): germ cell, sex cord-stromal. Rare: small cell, sarcoma.</p>
<p class="h">Risk factors for EOC <span class="r1">(</span><span class="r2">Nat Rev Dis Primers</span> <span class="r1">2016;2:16061)</span></p>
<p class="noindent1">• Nulliparity, early menarche, late menopause; EOC risk ↑ 2–7% each additional ovulatory yr</p>
<p class="noindent1">• <b class="calibre7">Genetics:</b> germline testing / genetics referral for all Pts (25% w/ heritable mutation), can inform Rx (eg, PARPi maintenance, <span class="r2">JCO</span><span class="r1"> 2020;38:1222</span>). 5% risk if one 1<sup class="calibre19">st</sup>-degree relative w/ ovarian cancer, 3.5% risk if one 2<sup class="calibre19">nd</sup>-degree relative <span class="r1">(</span><span class="r2">Obstet Gynecol</span> <span class="r1">1992;80:700)</span>. ↑↑ risk w/ hereditary syndromes: <i class="calibre6">BRCA1/2</i> (lifetime risk 17%/44%), Lynch syndrome (non-serous).</p>
<p class="noindent1">• History of pelvic radiation, endometriosis, or obesity (risk association less clear)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Nonspecific history of bloating, pelvic/abdominal pain, bowel sx, urinary sx</p>
<p class="noindent1">• Exam may reveal palpable pelvic mass, abdominal distention, or ascites</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• No screening modalities have shown survival benefit; no data to support at this time</p>
<p class="noindent1">• If concerning signs/sx (above), obtain pelvic U/S and/or CT A/P or pelvic MRI, CA-125</p>
<p class="noindent1">• Pathologic dx based on biopsy of lesion or sampling of ascitic fluid</p>
<p class="h">Treatment</p>
<p class="noindent1">• Cytoreductive surgery: survival benefit even for stage IV and relapsed disease <span class="r1">(</span><span class="r2">Gynecol Oncol</span> <span class="r1">2013;130:493;</span> <span class="r2">NEJM</span><span class="r1"> 2021;385:2123)</span>. Consider neoadj. chemo to ↑ likelihood of maximal cytoreduction at surgery and reduce surgical morbidity.</p>
<p class="noindent1">• Chemo: 1<sup class="calibre19">st</sup> line (neoadj., adj., adv.): carboplatin+paclitaxel (CP). PARPi maintenance (olaparib, niraparib, rucaparib; esp if homologous recombination deficient [eg, <i class="calibre6">BRCA1/2</i>]) or bevacizumab maintenance if homologous recombination proficient.</p>
<p class="noindent1">• Recurrence at &gt;6 mos = <b class="calibre7">platinum sensitive</b> → Rx w/ platinum doublet. If &lt;6 mos = <b class="calibre7">platinum resistant</b> → single agent chemo (eg, liposomal doxorubicin, gemcitabine) ± bevacizumab.</p>
<p class="h1cr">P<small class="calibre31">RIMARY</small> CNS T<small class="calibre31">UMORS</small> <small class="calibre31">AND</small> B<small class="calibre31">RAIN</small> M<small class="calibre31">ETASTASES</small></p>
<p class="h">Presentation and diagnosis</p>
<p class="noindent1">• Suspect if new focal neurologic deficits, seizure, memory or balance issues, or evidence of ↑ intracranial pressure (HA, n/v, vision change)</p>
<p class="noindent1">• <b class="calibre7">MRI brain</b> for suspected CNS tumors; CT less Se. Consider LP if c/f CNS lymphoma.</p>
<p class="h">Primary CNS tumors</p>
<p class="noindent1">• <b class="calibre7">Meningioma:</b> histopath. grading (WHO grades). Grade 1 = benign, asx/small → observe. Large or sx → resection if able, radiation if not. Grade 2–3 → resection + adjuvant RT (defer if risk of RT complication high and tumor totally resected).</p>
<p class="noindent1">• <b class="calibre7">Glioma:</b> histopath. grading, Grade 1/2/3: astrocytoma, oligodendroglioma most common; Grade 4: glioblastoma. Grade 3/4 = “high grade” <span class="r1">(</span><span class="r2">Neuro Oncol</span> <span class="r1">2021;23:1231)</span>.</p>
<p class="noindent1">• Notable testing: 1p/19q, <i class="calibre6">IDH</i>, <i class="calibre6">MGMT</i> methylation (predicts sensitivity to temozolomide)</p>
<p class="noindent1">• Treatment: <b class="calibre7">max resection as feasible</b> → adjuvant RT + temozolomide → surveillance. Steroids if neuro sx, hold until biopsy if c/f 1° CNS lymphoma. Anti-epileptics if seizures.</p>
<p class="noindent1">• Prognosis based on grade &amp; histology. For glioblastoma, overall survival 12–15 mos, based on extent of tumor resection <span class="r1">(</span><span class="r2">J Neurosurg</span> <span class="r1">2014;120:31)</span>.</p>
<p class="h">Metastatic CNS Lesions</p>
<p class="noindent1">• ↑ incidence than 1° CNS. Most common: lung, breast, melanoma, RCC, gastro-esoph.</p>
<p class="noindent1">• <b class="calibre7">Surgery</b> if oligomet disease or symptomatic &amp; resectable, steroids if neuro sx</p>
<p class="noindent1">• <b class="calibre7">Radiation</b> particularly if multiple mets or inoperable. Consider WBRT if many mets.</p>
<p class="noindent1">• Some systemic therapies (checkpoint inhibitors, targeted Rx in NSCLC) have CNS activity</p>
<h2 class="ct"><a id="h81" class="calibre8"></a><a id="page_5-36" class="calibre8"></a><a href="part0003.html#rh89" class="calibre8">IMMUNOTHERAPY &amp; CELLULAR THERAPY</a></h2>
<p class="h1cr">I<small class="calibre31">MMUNE</small> C<small class="calibre31">HECKPOINT</small> I<small class="calibre31">NHIBITORS</small> (ICI)</p>
<p class="h">Overview <span class="r1">(</span><span class="r2">Science</span> <span class="r1">2018;359:1350)</span></p>
<p class="noindent1">• Immune checkpoints: co-inhibitory signaling molecules that limit immune responses</p>
<p class="noindent1">• Cytotoxic T-lymphocyte-assoc. protein 4 (CTLA-4): ↓ T cell activation via negative signals and ligand competition w/ CD28 (activating co-stim. molecule).</p>
<p class="noindent1">• Programmed cell death protein 1 (PD-1): on activated T cells, turns off T cell responses</p>
<p class="noindent1">• Prog. death-ligand 1 (PD-L1): PD-1 ligand expressed on tumor and/or immune cells</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre25"/>
<col class="calibre23"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">ICIs</b> <span class="sm">(<i class="calibre6">Annals of Oncol</i> 2017;28:2377)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Target</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Drugs</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Select Indications</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Common Adverse Events</b></p>
<p class="tbody">(approx. incidence, any grade)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PD-1</p></td>
<td class="th1"><p class="tbody">Nivolumab</p>
<p class="tbody">Pembrolizumab</p>
<p class="tbody">Cemiplimab</p>
<p class="tbody">Dostarlimab</p></td>
<td class="th1"><p class="tbody">Melanoma, NSCLC, RCC, HNSCC, esoph., endometrial,</p>
<p class="tbody">MSI-high tumors</p></td>
<td class="th1"><p class="tbody">Rash (12%); hypothyroid (5%); pneumonitis (2%); colitis (&lt;1%); hepatitis (&lt;1%); type 1 DM (&lt;1%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PD-L1</p></td>
<td class="th1"><p class="tbody">Atezolizumab</p>
<p class="tbody">Avelumab</p>
<p class="tbody">Durvalumab</p></td>
<td class="th1"><p class="tbody">Urothelial carcinoma,</p>
<p class="tbody">NSCLC, SCLC,</p>
<p class="tbody">HCC (atezo)</p></td>
<td class="th1"><p class="tbody">Rash (5%); hypothyroid (2%); adrenal insufficiency (&lt;1%); colitis (&lt;1%); pneumonitis (&lt;1%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">CTLA-4</p></td>
<td class="th1"><p class="tbody">Ipilimumab</p></td>
<td class="th1"><p class="tbody">Melanoma, RCC (w/ PD1), mesothelioma (w/ PD1)</p></td>
<td class="th1"><p class="tbody">Rash (21%); colitis (5%); hypophysitis (1%); hypothyroid (1%); pneumonitis (&lt;1%); hepatitis (&lt;1%)</p></td>
</tr>
</tbody>
</table>
<p class="h">ICI toxicities <span class="r1">(</span><span class="r2">Nat Rev Dis Primers</span> <span class="r1">2020;6:38;</span> <span class="r2">Curr Cardiol Rep</span> <span class="r1">2021;23:98)</span></p>
<p class="noindent1">• ICIs can cause inflammation of any tissue (lungs, liver, colon, joints, skin, etc.)</p>
<p class="noindent1">• Common <b class="calibre7">immune-related adverse events (IRAEs)</b> above; ↑ incidence w/ combinations.</p>
<p class="noindent1">• Rare: myocarditis (can be fulminant), myositis, myelitis, uveitis, diabetes</p>
<p class="noindent1">• Workup: CT chest for dyspnea; colonoscopy and infectious workup for colitis; TSH, FT4, a.m. cortisol, glucose. Trend comprehensive metabolic panel and TSH while on ICI.</p>
<p class="noindent1">• IRAEs graded 1 (mild) to 4 (severe) <span class="r1">(</span><span class="r2">NCCN Guideline</span> <span class="r1">v4.2021)</span></p>
<p class="h">ICI toxicity treatment <span class="r"><i class="calibre6">(multidisciplinary care)</i></span></p>
<p class="noindent1">• Most IRAEs reversible with steroids</p>
<p class="noindent1">• <span class="underline">Mild</span> symptoms (grade 1): supportive care, can often continue Rx; <span class="underline">moderate</span> symptoms (grade 2): hold ICI, consider steroids; <span class="underline">severe</span> symptoms (grades 3–4): often requires admission to hospital, hold ICI, IV steroids, targeted therapies (eg, enteracept)</p>
<p class="noindent1">• Endocrinopathies (hypophysitis, hypothyroid) are not reversible, Rx hormone replacement</p>
<p class="noindent1">• Managing IRAEs with steroids likely does not reduce ICI efficacy <span class="r1">(</span><span class="r2">J Clin Oncol</span> <span class="r1">2019;37:1927)</span></p>
<p class="noindent1">• If ICI is restarted, Pts at increased risk for recurrent IRAE</p>
<p class="h1cr">C<small class="calibre31">HIMERIC</small> A<small class="calibre31">NTIGEN</small> R<small class="calibre31">ECEPTOR</small> (CAR)-T C<small class="calibre31">ELLS</small></p>
<p class="h">Overview <span class="r1">(</span><span class="r2">Nat Rev Cancer</span> <span class="r1">2021;21:145)</span></p>
<p class="noindent1">• Autologous T cells w/ chimeric receptor: antibody variable region fused to T cell co-stimulatory intracellular signaling domains → MHC independent Ag recognition</p>
<p class="noindent1">• CAR-T cells targeting CD19 used for ALL, DLBCL, FL, MCL. Targeting B-cell maturation antigen (BCMA) for MM. Strategies for solid tumors in development.</p>
<p class="h">Toxicities</p>
<p class="noindent1">• <b class="calibre7">Cytokine release syndrome (CRS)</b>: fever, HoTN, shock secondary to overwhelming cytokine release from proliferating T cells</p>
<p class="noindent1">• <b class="calibre7">Immune effector cell-associated neurotoxicitiy synd. (ICANS)</b>: cerebral edema → HA, aphasia, delirium, lethargy/obtundation. Graded using ICE score (vide infra).</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre28"/>
<col class="calibre34"/>
<col class="calibre33"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">CAR-T Toxicity</b> <span class="sm">(<i class="calibre6">Biol Blood Marrow Transplant</i> 2019;25:625)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Grade</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Mechanism &amp; Manifestations</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbodyc"><b class="calibre7">CRS</b></p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbody">Fever (≥38°C) ± other sx</p></td>
<td rowspan="4" class="th1"><p class="tbody">Supportive (fluids, O<sub class="calibre17">2</sub>), ± steroids ± anti-IL-6 (tocilizumab or siltuximab), depending on severity</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">2</p></td>
<td class="th1"><p class="tbody">Fever + HoTN not needing pressors ± O<sub class="calibre17">2</sub> by nasal cannula</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">3</p></td>
<td class="th1"><p class="tbody">Fever + pressor ± O<sub class="calibre17">2</sub> &gt; nasal cannula</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">4</p></td>
<td class="th1"><p class="tbody">Fever + &gt;1 pressor ± ⊕ pressure vent</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbodyc"><b class="calibre7">ICANS</b></p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbody">ICE 7–9 pts</p></td>
<td class="tb" rowspan="4"><p class="tbody">Steroids, anticonvulsants for seizures</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">2</p></td>
<td class="th1"><p class="tbody">ICE 3–6 pts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">3</p></td>
<td class="th1"><p class="tbody">ICE 0–2 pts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">4</p></td>
<td class="th1"><p class="tbody">Unarousable &amp; unable to perform ICE</p></td>
</tr>
</tbody>
</table>
<p class="tfn">ICE score: orientation (4 pts), name 3 objects (3 pts), follow commands (1 pt), write sentence (1 pt), count backward from 100 by 10 (1 pt)</p>
<h2 class="ct"><a id="h82" class="calibre8"></a><a id="page_5-37" class="calibre8"></a><a href="part0003.html#rh90" class="calibre8">ONCOLOGIC EMERGENCIES</a></h2>
<p class="h1cr">F<small class="calibre31">EVER AND</small> N<small class="calibre31">EUTROPENIA</small> (FN) <span class="r3">(</span><span class="r4">NCCN Guidelines</span> <span class="r3">v.1.2021)</span></p>
<p class="h">Definition</p>
<p class="noindent1">• Fever: single oral temp ≥38.3°C (101°F) or ≥38°C (100.4°F) for ≥1 h</p>
<p class="noindent1">• <b class="calibre7">Neutropenia:</b> ANC &lt;500 cells/µL or &lt;1000 cells/µL with predicted nadir &lt;500 cells/µL</p>
<p class="h">Pathophysiology and microbiology</p>
<p class="noindent1">• Predisposing factors: catheters, skin breakdown, GI mucositis, obstruction (lymphatics, biliary tract, GI, urinary tract), immune defect associated with malignancy</p>
<p class="noindent1">• Often thought due to seeding of bloodstream by GI flora, eg, GNRs (esp. <i class="calibre6">P. aeruginosa</i>)</p>
<p class="noindent1">• Neutropenic enterocolitis (typhlitis): RLQ pain, watery/bloody diarrhea, cecal wall thickening</p>
<p class="noindent1">• Gram ⊕ infections have recently become more common (60–70% of identified organisms)</p>
<p class="noindent1">• Fungal superinfection often results from prolonged neutropenia &amp; antibiotic use</p>
<p class="h">Prevention <span class="r">(only if intermediate or high-risk)</span></p>
<p class="noindent1">• Bacterial: consider FQ if neutropenic esp steroids+ALL; ↓ mortality <span class="r1">(</span><span class="r2">Cochrane</span> <span class="r1">2012 CD004386)</span></p>
<p class="noindent1">• Fungal: consider during neutropenia in blood cancers (posa/fluconazole, micafungin)</p>
<p class="noindent1">• Viral: consider during active Rx in blood cancers (acyclovir, famciclovir, valacyclovir)</p>
<p class="h">Role of hematopoietic growth factors <span class="r1">(</span><span class="r2">NCCN Guidelines</span> <span class="r1">v.4.2021)</span></p>
<p class="noindent1">• Granulocyte (G-CSF) and granulocyte-macrophage (GM-CSF) colony-stimulating factors can be used (<i class="calibre6">but not in AML</i>) as 1° Ppx when expected FN incidence &gt;20% or as 2° Ppx after FN has occurred in a prior cycle (to maintain dose-intensity for curable tumors)</p>
<p class="noindent1">• CSFs ↓ rate of FN but have not been shown to affect mortality <span class="r1">(</span><span class="r2">Cochrane</span> <span class="r1">2014 CD003039)</span></p>
<p class="h">Diagnostic evaluation</p>
<p class="noindent1">• Exam: skin, oropharynx, lung, perirectal area, surgical &amp; catheter sites; <i class="calibre6">avoid rectal exam</i></p>
<p class="noindent1">• Studies: U/A, blood (periph &amp; through each indwelling catheter port), urine, &amp; sputum cx; for localizing s/s → ✓ stool (<i class="calibre6">C. diff</i>, cx), peritoneal fluid, CSF (rare source)</p>
<p class="noindent1">• Imaging: CXR; for localizing s/s → CNS, sinus, chest or abdomen/pelvis CT</p>
<p class="noindent1">• Caveats: neutropenia → impaired inflammatory response → <i class="calibre6">exam and radiographic findings may be subtle;</i> absence of neutrophils by Gram stain does <i class="calibre6">not</i> r/o infection</p>
<p class="h">Risk stratification <span class="r">(factors that predict lower risk)</span></p>
<p class="noindent1">• History: outPt, ECOG 0–1, age &lt;60 y, solid tumor, no sx, no major comorbidities, no h/o fungal infection, MASCC Risk Index ≥21 <span class="r1">(</span><span class="r2">Support Care Cancer</span> <span class="r1">2013;21:1487)</span></p>
<p class="noindent1">• Exam: temp &lt;39 °C, no tachypnea, no HoTN, no Δ MS, no dehydration</p>
<p class="noindent1">• Labs: ANC &gt;100 cells/µL, anticipated duration of neutropenia ≤100 cells/µL &lt;7 d</p>
<p class="h">Initial antibiotic therapy <span class="r1">(</span><span class="r2">NCCN</span> <span class="r1">Guidelines v.1.2021)</span></p>
<p class="noindent1">• Empiric regimens should include <b class="calibre7">antipseudomonal activity</b>; consider VRE coverage if ⊕</p>
<p class="noindent1">• <b class="calibre7">Low risk:</b> PO abx or home IV abx may be considered in select Pts <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2013;31:1149)</span></p>
<p class="noindent2">PO options: cipro+amoxicillin-clavulanate; levofloxacin; moxifloxacin (avoid if FQ Ppx)</p>
<p class="noindent1">• <b class="calibre7">High risk: hospital admission &amp; IV abx;</b> <i class="calibre6">monotherapy preferred</i></p>
<p class="noindent2">options: <b class="calibre7">cefepime</b>, imipenem, meropenem, piperacillin/tazobactam, ceftazidime</p>
<p class="noindent1">• Antifungal Rx added for neutropenic fever ≥4 d despite abx: <b class="calibre7">micafungin</b>, liposomal amphotericin B, caspofungin, anidulafungin, voriconazole, &amp; posaconazole are options</p>
<p class="h">Modification to initial antibiotic regimen based on site-specific evaluation</p>
<p class="noindent1">• <b class="calibre7">Vancomycin</b> <i class="calibre6">only if</i> HoTN, PNA, clinically apparent catheter-related or soft-tissue infxn, gram ⊕ BCx, mucositis + on quinolone Ppx; d/c when BCx ⊖ × 48 h for GPCs</p>
<p class="noindent1">• Mouth/esoph (ulcer, thrush): anaerobic (if necrotizing), anti-HSV and/or antifungal Rx</p>
<p class="noindent1">• Sinus/nasal: add vanc if periorbital cellulitis, ampho if concern for Aspergillus/Mucor</p>
<p class="noindent1">• Abd pain/diarrhea: PO vanc if concern for <i class="calibre6">C. diff</i>; ensure adequate anaerobic coverage</p>
<p class="noindent1">• Lung infiltrates: consider atypical coverage; vanc/linezolid if c/f MRSA; TMP/SMX if c/f PCP</p>
<p class="noindent1">• CNS: ID consult; empiric meningitis Rx (incl. <i class="calibre6">Listeria</i>), high-dose acyclovir for encephalitis</p>
<p class="h">Duration of therapy</p>
<p class="noindent1">• Known source: complete standard course (eg, 14 d for bacteremia)</p>
<p class="noindent1">• Unknown source: continue antibiotics until afebrile <i class="calibre6">and</i> ANC &gt;500 cells/µL</p>
<p class="noindent1">• Less clear when to d/c abx when Pt is afebrile but prolonged neutropenia</p>
<p class="h1cr">S<small class="calibre31">PINAL</small> C<small class="calibre31">ORD</small> C<small class="calibre31">OMPRESSION</small></p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Lancet Neuro</span> <span class="r1">2008;7:459)</span></p>
<p class="noindent1">• Metastases located in vertebral body extend and cause epidural spinal cord compression</p>
<p class="noindent1">• <b class="calibre7">Prostate</b>, <b class="calibre7">breast</b>, and <b class="calibre7">lung</b> cancers are most common, followed by RCC, NHL, myeloma</p>
<p class="noindent1">• <b class="calibre7">Site of involvement: thoracic</b> (60%), lumbar (25%), cervical (15%)</p>
<p class="noindent1">• Signs and symptoms: <b class="calibre7">pain</b> (&gt;95%, <i class="calibre6">precedes neuro</i> Δ<i class="calibre6">s</i>), <b class="calibre7">weakness</b>, <b class="calibre7">autonomic dysfunction</b> (urinary retention, ↓ anal sphincter tone), <b class="calibre7">sensory loss</b></p>
<p class="h"><a id="page_5-38" class="calibre4"></a>Diagnostic evaluation</p>
<p class="noindent1">• Always take back pain in Pts w/ cancer seriously. Urgent <b class="calibre7">whole-spine MRI</b><span class="r">;</span> CT if unable.</p>
<p class="noindent1">• <b class="calibre7">Do <i class="calibre6">not</i> wait for neurologic signs to develop</b> before initiating evaluation b/c duration &amp; severity of neuro dysfunction before treatment are best predictors of neurologic outcome</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:1358)</span></p>
<p class="noindent1">• <b class="calibre7">Dexamethasone</b> (10 mg IV × 1 STAT, then 4 mg IV or PO q6h)</p>
<p class="noindent2"><i class="calibre6">initiate immediately</i> while awaiting imaging if back pain + neurologic deficits</p>
<p class="noindent1">• Emergent RT or surgical decompression if confirmed compression/neuro deficits</p>
<p class="noindent1">• Surgery + RT superior to RT alone for neuro recovery in solid tumors <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2005;366:643)</span></p>
<p class="noindent1">• If pathologic fracture causing compression → surgery; if not surgical candidate → RT</p>
<p class="h1cr">T<small class="calibre31">UMOR</small> L<small class="calibre31">YSIS</small> S<small class="calibre31">YNDROME</small></p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:1844)</span></p>
<p class="noindent1">• Large tumor burden or a rapidly proliferating tumor → spontaneous or chemotherapy-induced release of intracellular electrolytes and nucleic acids</p>
<p class="noindent1">• Most common w/ treatment of <b class="calibre7">high-grade lymphomas</b> (<b class="calibre7">Burkitt’s</b>) and <b class="calibre7">leukemias</b> (<b class="calibre7">ALL</b>, <b class="calibre7">AML</b>, <b class="calibre7">CML in blast crisis</b>). <i class="calibre6">Very rare w/ solid tumors</i>; rarely due to spont. necrosis.</p>
<p class="noindent1">• Electrolyte abnormalities: ↑ K, ↑ uric acid, ↑ PO<sub class="calibre10">4</sub> → ↓ Ca; <b class="calibre7">renal failure</b> (urate nephropathy)</p>
<p class="h">Prophylaxis</p>
<p class="noindent1">• Allopurinol 300 mg qd to bid PO or 200–400 mg/m<sup class="calibre19">2</sup> IV (adjusted for renal fxn) &amp; aggressive hydration prior to beginning chemotherapy or RT</p>
<p class="h">Treatment</p>
<p class="noindent1">• <i class="calibre6">Avoid</i> IV contrast and NSAIDs; treat hyperK, hyperPO<sub class="calibre10">4</sub>, and only <i class="calibre6">symptomatic</i> hypoCa</p>
<p class="noindent1">• Allopurinol + aggressive IV hydration ± diuretics to ↑ UOP for goal 80–100 cc/h</p>
<p class="noindent1">• Rasburicase (0.1–0.2 mg/kg or 6 mg IV fixed dose) for ↑↑ uric acid esp. in aggressive malig <span class="r1">(</span><span class="r2">JCO</span> <span class="r1">2003;21:4402;</span> <span class="r2">Acta Haem</span> <span class="r1">2006;115:35)</span>. <b class="calibre7"><i class="calibre6">Avoid in G6PD def</i></b> (hemolytic anemia). Consider G6PD testing in Jehovah’s Witnesses especially if Black (12% prevalence).</p>
<p class="noindent1">• Hemodialysis may be necessary; early renal consultation for renal insufficiency or ARF</p>
<h2 class="ct"><a id="h83" class="calibre8"></a><a href="part0003.html#rh91" class="calibre8">CHEMO SIDE EFFECTS</a></h2>
<p class="center"><i class="calibre6">Nausea &amp; vomiting common</i> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:1356; 375:134 &amp; 177)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Select Adverse Effects from Chemotherapy<sup class="calibre27"><a id="fn129-s1" class="calibre8"></a><a href="part0011.html#rfn129-s1" class="calibre8">*</a></sup></b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Toxicity</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Common Agents</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="6"><p class="tbodyc"><b class="calibre7">Cardiotoxicity</b></p>
<p class="tbodyc"><span class="sm">(<i class="calibre6">NEJM</i> 2016;375;1457)</span></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Anthracyclines</b></p></td>
<td class="th1"><p class="tbody">Dose-dependent CMP; ✓ EF pre-Rx</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">5-FU</p></td>
<td class="th1"><p class="tbody">Spasm → ischemia; CCB may prevent</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Trastuzumab</b></p></td>
<td class="th1"><p class="tbody">CMP, esp w/ anthracycline, TTE’s for EF</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Tyrosine kinase inhib (TKI)</p></td>
<td class="th1"><p class="tbody">QTc prolongation, CMP, angina</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cyclophosphamide</p></td>
<td class="th1"><p class="tbody">Myopericarditis (esp. in BMT)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cisplatin</p></td>
<td class="th1"><p class="tbody">AKI → HypoMg / HyperK → arrhythmia</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="5"><p class="tbodyc"><b class="calibre7">Pulmonary</b></p>
<p class="tbodyc"><span class="sm">(<i class="calibre6">Sem Oncol</i> 2006;33:98)</span></p></td>
<td class="th1"><p class="tbody">Busulfan</p></td>
<td class="th1"><p class="tbody">~8% fibrosis or DAH; if severe → steroids</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bleomycin</b></p></td>
<td class="th1"><p class="tbody">~10% IPF; ✓ PFTs pre-Rx; Rx: steroids</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">TKI (esp. dasatinib)</p></td>
<td class="th1"><p class="tbody">Pleural effusion</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cyclophosphamide</p></td>
<td class="th1"><p class="tbody">Pneumonitis, progressive fibrosis; Rx: d/c</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bevacizumab</b></p></td>
<td class="th1"><p class="tbody">Pulm. hemorrhage (esp. lung SCC)</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbodyc"><b class="calibre7">Nephrotoxicity/ urologic toxicity</b></p></td>
<td class="th1"><p class="tbody">Platinum Rx (<b class="calibre7">cisplatin</b>)</p></td>
<td class="th1"><p class="tbody">Esp. proximal tubule; pretreat w/ IV saline</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Methotrexate</p></td>
<td class="th1"><p class="tbody">Via deposition; Rx: alkalinize urine, IVF</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cyclophosphamide</p></td>
<td class="th1"><p class="tbody">Hemorrhagic cystitis; Rx: Mesna</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="5"><p class="tbodyc"><b class="calibre7">Neurotoxicity</b></p>
<p class="tbodyc"><span class="sm">(<i class="calibre6">Sem Oncol</i> 2006;33:324)</span></p></td>
<td class="th1"><p class="tbody">Platinum Rx (<b class="calibre7">cisplatin</b>)</p></td>
<td class="th1"><p class="tbody">“Stocking-glove” neuropathy; ototoxicity</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cytarabine</b></p></td>
<td class="th1"><p class="tbody">Cerebellar toxicity (irreversible 5–10%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Methotrexate (esp. intrathecal)</p></td>
<td class="th1"><p class="tbody">Late leukoenceph, meningitis; reverse w/ intrathecal glucarpidase, leucovorin</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ifosfamide</p></td>
<td class="th1"><p class="tbody">Enceph; Rx: methylene blue, thiamine</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Taxanes, vincristine</b></p></td>
<td class="th1"><p class="tbody">Sensorimotor long fiber neuropathy</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbodyc"><b class="calibre7">Hepatotoxicity</b></p>
<p class="tbodyc"><span class="sm">(<i class="calibre6">Sem Oncol</i> 2006;33:50)</span></p></td>
<td class="th1"><p class="tbody">TKI (eg, imatinib, nilotinib)</p></td>
<td class="th1"><p class="tbody">↑ LFTs, rarely necrosis; Rx: d/c ± steroids</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Gemcitabine</p></td>
<td class="th1"><p class="tbody">Common ↑ ALT/AST; ↓ dose if ↑ bili</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Methotrexate</p></td>
<td class="th1"><p class="tbody">↑ ALT/AST, rarely fibrosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Dermatologic</b></p></td>
<td class="th1"><p class="tbody">TKI (eg, imatinib)</p></td>
<td class="th1"><p class="tbody">Dermatitis, can be severe (eg, SJS)</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn129-s1" class="calibre8"></a><a href="part0011.html#fn129-s1" class="calibre8">*</a></sup>See “ImmunoRx” section for cytokine release and immune effector cell-associated neurotoxicity syndromes</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0010.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0012.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
